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Abstract
In this thesis we develop a mathematical cross-scale model for the evolution of influenza
within a single season. We model evolution as the emergence and spread of a mutant
strain in a population that is already invaded by a parent resident strain. This allows us to
investigate both the emergence dynamics of a mutant strain as well as the subsequent
competition dynamics between the two strains. Our main research goal is to study the
effects of a homologous vaccine against the resident strain on the epidemiological and
evolutionary dynamics of the disease.
Due to the complexity of cross-scale models, we first develop a simpler population-level
SIR-type model for the evolution of influenza. Assuming an outbreak that is initiated
by a single resident strain, we study the significance of the mutant’s emergence time
by introducing it in the population at different times. We then also derive a probability
density function for the emergence of the mutant in the population. Finally we incorporate
vaccination to our model, and arrive at the conclusion that intermediate levels of vaccine-
induced immuno-protection are the most beneficial for the emergence and spread of the
mutant strain.
We then start building towards a cross-scale model by developing a dynamical within-host
model for the evolution of influenza. Our goal is for emergence to be a stochastic event,
so we derive a probability density for the within-host emergence of a mutant strain. We
also incorporate vaccination to our model and assess its impact on the viral loads of the
two strains.
Having analyzed our within-host model, we then couple it with a between-host SI model.
The links between the two scales are the population-level transmission rates, which we
assume are linear functions of the within-host viral load. We first investigate how varying
the within-host parameters affects the population-level fitness of the two strains, and then
we study our model’s results under different forms of the within-host emergence density.
Finally we add vaccination to our cross-scale model, and arrive at the same conclusion
that intermediate values of immuno-protection are the most inducive to the emergence
and spread of a mutant strain in the population.
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1.1.1 The burden of influenza
Influenza viruses are among the most common causes of human respiratory infections
and can cause high morbidity and mortality. Influenza affects 2% to 10% of the global
population, resulting in 250,000 to 500,000 deaths annually [92]. The burden of influenza,
which according to the CDC takes into account the number of influenza illnesses, medical
visits, flu-associated hospitalizations, as well as flu-associated deaths, can be much
higher among the children, the elderly, and immuno-compromised individuals [179, 270].
Each year 15–45% of children are infected with influenza, and about 870,000 children
aged less than 5 years and 300,000 children aged less than 1 year all over the world
require hospitalization [203]. Influenza outbreaks have occurred since at least the Middle
Ages [287]. In addition to seasonal influenza outbreaks, pandemic influenza viruses have
been emerging occasionally in the last several centuries. Pandemic strains can cause
significantly more infections and deaths compared to seasonal ones. The "Spanish flu"
pandemic of 1918 is estimated to have caused the death of 50 million people worldwide
[158]. Vaccination is considered the most efficient public health intervention to reduce
the burden of influenza [261].
2 Introduction
1.1.2 Relevant biology
Influenza types, subtypes and strains
Influenza is a respiratory disease caused by certain RNA viruses of the Orthomyxoviridae
family. It is divided into four main types, A, B,C and D which are determined by antigenic
differences in their nucleoprotein (NP) and matrix protein [217]. Influenza type A is the
most interesting from an epidemiological and evolutionary perspective, because it can
infect humans and various other mammals as well as avian species and can undergo
significant immunological changes. Influenza B is confined primarily to humans and
contributes significantly to influenza-related deaths. Humans were considered the only
hosts of influenza B until 1999, when data showed that it can also infect seals [38]. Little
is known about influenza C compared to the other types, but so far it has been shown to
infect humans, dogs and pigs [318]. Influenza D was first isolated from clinically-ill pigs
with influenza-like symptoms in the USA in 2011. It was subsequently isolated from cattle,
which until then was a species never considered to be susceptible to influenza. While
phylogenetic analysis showed that type D shares some significant similarities with type
C, influenza D exhibits no cross-reactivity with human type C antisera, does not reassort
with influenza C to generate viable progeny and finally exhibits a new mechanism to
generate the M1 protein. As a result, influenza D has been classified as a new genus
of the Orthomyxoviridae family [146, 283]. In 2016 White et al. performed a serological
study on human serum samples from 35 cattle-exposed and 11 non-cattle-exposed
adults to screen for influenza D antibodies using hemagglutination inhibition (HI) and mi-
croneutralization (MN) assays [306]. The HI assay showed a 91% seroprevalence among
the cattle-exposed individuals, while the MN assay showed a 97% seroprevalence in the
same group. The authors emphasized that while it is still not known whether influenza D
causes disease in humans, their findings indicate that it could be an emerging pathogen
threat among cattle-workers.
Influenza A viruses have been responsible for the majority of recorded epidemics and
pandemics [3]. They are further divided into subtypes based on differences in the surface
proteins hemagglutinin (HA) and neuraminidase (NA). The CDC reports that there are
currently 18 different types of HA and 11 different types of NA, and that while that leads
to 198 potential different influenza A subtypes only 131 have been detected in nature. In
a 2011 paper, Deng et al. report that real-time Reverse-Transcription PCR (RT-PCR) is
the most widely used assay for influenza virus typing and subtyping [72]. A more recent
technology for the detection and subtyping of influenza A (though not limited to influenza)
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is pyrosequencing, which is a sequencing by synthesis technique that can be used for
short sequence and SNP analysis [81, 258]. It has been extensively used in influenza
molecular surveillance for SNP detection and for mutation screening [72]. We note that
several more influenza detection, typing and subtyping methods exist, including but not
limited to double immunodiffusion assays, ELISA and real-time PCR. Influenza types
(and subtypes in the case of influenza A) are also subdivided into strains, which are
distinguished by variations in their genetic sequence. The WHO Expert Committee on
Influenza recommended a two-part nomenclature system for influenza viruses in a 1980
memorandum [2]: a strain designation and a description of the HA and NA antigens.
This revised nomenclature followed the WHO’s classification systems published in 1953,
1959, 1971 and 1980. The revised strain designation for types A,B and C is required to
include the following information (taken directly from [2]):
1. A description of the antigenic type of the virus based on the antigenic specificity of
the NP and M proteins (A, B, C or D).
2. The host of origin. This is not necessary for strains isolated from humans, but is
mandatory for strains isolated from non-human hosts.
3. Geographical origin.
4. Strain number (or serial number/ laboratory identification number).
5. Year of isolation.
The description of the HA and NA antigens applies only to influenza A viruses, and needs
to include the following information:
1. An index describing the antigenic character of the HA subtype, such as H1 and H3.
2. An index describing the antigenic character of the NA subtype, such as N1 and N2.
Therefore, an example of an influenza strain would be "A/Alaska/135/2015(H3N2)" (taken
from the Influenza Research Database) where:
1. The type of the strain is A.
2. The host that the sample was isolated from is human, as otherwise the name of
the strain would have to include the non-human host.
3. The location where it was isolated is Alaska.
4. The serial number is 135.
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5. The sample collection year is 2015.
6. The strain’s subtype is H3N2.
In the same WHO 1980 memorandum, it is mentioned that "it is implicit that a given H
or N subtype designation will encompass strains exhibiting a considerable degree of
antigenic variation within the subtype. The precise antigenic position of an influenza
virus within a subtype may be defined by indicating similarities to designated reference
strains". A commonly used experimental method to define the antigenic phenotype of
an influenza strain is the hemagglutination inhibition (HI) assay, which measures the
cross-reactivity of one strain’s HA protein against antisera developed using a different
(reference) strain [150].
Influenza virus life cycle
Influenza viruses preferentially replicate in the epithelial cell layers of the respiratory tract
of their host, but their target cells can also include macrophages and other leukocytes
[159]. The infection process within the host begins as follows: the influenza virus enters
a host cell using its HA protein to bind to the sialic acid on the surface of the host cell
membrane and then releases its RNA, in the form of individual viral ribonucleoprotein
(vRNP) complexes, into the cell’s nucleoplasm. Inside the host cell nucleus, viral RNA
polymerase performs the transcription and replication of the influenza genome. The
newly synthesized vRNPs exit the nucleus and travel to the cell membrane for viral
assembly. Once there they combine with each other and become encased in protein
shells, called capsids, to form new viral particles which are referred to as virions [85].
These virions are then released from the host cell where they may find and infect new
susceptible target cells. The number of virions present in a given volume is called the
viral load or viral titer, and in the case of influenza is often measured in viral RNA copies
per milliliter of nasal swab or aerosol sample.
Immune responses to influenza
The immune system has several mechanisms to combat the spread of an infection. The
first line of defense is the rapid innate immune response. Viral endocytosis triggers
the activation of pattern recognition receptors within the host cell, which in turn triggers
the secretion of type I interferons (IFN). IFN is a type of cytokine with antiviral as well
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as immunostimulatory properties and plays an important role in regulating the immune
system. Infected cells also secrete other types of cytokines, such as proinflammatory
cytokines which enhance the binding of leukocytes to endothelial cells in the interior of
blood vessels, thus making their travel to the site of the infection easier. Additionally,
infected cells produce chemokines which act as messengers to leukocytes. Epithelial
cells as well as leukocytes have also been reported to undergo apoptosis in response to
influenza infections [159]. The innate immune response can be triggered within as little
as three hours of an influenza infection [220]. There is also the much slower adaptive
immune response which is vital for the establishment of protective immunity. The adap-
tive immune response can be divided into two main mechanisms: humoral and cellular
immunity. Humoral immunity involves the actions of antibodies, which are produced by
plasma B cells and whose main role is to bind to antigens that are found outside of
infected cells. Cellular immunity on the other hand occurs inside infected cells and is
mediated by T lymphocytes rather than antibodies. Antigen-presenting cells express a
pathogen’s antigens and in response helper T cells release cytokines whose function
is to help cytotoxic T cells bind to infected cells and kill them. It is important to note
that even independently of the innate and adaptive immune responses, the process of
viral protein synthesis, packaging and production of progeny virions is very damaging for
the target cells. This often leads to virus-induced cytolysis, which stops the new virion
synthesis and limits the spread of the infection.
We will now discuss in further detail the interferon response to the influenza virus. This
is because in chapter 3 we will study a within-host viral kinetics model which explicitly
takes into account the impact of the innate immune response on the viral growth via
the action of interferon. The IFNs are a family of antiviral cytokines and are classified
into three types based on their amino acid sequence and the type of receptor through
which they signal. Type I IFNs were discovered in 1957 [153] and consist of several
different molecules. Among them, in the case of humans, are 13 distinct IFN-α genes
and one IFN-β gene. These are among the major IFNs secreted following influenza
virus infection, both in-vivo and in-vitro [167]. The type III IFN family (IFN-λ ) has very
similar functions to the antiviral cytokines of the type I IFN family but restricted activity,
because its receptors are primarily restricted to epithelial cell surfaces in the respiratory
and gastrointestinal tracts while type I IFN receptors are expressed at the surface of
all cells [278]. It is important to mention that the type II IFN, which only has a single
member called IFN-γ , also has some well-characterized antiviral effects but is secreted
by activated T lymphocytes and natural killer (NK) cells rather than in direct response to
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viral infection [247].
The induction of IFN becomes stimulated following the recognition of pathogen-associated
molecular patterns (PAMPs) of invading viruses, which are absent in uninfected cells.
The subsequent binding of IFN into its receptors at cell surfaces leads to the upregulation
of several hundreds interferon-stimulated genes (ISGs), whose role is to establish an
antiviral state and limit the spread of the virus. Some of these ISGs that have been iden-
tified as pivotal during an influenza infection are the following: the Mx family of GTPases
which can retain the incoming viral genome in the cytoplasm and prohibit nuclear import
[133, 313], viperin which can inhibit viral release from the plasma membrane of infected
cells [299] and the IFN-induced transmembrane (IFITM) family members (especially
IFITM3) which can inhibit viral entry [45, 97]. For single stranded RNA (ssRNA) viruses
like influenza, PAMPs are often certain features of viral RNA which are not normally
present in cellular RNAs, such as regions of double-stranded RNA (dsRNA) made during
viral replication [167]. As early as 1967 Lampson et al. demonstrated that the presence
of dsRNA induces IFN production [181]. Research has shown that non-plasmacytoid
dendritic cells (DC) produce high levels of IFN-α in response to the presence of dsRNA
in the cytoplasm [74, 155]. However, influenza has evolved a mechanism to counteract
this aspect of the immune response by means of the non-structural protein 1 (NS1). The
primary function of NS1 is to inhibit the host IFN response through a variety of distinct
molecular mechanisms [94]. One of these mechanisms is by binding to and sequestering
dsRNA, thereby stopping the production of type I IFN by conventional DC [32, 114, 145].
Plasmacytoid dendritic cells (pDC) though, which are a unique subset of DC capable of
releasing large amounts of type I interferon following a viral encounter, have been shown
to produce high levels of IFN-α even after infection with wild-type influenza [62, 156].
In 2004 Diebold et al. tested the hypothesis that pDC possess a way of recognizing
influenza that does not depend on dsRNA detection. Their results showed that TLR7
receptors, which are pathogen-recognition receptors (PRRs) that belong to the Toll-like
receptor (TLR) family of transmembrane proteins, are capable of recognizing influenza
ssRNA and stimulate the production of IFN-α by pDC [73]. The authors underlined that
this is a unique property of pDC and that conventional DC cannot produce high levels of
IFN in response to TLR signalling. Another type of PRRs that has been implicated in the
induction of IFN by influenza viruses are the RIG-I-like receptors (RLRs), which play a
key role in the production of IFN by non-pDC [167]. The majority of RLRs though are
confined to the cytoplasm, while influenza virus transcription and replication occurs in
the nucleus (unlike many other RNA viruses which replicate exclusively in the cytoplasm).
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As a result the RIG-I and MDA-5 receptos of the RLR family, which cannot access
the nucleus, cannot directly sense the viral replication and activate the IFN response.
Moreover incoming as well as progeny vRNAs are encapsidated into vRNPs and can
therefore evade PRR recognition as they traverse the cytoplasm, whereas naked vRNAs
would have been detected by RIG-I and MDA-5 receptors and activated the IFN response.
Furthermore, the NS1 protein has been shown to directly inhibit the activation of the
RIG-I receptors [234].
Mutation and antigenic drift, shift and thrift
Research has shown that influenza has a high mutation rate, estimated roughly at
2× 10−5 substitutions per nucleotide per cellular infection [216, 225, 264]. This has
been primarily attributed to the error-prone replication of the virus within the target cells.
The influenza viral RNA-polymerase lacks a proofreading function, and often places the
wrong nucleotide (or sequence of nucleotides) in the wrong position of the influenza
genome. These point mutations are often neutral or deleterious for the virus, but can
also be beneficial. A study by Visher et al. in 2016 in which the researchers generated
mutant variants from a parent influenza strain found that approximately 30% of the
mutations were lethal, and among the viable mutants most were weakly deleterious or
neutral, some were very deleterious and only very few were weakly beneficial [297].
Lyons & Lauring reported very similar findings in [200]. Beneficial mutations that occur
in antigenic sites are particularly important because they can help the virus escape
neutralizing antibodies. Other beneficial mutations might lead to drug resistance, faster
replication, better binding to target cells or even cross-species transmission [144, 297].
Even small genetic changes can have a strong impact on the virus’ phenotype. In [67]
Conenello et al. compared sequences of human influenza A strains isolated during some
major outbreaks, including the 1918 pandemic. Using a mouse model, they identified
a single mutation in the PB1-F2 protein to be responsible for the large increases in the
viral growth and virulence of these strains.
The gradual accumulation of mutations in the HA and NA proteins (and more generally
in the influenza genome) is referred to as antigenic drift, and is partially responsible
for the virus’ ability to escape the immune response and re-infect hosts. The effects of
antigenic drift were observed as early as 1947 [106]. In 1979 Laver et al. used antigenic
mapping and sequence analysis of the escape mutants which emerged in the presence
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of monoclonal antibodies against the HA and NA proteins to identify four antigenic sites
(also referred to as epitopes) on the head domain of the HA [184]. In 1990 Wilson and
Cox identified a fifth antigenic site on the head of HA [310]. In the same paper they
further reviewed the cumulative molecular changes in the HA of various influenza strains
from 1968 to 1987 and concluded that the amino acid substitutions which led to the
antigenic drift of the virus were largely confined to those five epitopes. In 1992 Webster et
al. established an antigenic map of the N2 neuraminidase molecule using neuraminidase
inhibition (NI) and ELISA tests and identified three and possibly four antigenic sites
[301]. As the antigenic sites are what the host immune system uses to recognize and kill
influenza viruses, if their phenotype changes due to mutations then the immune cells
might fail to recognize them even if the host has been previously infected by a different
influenza strain.
Influenza A viruses can undergo antigenic changes via another route, which is referred
to as antigenic shift. Antigenic shift occurs when more than one strains coinfect the
same host and exchange gene segments in a process called reassortment. The most
dramatic antigenic changes have happened when segments from strains circulating in
non-human hosts, such as birds and swine, were combined with segments from human
strains. Two examples are the 2009 H1N1 pandemic, which originated from swine, and
the 1918 Spanish flu pandemic, whose source was a an avian influenza-like lineage
[212]. While reassortment had been recognized at least as early as 1982 as a mech-
anism via which novel influenza genotypes with pandemic potential can emerge [304],
the more recent advancements in gene sequencing technology have allowed for very
descriptive evolutionary studies using genomic data [151]. Various such studies have
shown that mixed infection, a prerequisite for reassortment, is a common occurrence
during seasonal influenza [118, 151, 237]. Studies have shown that reassortment occurs
frequently between the H1N1 and H3N2 subtypes. Since the reemergence of H1N1
in the human population in 1977, these viruses have co-circulated with viruses of the
H3N2 subtype. While it was only in 2001 that influenza A H1N2 viruses emerged via ge-
netic reassortment between viruses of these two subtypes, earlier reassortants between
them had briefly circulated from 1978 to 1980 and 1988 to 1989 but did not become
established in the human population [123]. Evidence has also shown that reassortment
occurs frequently within the H3N2 subtype. In 2006 Schweiger et al. used H3N2 viruses
isolated in Germany from 1998 to 2005 to show that a surprisingly high 70% of viruses
from 1998-1999 were the result of reassortment and had distinct genome compositions
[266]. They also found though that the next year was characterized by the prevalence
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of a single reassortant strain, which they assumed was because the 1999-2000 H3N2
viruses achieved the best evolutionary fitness. It is important to note that the authors
isolated reassortant strains in each of the seasons studied. In 2016 Poon et al. performed
whole genome deep sequencing on swabs collected from a set of 84 individuals, which
consisted of index cases with confirmed influenza along with their household contacts, in
Hong Kong [237]. The virus samples were collected during the first wave of the 2009
H1N1 pandemic in Hong Kong, when seasonal H3N2 viruses were also confirmed to be
circulating. The author’s analysis showed that approximately 66% of the H3N2-infected
patients and 40% of the H1N1/2009-infected patients likely harbored mixed lineage
infections. Bourret et al. in 2013 [42] and Bourret et al. in 2017 [43] studied the evolution
and adaptation mechanisms of a duck influenza A virus isolate during passage in swine
tracheal cells. Their work was motivated by evidence that swine might be an intermediate
host for adaptation of avian influenza strains to humans and for enabling reassortment
between strains of avian and human origins. The results of their 2013 study showed
that while the original isolated virus was a mixture (specifically had two different versions
of 6 of the 8 gene segments), the adaptation to swine led to multiple genetic changes
and to the fixation of a single version on all gene segments. The authors reported that
all the nucleotide differences observed in segment 2 of the adapted virus originated
simultaneously during the adaptation and were therefore the result of reassortment. They
concluded that the wildtype field isolates of duck influenza were most likely the result
of coinfection in the natural reservoir, and are what provided the virus with the genetic
diversity to adapt to the new host system. Using the same experimental setup in 2017,
Bourret et al. studied the functional impact on viral fitness of the genetic changes in the
different segments, as well as their interactions. Their analysis showed that rescued virus
bearing all 8 segments from the adapted virus showed a clear growth advantage over
rescued virus bearing all eight segments from the parental, wildtype virus. The authors
were further able to identify using reverse genetic studies exactly which segments from
the adapted virus had the most positive main effect on viral growth (segments 2 and 4),
and which had only weak or no effects. In 2021 Ganti et al. coinfected mallards and
guinea pigs with H3N8 and H4N6 subtypes (both typical viruses isolated naturally from
mallards) to quantify reassortment and also study the effects of host-species on the
within-host genetic diversity attributed to reassortment [112]. The authors isolated virus
from several different time points during the mallards’ and guinea pigs’ infections and
then performed genotyping of all eight segments to evaluate whether they were from
H3N8 or H4N6 origins. They reported that in all individuals of both species and at all the
time points examined, reassortment was detected, though reassortant genotypes were
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considerably less common in guinea pigs than in mallards. The authors attributed this to
the negative selection of less fit variants and the relatively little opportunity for reassort-
ment since both the avian subtypes used cannot replicate efficiently in mammalian hosts.
It is important to underline that reassortment may also be deleterious, in which case the
resulting viruses are removed by purifying selection [246].
The high mutation rate of influenza alone should lead to a "diffuse cloud of antigenic
types on a variety of genetic backgrounds", as Wikramaratna et al. argue in [309]. An
examination of influenza’s evolution within the last century though shows that the virus
is characterized by the replacement of circulating strains with new distinct strains that
are able to re-infect hosts immune to earlier subtypes [98, 309]. Research has identified
a few different factors that may contribute to this perhaps paradoxical limited antigenic
diversity of influenza:
• New mutants are short-lived because of a nonspecific, strain-transcending immune
response which decays rapidly with the time since last exposure but prevents
reinfection by any new strain [98].
• While the genetic changes of the influenza virus are gradual, the antigenic changes
are punctuated due to complex genetic-to-antigenic change maps [169]. As Koelle
et al. report in [169], the traditional distance metrics which translate the genetic
differences between two strains to the degree of cross-immunity between them
tend to consider strains whose genetic sequences vary by a larger number of
amino acid changes as more antigenically distant. But evidence has shown that
even a single amino acid change can be enough to create an immune-escape
mutant, while as many as 19 amino acid changes can have a very small impact
on the antigenic properties of a new mutant. To account for this Koelle et al.
focused on the epidemiological and evolutionary dynamics of clusters of influenza
strains instead of individual strains, where each cluster consisted of strains that are
antigenically equivalent. This prevented reinfection by strains in the same cluster
and effectively extended cross-immunity until an antigenically novel strain emerged.
• The antigenic distances between strains coupled with the host’s recent immune
history only allow for a small number of predominant phenotypes [30]. Bedford
et al. modelled the genetic and antigenic evolution of influenza in 2012 using a
two-dimensional Euclidean space to describe the antigenic phenotype of each
strain [30]. The concept of strain space and the idea of representing antigenic
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distance as the distance between points in geometric space had already been
investigated by Lin et al. in 1999 [190] and by Gog and Grenfell in 2002 [121].
Bedford et al. used the HI between sampled strains to inform their distance in the
antigenic space. Within this framework various genetically distinct strains occupied
the same position in the antigenic space. As a result, following infection by a certain
strain reinfection was highly unlikely by strains which occupied either the same or
some neighboring antigenic space.
• The host immune response against epitopes of low to intermediate variability that
are shared between strains, together with antibodies targeting highly variable strain-
specific epitopes, generate a network of cross-protection that limits the antigenic
diversity of influenza [249, 309, 322]. This model is referred to as "antigenic thrift"
in the literature. Recker et al. argue in [249] that there is no need for models
to "explicitly represent mutation as a process with many degrees of freedom"
because that requires making assumptions about the manner and rate at which
genetic diversity is generated as well as how it translates to antigenic diversity.
The authors instead developed a multi-epitope model which incorporates various
alleles encoding the dominant epitope regions and further allows for life-long partial
cross-immunity to accumulate as hosts become infected with the different alleles
that define a particular antigenic type. The key immunological parameters that the
authors investigated were the degree of cross-immunity that results from previous
infection by an antigenic type that contains at least one allele in common with
the current challenge strain, and the degree of additional cross-immunity arising
from accumulated exposure to more than one allele. Their results showed that
single-strain epidemics can occur for many different values of these two parameters
and further illustrated that explicitly modeling the mutational process is not required
in order to generate cyclical epidemics and antigenic type switching.
1.1.3 Vaccination
Vaccination is the primary strategy for the prevention and control of influenza outbreaks.
In 1933 Smith, Andrewes and Laidlaw first isolated the influenza A virus from the nasal
secretions of infected patients [276]. In 1936 Burnet discovered that the flu virus can be
grown in embryonated hen’s eggs [101]. These were only two of the many significant de-
velopments that led to the first clinical trials of experimental influenza vaccines beginning
in 1936 [107]. The first inactivated influenza vaccine only targeted influenza A. Much
progress has been made since then and nowadays there are various different types of
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influenza vaccines in circulation.
Two different strategies by which influenza vaccines induce an immune response is
by introducing either killed or weakened viruses into the vaccinated individual. These
result in the inactivated influenza vaccine (IIV) and the live attenuated influenza vaccine
(LAIV) respectively. IIVs contain killed viruses, which cannot replicate within vaccinated
individuals, and are safe for both healthy and immunodeficient individuals. LAIVs on the
other hand contain live virus and are the result of genetic reassortment between some
given wild type and some cold-adapted, temperature-sensitive, phenotypically attenuated
Master Donor Virus (MDV) strains [157, 257]. LAIVs need to replicate within vaccinated
individuals to induce an immune response, and are therefore contraindicated for im-
munosuppressed individuals. The CDC reports that the immune response to an LAIV
is virtually identical to that following natural infection, while an IIV leads to humoral but
little to no cellular immunity and also to diminishing antibody titers against the inactivated
antigens over time.
While the first influenza vaccine targeted only a single strain of influenza A, nowadays
there are vaccines which are designed to immunize against three or four strains of
influenza A and B. The valence of an influenza vaccine refers to the number of strains
it immunizes against. Until a few years ago the most prevalent influenza vaccine was
trivalent and targeted two influenza A strains and one influenza B strain. In 2012 a
new vaccine was introduced which targeted four influenza strains [290]. This quadriva-
lent vaccine protects against two different lineages of influenza B virus (B/Victoria and
B/Yamagata), which in recent years have been co-circulating during most seasons and
have been shown to be so antigenically different that vaccination of immunologically
unprimed children with a strain from one lineage did not induce detectable neutralizing
antibodies to viruses from the other [269]. Despite the progress in vaccine production and
the growth of influenza vaccination programs since the production of the first influenza
vaccine though, the virus’ capacity for immune escape makes the continual update of
current vaccines necessary. Recent advancements in vaccine technology are attempting
to resolve this issue by developing cross-protective and even universal vaccines that
can potentially protect against all influenza strains [238]. Such vaccines aim to raise
antibodies against viral components of influenza that have been shown to be more
conserved compared to the head region of HA and the NA [284], which most current
inactivated vaccines target. More specifically, vaccines that target the head region of
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HA have been shown to reduce susceptibility to infection but also to be strain-specific
and immunodominant, which makes it necessary for them to be updated regularly [221].
Vaccines that target the stalk region of the HA protein have been shown to reduce
susceptibility to infection as well as offer cross-protection within and across subtypes in
animal models [204]. Vaccines that target influenza’s matrix proteins and nucleoprotein
have been demonstrated to reduce viral shedding, offer cross-protection and potentially
reduce disease severity and infectiousness but have no effect on susceptibility (both in
animal models and human challenge studies) [34, 189, 239, 298]. Immunity to these
proteins is mediated by T-cells rather than antibodies [147]. Early work by McMichael et
al. in 1983 suggested that T-cells have a half-life of 3 years [209], while a 2015 study
by van de Sandt et al. found that T-cell immunity can last as long as 10 years [263].
Finally vaccines that specifically target epitopes of limited variability in the head domain
of HA have been shown to be cross-reactive [289]. Mathematical modeling studies by
Arinaminpathy et al. in 2012 [17] and 2020 [18] , Zhang et al. in 2013 [320] and 2014
[321] and Subramanian et al. in 2016 [284] have demonstrated the various beneficial
effects of cross-protective and universal vaccines in controlling influenza’s transmission
and evolution.
In 2012 Arinaminpathy et al. [17] investigated the results of cross-protective vaccines
on the epidemiological and evolutionary dynamics of influenza by incorporatig cross-
protective vaccination to the "epochal evolution" model developed by Koelle et al. in 2006
[169] and then expanded upon by Koelle et al. in 2010 [171]. The epochal evolution
model assumes that HA evolves along a neutral antigenic network and that, while most
substitution mutations do not result in a significant antigenic change, the accumulation of
these genetic mutations can ultimately result in a context-specific mutation that facilitates
immune escape. Arinaminpathy et al. assumed that cross-protective immunity acquired
by vaccination reduces transmission but has no effect on susceptibility. Their results
showed that cross-protective vaccination significantly slows down antigenic drift via its
transmission-dampening effect, which they attributed to two main reasons. Firstly, by
lowering infection prevalence mutants are generated at a reduced rate. Secondly, the
lower cumulative incidence implies fewer individuals with HA immunity acquired via
infection, thereby eroding the transmission advantage of any antigenically novel strain
that might arise. The authors concluded that large scale immunization programs with
cross-protective vaccines can be very effective in limiting both seasonal and pandemic
sizes and slowing down antigenic drift, but also highlighted the importance of existing
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strain-specific vaccines for certain risk groups.
In 2016 Subramanian et al. used a two-component model to directly compare the ef-
fects of two different vaccination programs, one based on conventional strain-matched
vaccines and the other on universal vaccines targeting T-cell antigens, on the epidemio-
logical and evolutionary dynamics of influenza [284]. The first component of their model
described the acquisition of immunity via natural infection and vaccination, while the
second, interepidemic, component described the loss of immunity through antigenic drift,
waning cross-protective immunity and population turnover. Their results showed that
large-scale universal vaccination slows down antigenic evolution by dampening seasonal
transmission and therefore allowing for little strain-specific immunity to drive selection
of new variants. On the contrary, strain-specific vaccines were shown to accelerate
antigenic drift. The authors also showed that both strain-specific and universal vaccines
can reduce seasonal epidemic sizes, but that universal vaccines were more effective at
interrupting transmission. Finally, universal vaccines were shown to reduce the epidemic
size in the case of a pandemic, whereas strain-matched vaccines allowed for an in-
creased pandemic size. This is consistent with experimental findings in a ferret challenge
study by Bodewes et al. in 2011 [37], which showed that vaccination against a seasonal
influenza A strain (A/H3N2) reduced the induction of heterosubtypic immunity against
the highly pathogenic avian influenza A/H5N1. It is important to underline though that
Subramanian et al. concluded that universal vaccines should be considered strategically
complementary to strain-matched vaccines, rather than their replacement. The sterilizing
immunity of strain-specific vaccines is essential for the protection of specific risk groups
such as the immunocompromised and the elderly, while the long-lived cross-protective
T-cell immunity offered by universal vaccines can significantly reduce transmission and
does not contribute to HA selection pressure.
Finally, in a 2020 study Airnaminpathy et al. investigated the potential unintended popu-
lation consequences of universal influenza vaccines [18]. The authors built on previous
work by Arinaminpathy et al. in which they developed a deterministic, compartmental,
age-structured model, which also took into account different levels of prior immunity for
each of the age groups, to describe the effects of vaccination on seasonal influenza
at a national level in the USA [16]. Arinaminpathy et al. incorporated two types of
immunity in their 2020 model. Firstly, HA-specific immunity which is acquired either
via infection or strain-matched vaccination and reduces susceptibility to infection but is
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strain-specific and does not offer any protection against the novel pandemic viruses that
the authors investigated. Secondly, cross-protective immunity which can be acquired
either via infection or a universal vaccine and offers protection across different subtypes,
but does not affect susceptibility to infection. Rather, it is mediated by T-cell immunity
and reduces the viral load during infection thereby reducing transmissibility. The authors
initially simulated a population that undergoes a universal vaccination program and is
then exposed to a seasonal influenza strain, and then tested how such a population
would react to a subsequent pandemic strain. Their results showed that at low levels of
coverage, universal vaccination may actually increase the pandemic size. They attributed
this to the fact that the universal vaccine significantly reduced seasonal incidence (even
at low coverage), thereby allowing for a large pool of individuals who have been neither
vaccinated nor infected and are consequently very vulnerable to an emerging pandemic
strain. At larger coverages though, the authors illustrated that a universal vaccine can
reduce both the seasonal epidemic and the pandemic sizes, relative to the absence of
vaccination. The authors further studied how a population which has already undergone
a seasonal vaccination program, either with a strain-matched or a universal vaccine, as
well as a seasonal epidemic, would react to a universal vaccine escape variant. They
defined such an escape variant as a virus showing vaccine escape to all the antigenic
targets of a universal vaccine but still remaining susceptible to HA-specific immunity. The
authors underlined that recent research has demonstrated that single mutations can
affect escape both from narrow and broad antibodies against HA [86] and therefore the
possibility of such universal vaccine escape variants emerging should not be overlooked.
In the case where the vaccination program was simulated using strain-matched vaccines
the authors found that the two epidemics, the seasonal one and the subsequent escape
variant one, are of comparable size. But in the case where the vaccination program was
simulated with a universal vaccine, while the first epidemic size was smaller compared to
the case of vaccination with a strain-specific vaccine, the subsequent epidemic brought
on by the escape variant was considerably larger. The authors therefore concluded
that a vaccination program which combines conventional, strain-matched vaccines with
universal vaccines could offer the best protection, especially at large coverages.
It is important to have the appropriate terminology to describe the effects of a vaccine. As
Shim and Galvani point out in [271], the terms vaccine efficacy and vaccine effectiveness
are sometimes used interchangeably in the modeling literature. For the sake of clarity
and consistency, throughout this thesis we will refer to the reduction in susceptibility
of vaccinated individuals as the vaccine efficacy. We will use vaccine effectiveness
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to refer to the reduction in the transmission rate of an average individual in a popula-
tion that consists of both vaccinated and fully susceptible individuals compared to the
transmission rate of an average individual in a population that consists only of fully
susceptible individuals. These definitions are in accordance with [271] and will be useful
to our work because they highlight that efficacy refers only to a single-host level while
effectiveness also takes into account the indirect protection offered both to vaccinated
and unvaccinated individuals as a result of the lower infection prevalence in a population
with a vaccination program. A vaccine’s effectiveness is often estimated using a case
test-negative design, which is defined in the following way [109]. The study subjects
are patients who visit medical institutions due to influenza-like illness (ILI) during the
influenza season. Those who test positive for influenza are classified as cases and those
who test negative as controls. Since the number of individuals who have already received
the vaccine is known for each category, the vaccine effectiveness (V E) is then calculated
as V E = (1−vaccination odds ratio)×100%.
Routine annual vaccination against influenza is now a standard measure as part of many
countries’ public health programs. Despite the success of vaccination in reducing the
burden of influenza, vaccines do not affect all individuals equally. The vaccine-induced
protection is critically dependent on an individual’s immune status and history. For in-
stance, antibodies from a previous exposure can inhibit the effects of the vaccine. This
heterogeneity in the strength of the vaccine-induced immunity leads to varied levels
of vaccine efficacy among vaccinated individuals, and could even lead to as many as
60-70% of elderly or immuno-compromised individuals having little to no response to the
vaccine [3]. Moreover, the vaccine-induced protection may be hindered by the antigenic
drift of the virus. In the Northern hemisphere, where the flu season is from November
to April, the decision of which strains the next season’s vaccine is going to include is
made by the WHO by February of the current season. This is necessary in order to give
adequate time for the vaccine manufacturing and distribution process, but also means
that the virus has enough time to undergo antigenic changes. Anti-influenza drugs, such
as oseltamivir, have also been developed but vaccination still remains the main method
of controlling influenza.
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1.2.1 Between-host models
The study of infectious disease data began with the work of John Graunt in his 1662 book
"Natural and Political Observations made upon the Bills of Mortality", as Brauer reports
in [48]. The Bills of Mortality were weekly records of numbers and causes of death in
London parishes which began in 1592 and were then kept continuously from 1603 on.
Infectious disease modelling also has a very long history, starting with the pioneering
work of Daniel Bernoulli in 1760 [33]. Bernoulli developed what is regarded as the first
epidemic model in order to study the benefits of inoculating against smallpox based on
data regarding its incidence and case fatality, as well as the safety of variolation. Many
years after that the public health physician Sir Ronald Ross developed what eventually
became one of the most influential modeling frameworks in epidemiology. In the second
edition of his book The Prevention of Malaria published in 1911, Ross introduced a simple
compartmental model to study the dynamics of the transmission of malaria between
mosquitoes and humans. At the time it was generally believed that malaria could not be
eliminated so long as mosquitoes were present in a population. Ross instead showed
that reducing the mosquito population below a critical threshold would be sufficient to
eliminate malaria, and subsequent field trials supported his results, leading to significant
advancements in malaria control. More specifically, as Bacaër reports in his book A
Short History of Mathematical Population Dynamics [23], one of the mathematical models
published by Ross in 1911 consisted of a system of two differential equations, one to
describe how the number of humans infected with malaria I(t) varies with time and one to
describe how the number of mosquitoes infected with malaria i(t) varies with time t. Ross
considered the non-trivial steady state solution to his system of equations and found an
expression for a critical threshold n⋆ for the mosquito population, above which I > 0 and
i > 0 and therefore the disease becomes endemic. He concluded that if the total number
of mosquitoes n is reduced below this critical level n⋆ then the only remaining steady
state of his system would be the trivial one, namely I = 0 and i = 0, and therefore malaria
would be eradicated. It is of particular importance that Ross’s work showed that it is not
necessary to exterminate all mosquitoes in a population in order to eliminate malaria.
In a sequence of three papers between 1927 and 1933 [163–165], Kermack and McK-
endrick extended Ross’ work on compartmental disease models by introducing new
ideas such as the stochastic aspect of infection and recovery and generalizing already
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published ideas such as the effects of an individual’s age of infection, which had already
been introduced by Ross and Hudson in 1917 [260]. In what is nowadays referred to as
the standard Susceptible-Infected-Recovered (SIR) model [90], susceptible individuals
S come into contact with infected individuals I and become infected at a constant per-
capita rate β . Infected individuals recover after an average of 1/ν days, having gained
full immunity. It is assumed that the initial population of N individuals remains fixed
and that there are no births or natural deaths. While this model has become known
as the Kermack-McKendrick epidemic model, it is actually only a special case of their
1927 model [163]. In the more general model both the infectiousness and the recovery
rate depend of the time since infection. We will present the SIR model in more detail
in chapter 2, where we will extend it to study the spread and evolution of influenza
in a heterogeneous population that consists of fully susceptible as well as vaccinated
individuals.
The concept of R0
An important parameter in disease modeling is the basic reproduction number of a
pathogen, which is denoted as R0 and defined as the expected number of secondary
cases per primary case in an otherwise uninfected population. Dietz reports in [79] that
the concept of R0 goes back to demography, where it is called the net reproduction rate,
and can be found in publications as early as 1886. Macdonald adapted it and introduced
the "basic reproduction rate" to epidemiology in 1952 [202] in the context of malaria.
In 1964 Smith used Macdonald’s definition of R0 to calculate the minimum population
proportion that needs to be vaccinated to stop the transmission of arboviruses. In 1990
Diekmann, Heesterbeek and Metz developed a mathematically rigorous framework for
R0 and proposed to name it the "basic reproduction number" instead of "rate", as it is
dimensionless [76].
As Heesterbeek argues in [149], "the most fundamental step in the development of R0 in
epidemiology was taken in the seminal paper by Kermack and McKendrick in 1927", even
though they did not attach a symbol or a name to their threshold concept. Heesterbeek
enumerates the assumptions made by Kermack and McKendrick in their 1927 paper
[163]:
1. A single infection triggers an autonomous process within the host.
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2. The disease has only two possible outcomes: complete immunity or death.
3. Contacts are according to the law of mass-action.
4. All individuals are equally susceptible.
5. The population is closed.
6. The population size is large enough to justify a deterministic description.
Let S(t) be the density of susceptibles in the population at time t. The time that has
elapsed since an individual became infected is called the infection age and denoted by τ .





A(τ)Ṡ(t − τ)dτ (1.1)
where Ṡ represents dSdt and A(τ) is defined as the expected infectivity of an individual with
infection age τ . To better understand this equation we note that given the closedness of
the population the quantity −Ṡ(t) is precisely I(t,0), which is the density of new infected
individuals emerging at time t. This leads to:
−Ṡ(t − τ) = I(t − τ,0) = I(t,τ)
where I(t,τ) describes the incidence of infected individuals at time t who have been











A(τ)I(t − τ,0)dτ (1.3)






is called the force of infection and describes the per capita probability per unit time to
become infected. In order to obtain a formula for R0, we may consider the steady state at
the absence of an infection. Then S(t) in equation (1.1) may be replaced with the constant
S0, which denotes the density of the population at the start of the epidemic where every
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If we assume as in the SIR model that the per capita transmission rate β and recovery
rate ν remain constant both over the real time t and the infection age τ , and that the
probability that an infected individual remains infectious at infection age τ follows an
exponential distribution, then A(τ) is given by the expression:
A(τ) = βe−ντ
Substituting this into equation (1.4) and performing the integration leads to the well known




We note that given the simplicity of the SIR model we may also arrive at the same
expression for R0 in a more intuitive way. Since an infection lasts for an average of 1/ν
time units and an infected individual transmits the disease at a per-capita rate β , then
each infective makes on average βS0 successful transmissions per unit of time and does




The R0 can be used to answer critical questions such as when will a primary case lead
to an epidemic. It is straightforward to show that the disease will spread if R0 > 1 and will
go extinct otherwise. We will demonstrate this in chapter 2, where we will give a more
detailed analysis of the SIR model and its properties.
Evolution at the between-host level
In 1987 Pease argued that a significant obstacle to modeling influenza using simple com-
partmental models such as the classical SIR is antigenic drift [228]. Influenza outbreaks
are often characterized by the co-circulation of interacting strains with different pheno-
types, where infection by one strain might lead to various degrees of cross-protection
from other strains. It is therefore important to understand the factors that drive strain
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turnover and evolution.
In 1981 Levin and Pimentel published a paper in which they investigated the compe-
tition between two types of parasites for available hosts [188]. Since then this type of
"competition for available hosts" model and its extensions have been used extensively
in the influenza modeling literature to describe the effects of the competition between
co-circulating strains. As Kucharski et al. report in [177], early models assumed that
infection from one strain confers total immunity to the other for the duration of the infection.
In 1964 Elveback et al. studied the competition dynamics between two strains under
this assumption of total interference by extending the discrete, single-strain Reed-Frost
epidemic model [93]. In 1979 Dietz adapted the 1964 Elveback et al. model to continuous
time, extended it to include population birth and death rates and then studied the steady
states of the resulting system and their stability [78].
Motivated by the cross-protective immune responses induced by natural infection with a
given strain of influenza, Castillo-Chavez et al. in 1989 [54] and Andreasen et al. in 1997
[14] extended the classical SIR model to allow for the co-circulation of cross-reactive
strains where infection by one strain leads to partial cross-immunity from the others. In
their 1989 paper, Castillo-Chavez et al. studied a two-strain discrete-time model that
included partial cross-immunity, age structure and age-specific mortality. The authors
found that the model exhibited very complicated dynamics, such as damped oscillations,
sustained periodic behavior and chaotic behavior. Motivated by the difficulty in analyzing
such a model, the authors also extended the Dietz-Elveback continuous time model for
homogeneous populations to include different degrees of cross-immunity.
In 1994 Gupta et al. and Gupta and Day investigated the impact of the antigenic diversity
of malaria on the parasite’s transmission dynamics [126, 129]. The authors report that
the average age of humans at their first infection with malaria is typically less than 1 year
in most endemic areas, and that this has been interpreted as evidence of the parasite’s
high transmissibility. A different interpretation though, which can also explain why there
can be a high risk of infection and prevalence even when the parasite transmissibility is
low, is that a long period is required to develop immunity due to the antigenic diversity
of the parasite. In this framework, immunity is acquired only after exposure to many
different circulating strains. Gupta et al. developed an age-structured model which
consisted of a system of partial differential equations and incorporated overlapping
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categories of immune and exposed hosts and applied it to epidemiological data of five
antigenically distinct strains, collected in a highly malarious area of Papua New Guinea.
Their results showed that infection by a given malaria strain induces some degree of
strain-specific, infection-blocking immunity and that reinfection is often a consequence of
exposure to different, independently transmitted strains (though this does not preclude
the possibility of reinfection with the same strain). In 1998 Gupta et al. demonstrated that
the co-circulation of several antigenically diverse pathogens can result in very complex
dynamics [127]. The authors showed that a sufficiently small level of cross-immunity
led to all strains coexisting in the host population with stable abundance. A sufficiently
high level of cross-immunity on the other hand led to stable discrete strain structure,
which was characterized by a set of strains which share no alleles (and are assumed
to not interfere with each other’s transmission or within-host fitness) dominating the
population. Finally, at intermediate levels of cross-protection the authors found no stable
strain structure. Instead, the relative proportions of the different strains exhibited cyclical
or chaotic dynamics. In 1999 Lin et al. used a simpler "linear three-strain model", in
which one of the strains confers partial cross-protection to the other two while these
two induce no reciprocal cross-reaction, to show that herd immunity alone can lead to
sustained oscillations in the case of influenza A [190].
A major drawback of various multi-strain models is that their analysis can become very
complicated as the number of strains increases. In 2002 Gog and Grenfell developed
a model that was capable of capturing the dynamics of a large number of antigenic
strains under the assumptions of reduced transmissibility and polarized immunity, which
states that partial cross-immunity acts to render only some of the hosts totally immune
[121]. The authors initially used a linear strain space to describe the mutation and cross-
immunity interactions between strains, but also studied the effects of a two-dimensional
strain space. Their results showed that, given a short-infection/long host-lifetime time
scale, strains occur in clusters but are transient due to strain-specific immunity accumu-
lating and mutation giving rise to increasingly distant strains.
Many early multi-strain models assumed that strain turnover is mediated by the loss of
immunity due to the birth and death of hosts. The Pease Susceptible-Infective-Recovered-
Susceptible (SIRS) model published by Pease in 1987 [228] assumed instead that strain
turnover is governed mainly by the frequent introduction of novel genetic variants in the
population to which hosts only have partial immunity. This shift in perspective has proven
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to be very influential in the field of evolutionary epidemiology. As Andreasen and Gog
report in their review of Pease’s 1987 paper [13], the Pease model was actually the "first
epidemic model that could account for how the association between influenza and its
human host evolved over long periods" and "hinged on the view that the epidemiological,
immunological and evolutionary dynamics cannot really be separated". We note though
that Pease assumed that only one strain may circulate in the population at any given
time. Motivated by Pease’s evolutionary model and by experimental data which showed
that the probability of recovered individuals being reinfected by new circulating strains
increases linearly with the time since last infection, Casagrandi et al. developed the
Susceptible-Infective- Recovered- Cross-immune (SIRC) model in 2006 [53]. The new
compartment C describes individuals who have already been infected by a given strain
and are therefore partially protected from antigenically similar strains. Given a dominant
circulating strain, individuals in R are those who recovered from the dominant strain and
are currently completely immune to it. After some period of time though, those individuals
move to the C class because they now only have partial immunity to the new dominant
strain that has emerged since they were last infected. The resulting framework of a
moving frame in immune space is exactly the same as in Pease’s approach. In 2004
Grenfel et al. created the term "phylodynamics" to describe the melding of epidemiology,
immunodynamics and evolutionary biology [125].
1.2.2 Within-host models
In recent years the advancements made in quantitative virology have helped the devel-
opment of mathematical models which can describe the dynamics of influenza within a
particular host or cell culture. This within-host modeling of influenza viruses has such a
relatively short history that in fact, according to Baccam et al. in [24], prior to 2006 there
appear to have only been three papers written in English on the dynamics of influenza
within a single host. The first of these was in 1976, and introduced a compartmental
model of influenza A dynamics in experimentally infected mice [182]. While the model
captured well the trajectory of the viral load during the course of the infection, its compart-
ments did not correspond to the host immune response and therefore could not explain
how immunological factors affect viral dynamics. The second paper was published in
1994 and introduced a model that was a system of ten ordinary differential equations
(ODEs), each describing the dynamics of cells that are involved in the immune response
[36]. The drawback was the number of parameters, which was more than sixty due to
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the author’s attempt to capture the complexity of the human immune system. The third
paper was published in 2005 and introduced a cellular automaton model that described
the effects of spatial heterogeneities in the spread of influenza A within a single infected
host [27].
A significant amount of experimental and mathematical research has been done on the
within-host dynamics of influenza since the work by Baccam et al. in 2006. Here we
will briefly review the general form of one of the simplest and most influential models of
within-host influenza kinetics published by Baccam et al. in 2006 [24]. We will refer to
this model as the TIV model throughout this thesis. In this section we will only describe
the model and mention some of its properties. In chapter 3 we will go into more detail
regarding the TIV model, since we will use it as the foundation of a within-host model we
will develop to study the dynamics and evolution of influenza within-host. The TIV model
consists of a series of ODEs that describe how the populations of target cells, infected
cells and virions change throughout an individual’s infection. Target cells T become
infected by virions V at some rate β and enter the infected compartment I. Infected cells
I release new progeny virions at some rate p and die at some rate δ , which means that
their lifespan is exponentially distributed with a mean of 1/δ days. It is assumed that
infected cells start releasing new virions as soon as they become infected. Finally free
virions that are circulating within the host are cleared by the immune system at some
rate c. The immune response is incorporated implicitly in the TIV model via the death
rate of infected cells δ and the clearance rate of free virions c, and is assumed to be
constant throughout the infection.
The TIV model could be considered the within-host conceptual analogue of the classical
SIR model from population disease modeling. The target cells can be mapped to the
susceptible hosts at the between-host level and the infected cells to the infected hosts.
Moreover in the TIV model infection always leads to cell death, which is mathematically
equivalent to infection leading either to host death or to recovery with no chance of
reinfection in the context of the SIR model. Finally the infection of target cells by virions
in the TIV model and the inability of infected cells to directly infect other cells can be
mapped to the infection pathway of a vector-borne disease in the between-host context.
Both models have been very influential in the influenza modeling literature, partially
because they can be used to extract a great deal of information about the research topics
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at hand while maintaining their simplicity.
Similarly to population disease modeling, an important parameter in within-host disease
modeling is the basic reproduction number R0, which in this context is defined as the
average number of secondary infections that would be caused by the introduction of a
single infected cell into a population of fully susceptible cells [195]. We note that this
definition is equivalent to the population-level R0 which we defined earlier in section
1.2.1. The TIV model’s simplicity means that the R0 can be obtained by multiplying the
number of free virions that an infected cell produces over its lifespan by the number of




where T0 denotes the initial target cell population.
The TIV model has proven to be a very powerful tool in analyzing within-host influenza
dynamics [65]. This is partially because the simplicity of the model agrees with the sim-
plicity of viral titer curves, which have been shown experimentally to grow exponentially
until they reach a peak and then decay exponentially [28]. More complex models have
been developed, and we will briefly discuss some of them here.
In 2006 Baccam et al. added a delay in the virion production by infected cells [24]. This
latency phase, which is often denoted E in the literature, occurs between the infection of
a target cell by a virion and the production of new virions by the newly infected cell. We
will refer to the TIV model with delay as the TEIV model throughout this thesis. Hancioglu
et al. in [136] and Lee et al. in [185] attempted to incorporate the complexity of the
immune response into the TIV model and considered, among others, the actions of
cytotoxic T-cells, antibodies and antibody-producing plasma cells. While their models
are more biologically accurate than the much simpler TIV model, their results are limited
by overparametrization. This is an inherent issue with within-host models of this form,
since obtaining the appropriate experimental data to inform the model parameters is very
difficult given the many different and interacting layers of the immune response. Therefore
many researchers have opted for a better balance in this trade-off between capturing
biological complexity and inferring parameters from data. In 2010 Saenz et al. extended
the TEIV model by explicitly incorporating the innate immune response via the action of
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type I interferon (IFN) [262] and tested it using a dataset of viral load and infected cell
levels in horses. Their results showed that the inclusion of IFN alone was enough to de-
scribe the disease dynamics, whereas a model without it could not fit the data adequately.
A different class of TIV-based models are those which consider cell tropism, defined
as the degree to which different types of host cells support viral replication. In 2010
Dobrovolny et al. extended the TEIV model to include two different target cell populations,
a default and a secondary [83]. The authors’ motivation was to capture the preferential
binding of different influenza strains to cells depending on the presence of certain re-
ceptors on their surface. They also used their model to implicitly capture the immune
response by having the secondary target cell population represent cells that are protected
from infection at various degrees. In 2012 Reperant et al. investigated the effects of
spatial structure and cell tropism by developing a TIV-based model with two different
target cell populations (which also included the actions of interferon, cytotoxic T cells
and antibodies) and applying it to three different respiratory compartments [253]. Each
compartment was characterized by its unique set of initial conditions, which included the
initial target cell population and the virus clearance rate and pathogenicity. The authors
allowed virions and interferon to flow between compartments. Their work described
how influenza spreads in a spatially-structured respiratory tract and shed light into the
different ways that disease progression may occur.
Evolution at the within-host level
Theoretical and experimental research has shown that within-host evolution can have
strong effects not only on the disease expression within the infected individual but also on
the epidemiology of pathogens [5]. A common strategy to study evolution in vitro, which
we also use in this thesis, is to model a within-host infection with two or more competing
strains [5, 229, 235, 252]. The strains are often assumed to be phenotypically distinct,
and can differ in traits such as their replication rate or virulence. Depending on the
research question at hand, the strains might be introduced into the host at the same or
different times during the infection or the infection might start with only a resident or wild
type strain present and a mutant strain might emerge stochastically later in the infection.
This strategy is easy to implement with TIV-like models because it simply requires the
model to be broken down into sub-compartments which correspond to the different viral
strains.
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1.2.3 Cross-scale models
So far we have briefly presented some published models which have been vital for the
understanding of disease dynamics either at the between- or the within-host scale. A
generic way to define and differentiate these two scales is that between-host models
describe the dynamics of a disease by keeping track of the number of susceptible and
infected individuals in a population, while within-host models describe how a disease
spreads within one infected individual, usually by following the number of target cells,
infected cells and virions inside the host (at minimum). But researchers have made the
observation that the transmission of a virus is largely affected by the disease expression
within infected individuals, which is in turn determined by the within-host viral dynamics.
This has led to the development of models which link the between- and within-host scales.
We will refer to these as cross-scale models throughout this thesis, but we note that they
are often called nested models in the literature [68, 119, 210].
For the purposes of this thesis, we will focus on cross-scale models which explicitly link
within- and between-host dynamics. As a result we require cross-scale models to include
an explicit dynamical model at the within-host scale, so the equations which describe
the between-host dynamics need to keep track of the age of infection. This is because
between-host parameters such as the transmission rate, the virulence and the recovery
rate need to rely explicitly on within-host quantities such as the viral load and the number
of healthy target cells, which change throughout an individual’s infection. We note that
various models have been published which consist of a population-level model that only
implicitly depends on within-host processes. While such models are not the primary
focus of this thesis, they have yielded insightful results and we will give a short overview
of some of them.
We will briefly discuss some of the earliest cross-scale models which do not explicitly
link the within- and between-host scales. In 1994 Nowak and May published a model for
the evolution of parasitic virulence which included superinfection [219]. They extended
an SI-type model to include superinfection by adding multiple infectious compartments
that corresponded to a variety of parasites, each with a different virulence value. Nowak
and May assumed that in the case of a superinfection a more virulent strain always takes
over a host infected by a less virulent strain. Therefore while they did not explicitly con-
sider the within-host competition dynamics between parasites of different virulences that
infect the same host, their definition of superinfection still inherently relied on within-host
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processes and had an effect on between-host transmission. It is interesting to point out
that even with this arguably simple definition for superinfection, Nowak and May’s model
still exhibited some very complicated dynamics. In 1995 May and Nowak published a
model for the evolution of parasitic virulence that included coinfection [206]. The authors
again extended an SI-type model to include multiple infectious compartments which
corresponded to different parasites invading a population. They assumed that individual
hosts can be coinfected by a number of different parasites with different virulence values
and that there is no competition among the different parasites within the same host. In
their model the infectivity of each parasite was completely unaffected by the presence of
other parasites in the same host. As May and Nowak pointed out in their 1995 paper, their
superinfection [219] and coinfection [206] models "represent the two opposite extremes
in situations where hosts experience multiple infection with many different strains of a
parasite". It is not surprising then that they yield very different results when it comes to
the number and virulence range of persisting parasites.
We will now briefly present some published work in cross-scale modeling and discuss
its findings. Our goal here is to highlight some interesting results which suggest that
cross-scale models can be crucial for the understanding of influenza’s dynamics, but also
to point out some of the challenges inherent to cross-scale modeling.
In 2009 Chen et al. published a paper in which they investigated the effects of within-
host viral kinetics and exhaled droplet size on the indoor transmission of influenza [63].
The authors utilized a within-host TIV-type model to obtain the viral load throughout an
individual’s infection with influenza A. They then defined a droplet generating function
for the amount of a host’s exhaled virus-carrying bioaerosol droplets per time, which
depended on the within-host viral load as well as the size and number of exhaled particles
either via coughing or sneezing. The amount of a host’s exhaled droplets per time was
then used to obtain a between-host transmission rate that depended on the age of the
infection. Therefore the authors’ droplet generating function was key to their model’s
results, as it provided the link between the within-host viral load and the population-level
transmission rate. The authors used experimental data to fit this function, and found
that a linear dependence on the viral load gave satisfactory results. As they pointed
out though, their results are difficult to validate due to the scarcity of experimental data
on the amount of exhaled virus-carrying droplets in indoor environments. A similar
breath plume model published by Halloran et al. in 2012 also found that a linear relation
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between the viral load and the concentration of exhaled pathogens per unit volume of
air could capture well a different empirical dataset [134]. It is interesting to note though
that in a 2020 study Leung et al. reported that the majority of influenza patients they
tested did not shed any PCR-detectable virus in respiratory droplets or aerosols during a
30-minute breath exhale collection [187]. The few patients that shed virus only did so
in very low amounts and some of them did not cough at all during the procedure. As
the authors highlight, such a finding could indicate that transmission via the inhalation of
viral particles requires prolonged closed contact. It also implies that further experimental
testing is needed to quantify the effects of coughing and sneezing. An earlier study
published by Yan et al. in 2018 found no detectable viral RNA in respiratory droplets
in the majority of influenza patients tested, but detected influenza RNA in fine aerosols
in the majority of patients [317]. We note that both sets of researchers used the same
human source bioaerosol sampler (named Gesundheit-II) for their 30 minute breath
exhale collections and both used reverse transcription PCR to quantify the viral RNA
in the breath samples. The discrepancy in their findings further highlights the need for
additional experimental testing on the amount of viral load in exhaled breath, coughs and
sneezes. Accurate estimates of this could offer very valuable insight into the link between
viral shedding and infectiousness, and would therefore have a significant impact on cross-
scale models such as the ones we discussed by Chen et al. [63] and Halloran et al. [134].
In 2013 Handel et al. used a cross-scale model to study the effects of temperature on the
between-host fitness of various strains of influenza A [137]. To describe between-host
transmission they used a system of coupled differential equations which kept track of the
age of infection and which could also take into account both direct and environmental
transmission routes. The authors used a TIV model to inform the between-host transmis-
sion rate as a function of the age of infection. More specifically they considered three
different scenarios: the transmission rate being a linear function of the within-host viral
load, the transmission rate being proportional to the logarithm of the viral load and the
transmission rate being proportional to the viral load multiplied by total amount of shed-
ding (the latter was described as a sigmoid function of the viral load). The authors cited
previously published experimental work to justify all three scenarios. Based on these
they developed different expressions for the population-level R0 of the virus and used
them as a measure of the virus’ between-host fitness. Their analysis showed evidence
for a trade-off between virus persistence at low vs high temperatures. Depending on
the main route of transmission (direct or environmental) and the presumed link between
the transmission rate and the viral load, the authors showed that strains which had high
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persistence at high temperatures and therefore reached high viral loads within-host were
in some cases less fit at the population-level than strains which had a smaller persistence
at high temperatures, and thus were not able to replicate as effectively within-host. This
work illustrates a significant advantage of cross-scale models, namely that they offer a
way to directly compare the effects of factors from different scales on the question at hand.
It further highlights the cross-scale models’ usefulness when investigating competing
selection pressures from different scales, since in this case single-scale models might
even fail to give accurate qualitative predictions. Handel et al. emphasized the need for
further experimental data in the discussion section of their paper. We note that this is
a common issue with cross-scale models, as they require appropriate data from both
the between- and within-host scales. The results of Handel et al. are sensitive to the
presumed relationship between the transmission rate and the viral load, but the scarcity
of experimental data makes all three of their choices reasonable. Therefore, it would be
very difficult to use their results in order to make accurate quantitative predictions. This
is not a criticism of the authors’ work though, as their analysis was not aimed at mak-
ing quantitative predictions. We simply highlight the difficulty in obtaining experimental
datasets that can accurately inform cross-scale models.
1.3 Thesis Motivation
There are two key papers which motivated this thesis, and the aim of both was to discuss
some interesting open problems in disease modeling. The first was published by Gog et
al. in 2015 and reviewed some of the main challenges in modelling pathogen dynamics
both within-host and across-scales [122]. The second was published by Wikramaratna
et al. also in 2015 and focused on the main challenges in modeling interacting strain
dynamics [308].
Some of the key questions that have been inspired by these papers and that this thesis
aims to answer are:
• How does vaccination with a strain-specific vaccine affect the spread and evolution
of influenza within-host, between-host and across scales? This is the main question
that drives our work.
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• Is the explicit linking of the scales necessary to describe the effects of the com-
peting factors from different scales which determine how vaccination affects the
epidemiological and evolutionary dynamics of influenza? Can we capture the same
dynamics using a simpler single-scale model?
• How can we simulate efficiently a computationally intensive cross-scale model?
• Given the scarcity of empirical data, how can we model the within-host emergence
of a mutant influenza strain? Is it enough to use a TIV model with two-strain
structure? If not then what are the minimum extensions necessary (innate immunity,
adaptive immunity, spatial structure)?
1.4 Thesis Summary
One of our main goals in this thesis is to develop a cross-scale vaccination model for the
epidemiological and evolutionary dynamics of influenza within a single season. We will
model the evolution of influenza as the emergence and subsequent growth of a mutant
strain, either at the within- or the between-host scale. We are particularly interested in
comparing the results of our cross-scale vaccination model to those of a between-host
vaccination model that describes the population-level emergence dynamics of a mutant
strain and the subsequent competition dynamics with its parent resident strain.
In Chapter 2 we will develop a two-strain SIR model that includes vaccination and de-
scribes the emergence dynamics of a mutant strain in the population as well as the
competition dynamics with its parent resident strain. We will initially treat the appearance
time of the mutant strain as a fixed parameter of our model and study its effect on the
spread and final size of the mutant. Afterwards we will develop an expression for the
probability of a mutant strain emergence at any given time throughout the epidemic. Fi-
nally we will vary the efficacy of the vaccine against each strain as well as the vaccination
coverage to identify which conditions are the most beneficial for the emergence and
successful spread of a mutant strain in the population.
In Chapter 3 we will develop a two-strain within-host model to describe the emergence
dynamics of a mutant strain and its subsequent competition dynamics with the parent
resident strain. We will begin by extending the TIV model published by Baccam et al. in
2006 [24] to include two strains and investigate how the within-host time of appearance
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of the mutant strain affects its survival and growth. Our analysis of the two-strain TIV
model will motivate us to adapt a slightly more complicated model published by Saenz
et al. in 2010 [262] because it incorporates explicitly the action of the innate immune
response. We will extend the Saenz model to include two strains and examine how the
additional components of our extended Saenz model change the emergence dynamics
of the mutant strain. We will then develop an expression for the within-host emergence
density of the mutant strain and finally we will add vaccination to our two-strain Saenz
model and show how it affects the emergence and subsequent competition dynamics
between the two strains.
In Chapter 4 we will develop a cross-scale model to describe the epidemiological and
evolutionary dynamics of influenza within a single season, which does not yet incorporate
the effects of vaccination. The model that we will use as the foundation of our own cross-
scale model was published by Coombs et al. in 2007 [68]. Our cross-scale model will link
explicitly the between- and within-host scales via the between-host transmission rates,
which we will assume are linear functions of the within-host viral load. The between-host
tier of our cross-scale model will be a simple SI model while the within-host tier will be our
extended Saenz model. Our analysis will initially focus on how the within-host parameters
affect the population-level fitness of the two strains. We will then examine closely how the
within-host emergence time and the age of infection affect the between-host transmission
rates, as this is what differentiates our cross-scale model from standard population-level
models that only consider constant transmission rates. Finally we will study our model’s
results using three different functional forms for the within-host emergence density of the
mutant strain.
In Chapter 5 we will incorporate vaccination to our cross-scale model. We will capture
the effects of vaccination simply as an increase in one of the within-host strain-specific
parameters, specifically the viral clearance rates for the resident and the mutant strains.
Then by varying the within-host clearance rates as well as the vaccination coverage, the
fitness of the mutant strain, the within-host mutation rate and the assumed form of the
within-host emergence density we will study the resulting impact on the final sizes of
the two strains in the population and identify which conditions promote the within-host
emergence and growth and subsequent population-level spread of a mutant strain.
Chapter 2
A between-host model for the
evolution of influenza
2.1 Introduction
In this chapter we will present a population-level model for the epidemiological and evolu-
tionary dynamics of influenza. We will develop a model which describes the emergence
dynamics of a mutant strain in a population during a single influenza season, and the
subsequent competition dynamics with its parent resident strain. We will further examine
how vaccination affects the emergence potential and growth of the mutant strain and
arrive at the perhaps counter-intuitive conclusion that intermediate values of immunopro-
tection are the most beneficial for the emergence and spread of the mutant.
2.2 Background
We will first present the well-established SIR model, which we will use as the foundation
of our own model in section 2.3. We discussed the SIR model in chapter 1, but in
section 2.2.1 we will explore it in further detail and analyze some of its key results. Then
in section 2.2.2 we will discuss a published extension of the SIR model that includes
vaccination.
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2.2.1 The classical SIR model










with the initial conditions
S(0) = S0 ∈ R+, I(0) = I0 ∈ R+ and R(0) = R0 ∈ R+
Here S(t) denotes the fraction of susceptible individuals in the population at time t,
I(t) the fraction of infected individuals and R(t) the fraction of recovered individuals. The
total size of the population is N = 1 and remains constant throughout the duration of
the epidemic. The parameter β > 0 is the transmission rate of the disease, and is often
regarded as the product of the contact rate and the probability of infection given a contact
with an infectious individual. The parameter ν is the recovery rate of infected individuals,
from which it follows that 1/ν is the average length of the infectious period. We note
that there is an equivalent formulation of the SIR model where N > 1, S(t), I(t) and
R(t) represent numbers of individuals and the units of the transmission rate β and the
recovery rate ν are per-capita. However in this chapter we will use the N = 1 formulation.
The classical SIR model is based on a number of underlying assumptions:
• The only way that an individual can leave the susceptible compartment is to become
infected, and the only way that an individual can leave the infected compartment is
to recover. Therefore the total population S(t)+ I(t)+R(t) = N = 1 is fixed.
• Those who recover from the disease gain full immunity.
• The transmission rate is constant among all individuals of the population because
all members of the population mix homogeneously with one another, and each
member has exactly the same probability of becoming infected given a contact with
an infected individual.
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• The infectious period is exponentially distributed with a recovery rate that is con-
stant among all infected individuals. Therefore variables such as age, sex, social
structure and age of infection do not have any effect on the dynamics of the disease.
It is interesting to note that Kermack and McKendrick’s general epidemic model
in [163] allows for a dependence on the age of infection, which in turn allows for
recovery rates that are not exponentially distributed.
We will now present some established results of the SIR model. This is because we will
derive some similar results for our extended SIR model in section 2.4. As we mentioned
in chapter 1, one of the most important epidemiological parameters in infectious disease





where β is the rate at which new cases are produced by an infectious individual in a fully
susceptible population (N = S(0) = 1) and 1/ν is the average infectious period.
In order for an epidemic to occur the number of infected individuals needs to increase at
the onset. This is equivalent to requiring dI/dt > 0 at the initial stages after I(0) infectives





and since at the outset of the epidemic it is valid to approximate S(0) = 1, then the
disease can invade if and only if
R0 > 1
2.2.2 Adding vaccination to the classical SIR model
We will now discuss an extension of the SIR model that includes vaccination. Vaccination
can be incorporated into the classical SIR model via the simple addition of a new compart-
ment, usually named V , designated to keep track of the fraction of vaccinated individuals
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in the population. Some of the earliest SVIR models appear in [3, 19, 176, 194, 271],
though the history of incorporating vaccination in epidemiological models is considerably
longer [9, 80]. An example of an SVIR model for an acute infection in a closed, homoge-













with the initial conditions
S(0) = S0 ∈ R+, V (0) =V 0 ∈ R+, I(0) = I0 ∈ R+ and R(0) = R0 ∈ R+
The SVIR model presented in equations (2.4)-(2.7) is a simplification of the original SVIR
model by Alexander et al. in [3]. This is because we chose to present the portion of
the Alexander SVIR model that will be relevant to our own SVIR-type model, which
will be presented in the next section. We note though that the Alexander SVIR model
from [3] further incorporates the recruitment of new individuals to the population via
birth and immigration, as well as the reduction of individuals due to natural death and
emigration. Here we omitted the relevant terms because in our own SVIR-type model
we will assume that the population remains closed during the epidemic. Moreover, the
Alexander SVIR model considers the effects of waning immunity. Here we omitted those
terms too because our model will not consider waning immunity. Finally the Alexander
SVIR model assumes that susceptible individuals become vaccinated at some constant
rate throughout the epidemic. This is an assumption that we will investigate later in
section 2.7.4.
In the SVIR model from equations (2.4)-(2.7), the parameter σ ∈ [0,1] is the reduction in
susceptibility of a vaccinated individual. When σ = 0 the vaccine has no effect against
the disease, while σ = 1 implies that the vaccine provides full immunity to every indi-
vidual who receives it. Given the definition of σ , this model assumes that vaccination
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reduces the susceptibility of vaccinated individuals to infection. Other alternatives in-
clude assuming that the vaccine reduces infectiousness (or equivalently transmissibility)
or that it reduces both susceptibility and infectiousness. We chose to first present a
reduced-susceptibility version of the SVIR model because it provides the simplest way to
incorporate the effects of vaccination to the SIR model. In section 2.7.5 though we will
also discuss the slightly more complicated reduced-transmissibility version of the SVIR
model. We investigate both versions because in chapter 5 we will develop a cross-scale
vaccination model which will use the reduced-transmissibility vaccination assumption by
construction, and we want to facilitate a direct comparison between the results of the
population-level model of this chapter and the cross-scale model of chapter 5.
The SVIR model presented in this section is based on all the assumptions of the classical
SIR model. It further assumes the following:
• Once the outbreak starts no further vaccination takes place.
• Vaccination reduces susceptibility to infection.
2.3 A two-strain SVIR model
We will now present a two-strain SVIR model we developed to study the evolution of
influenza, which is modelled here as the successful emergence and growth of a mutant







=−(1−σ1)β1V I1 − (1−σ2)β2V I2 (2.9)
dI1
dt
= β1SI1 +(1−σ1)β1V I1 −ν1I1 (2.10)
dI2
dt
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with initial conditions
S(0) = S0 ∈ R+, V (0) =V 0 ∈ R+, Ii(0) = I0i ∈ R+ and Ri(0) = R0i ∈ R+
for i = 1,2 and more specifically
V (0) = c ∈ [0,1], Ii(0) = I0i ∈ [0,1], Ri(0) = 0 and S(0) = 1− c− I01 − I02 ,
where c is the vaccination coverage, namely the proportion of the population that receives
the vaccine.
Here S(t) and V (t) are the fractions of unvaccinated and vaccinated individuals in the
population who are susceptible to either strain at time t, respectively. Ii(t) is the fraction
of individuals infected with the ith strain at time t and Ri(t) the fraction recovered from
the ith strain, for i = 1,2. The parameters βi and νi are the transmission and recovery
rates associated with the ith strain respectively. The parameter σi ∈ [0,1] is the vaccine
efficacy, namely the proportion by which the vaccine reduces the susceptibility of an
individual to the ith strain.
The two-strain SVIR model is based on all the aforementioned assumptions of the classi-
cal SIR and SVIR models from sections 2.2.1 and 2.2.2 respectively. It further assumes
the following:
• Infection by one strain leads to total immunity not only to the infecting strain, but
also to the second one. This form of immunity is referred to as full cross-immunity.
• A host can be infected by one strain at most. Coinfection is not possible.
We note that the two assumptions of the Alexander SVIR model from section 2.2.2,
namely that once the outbreak starts no further vaccination takes place and that vaccina-
tion reduces susceptibility to infection, will both be changed and investigated later in the
chapter. More specifically in section 2.7.4 we will assume that vaccination takes place at
some constant rate during the epidemic, and in section 2.7.5 we will assume that the
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vaccine reduces infectiousness instead of susceptibility.
For the sake of convenience we will break down the epidemic into two sub-epidemics
in the analysis of our model. More specifically, we will refer to the increase of individ-
uals infected by the resident strain as the sub-epidemic driven by the resident strain
and equivalently the increase of individuals infected by the mutant as the sub-epidemic
driven by the mutant. This division is supported in our model by our assumptions of full
cross-immunity and no coinfection.
2.4 Basic properties
2.4.1 The basic, control and effective reproduction numbers
In the absence of vaccination, the ith strain’s basic reproduction number in our two-strain
SVIR model is simply the average number of secondary cases of strain i produced





, for i = 1,2 (2.14)
But to account for the partial immunity of vaccinated individuals, it is useful to consider











Setting the vaccine coverage as V (0) = c and assuming that S(0)+V (0) = N = 1 then
leads to




= R0,i × (1− cσi) (2.16)
Equation (2.16) can then be used to derive the threshold vaccine coverage required to
prevent an outbreak by the ith strain, which translates to finding the vaccine coverage c
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Equation (2.17) gives us a formula for the minimum vaccine coverage c⋆i for which the ith
strain cannot cause an outbreak, but it could be the case that c⋆i > 1. More specifically,
we may derive from equation (2.17) that




Therefore, unless the vaccine has perfect efficacy against the ith strain (which occurs
when σi = 1), there can be cases where no amount of vaccination can prevent an epi-
demic. The relationship between c⋆, R0 and σ is illustrated in figure 2.1 for a single strain
epidemic.
Fig. 2.1 The minimum vaccination coverage c⋆ for a single strain
epidemic as a function of the basic reproduction number R0 and
the vaccine efficacy σ .
Both calculations for R0 and Rc assume that everyone in the population is susceptible,
with the only exception being those who have immunity through vaccination. But if the
two strains are introduced at different times, then the full cross-immunity assumption
implies that everyone who has been infected by the earlier strain will have full immunity
against the later one. Therefore a more suitable measure for the transmission potential of
each strain in this case is the effective reproduction number Re f f (t), which can account
for the depletion of susceptibles due to infection by one strain. In a fully susceptible
population it is defined as
Re f f ,i(t) =
βi
νi
×S(t) = R0,i ×S(t) (2.18)
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where S(t) is the fraction of susceptible individuals at time t. Finally, the control effective
reproduction number Rce f f (t) further accounts for the imperfect immunity of vaccinated
individuals and is defined as





As was the case with the classical SIR model in the previous section, we are again
interested in finding a threshold which determines whether the outbreak will occur. Since
we are now considering two strains though, and because we will be especially interested
in studying the conditions under which a mutant strain can appear in the population and
grow, we will develop two thresholds: one to describe whether the sub-epidemic driven
by the resident strain will occur and an equivalent one for the mutant strain. In order for
the resident strain to successfully cause a sub-epidemic it requires dI1/dt > 0. Using
equation (2.10) of our two-strain SVIR model, this translates to:







Evaluating the second expression at time t = 0 and subbing in for Rc,1 leads to the
conclusion that the resident strain can invade the population if
Rc,1 > 1
A similar calculation leads to the conclusion that the mutant strain can cause a sub-
epidemic if
Rc,2 > 1
but that is under the assumption that the mutant strain is present in the population at
time t = 0. In our implementation of the two-strain SVIR model though we will assume
that initially only the resident strain is present and that the mutant may appear in the
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population as a result of random mutations occurring within hosts infected with the
resident. Therefore a more appropriate threshold to determine whether the mutant will
generate a sub-epidemic if it appears in the population at some time t = τ is:
Rce f f ,i(τ)> 1 (2.20)
2.5 The probability of a mutant strain emergence
In order to motivate our expression for the probability of a mutant strain emergence,
we will first discuss some of our relevant modeling choices. We assume that initially
there is only a resident strain causing an epidemic. At any time during the outbreak, we
assume that a new strain may appear in the population as a result of random mutations
within an infected host. The mutant strain might disappear before it has a chance to grow
or it could spread in the population, which would then lead to two strains, the resident
and the mutant, co-circulating. We assume that individuals can only be vaccinated at
the beginning of the outbreak and primarily against the resident strain. We refer to
such a vaccine which contains the same strain as the one causing the epidemic as a
homologous vaccine. The efficacy of the vaccine against the mutant strain will be varied
for our purposes. In section 5.8 of this chapter we will discuss in more detail how a
homologous vaccine could offer some partial immunity to a newly emerged mutant strain
if the mutant is antigenically similar enough to the resident strain, and equivalently how it
might offer little to no protection if the resident and mutant strains are antigenically distinct.
Given a mutation rate ε per infection from the resident to the mutant strain, and given
that at time τ there are I1(τ) individuals infected with the resident strain (strain 1), then
the rate of appearance of the mutant strain in the population at time τ is εI1(τ). We
can use the probability of extinction of a branching process to account for the case that
the mutant appears in the population but fails to cause a sub-epidemic. Assuming that
a mutant strain appears in a fully susceptible population it will survive with probability(
1−1/R0,2
)
, as it is established by Allen et al. in [6], where R0,2 is the mutant’s basic
reproduction number. This probability has been used extensively in epidemic models and
originates from a paper published by Whittle in 1955 [307], in which he showed that for a
single-strain epidemic in a stochastic Markov chain SIR model if R0 > 1 then a major





)i0], where i0 is the number of the initial
infectious individuals. In the same paper Whittle demonstrated that this threshold is the
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to test for a mutant strain emergence in the scope of our model is that
this expression assumes that the R0 of the mutant strain remains constant throughout
the outbreak and therefore fails to account for the depletion of susceptible hosts due to
infection by the resident strain. Since we assume full cross-immunity, using R0,2 would
overestimate the mutant’s probability of survival. Furthermore we will examine cases
where the vaccine against the resident strain has some effect on the mutant strain as well,
so instead of R0 we use the control effective reproduction number Rce f f ,2(τ). Therefore,
the rate of emergence of the mutant strain at time τ can be estimated by
λ (τ) = εI1(τ)×
(
1− 1
Rce f f ,2(τ)
)
(2.21)
with emergence here referring specifically to the appearance and subsequent survival
of the mutant strain and Rce f f ,2(τ)≥ 1 ∀τ . In the case that Rce f f ,2(t)< 1 then we simply
define λ (t) = 0. In the analysis of our model we will be studying not only whether the
mutant strain is able to emerge at some given time τ , but also what its final size will be at
the end of the epidemic. Using a survival analysis framework and treating λ (τ) as the
hazard function, we may then express the probability density function for the emergence
of a mutant strain at time τ as
f (τ) = λ (τ)× e−
∫
τ
0 λ (t)dt (2.22)
where the second term is the probability that the mutant has not emerged before time
τ and corresponds to the survival function S(τ) used in survival analysis. This term is
necessary since emergence at time τ inherently assumes that no successful appearance
and survival has occurred before time τ . We emphasize that f is an improper probability
density since emergence may not occur at all during the outbreak. This means that f may
fail to integrate to 1. So given an epidemic duration of D days, we set pD = 1−
∫ D
0 f (τ)dτ
as the probability that no emergence occurs during the outbreak.
Given a probability density function f for the emergence of a mutant strain in a population,
we may express the ith strain’s expected final size E(FSi) as:





(FSi|τ) f (τ)dτ (2.23)
where FSi|τ is the final size of the ith strain given that the mutant strain appears at time
τ . We note that for a given τ and considering that infection can only lead to recovery in
our model, the final size of each strain can be calculated as Ri(D), namely the proportion
of individuals throughout the epidemic who became infected with the ith strain and recov-
ered. Furthermore, we emphasize that by assuming the appearance of the mutant strain
at some time τ during the outbreak we may be forcing the mutant to appear at a time
when it cannot grow. We do not consider such a case to be a mutant strain emergence,
merely an appearance. We will explore the effects of τ in detail in section 2.7.1.
2.6 Methods
The primary goal of our two-strain SVIR model is to explore the infection dynamics when
a mutant strain emerges during an influenza outbreak in a population that consists of both
vaccinated and fully susceptible individuals. To that end, we assume that the epidemic
is initiated by a single strain which we refer to as the resident strain or strain 1. Some
proportion of the population is assumed to be vaccinated against the resident strain by
the start of the outbreak. We assume that the vaccine is homologous to the resident
strain and reduces susceptibility to infection. We further assume that once the outbreak
begins no more individuals become vaccinated. When an individual becomes infected
with the resident strain there is a chance that mutations will occur inside them which will
lead to a mutant strain (strain 2) emerging in the population at some time τ during the
epidemic. Then from time τ onward there are two strains, the resident and the mutant,
circulating in the population and competing for hosts either until the end of the outbreak
or until one of them disappears. The efficacy of the vaccine against the mutant strain
varies between simulations, ranging from no effect to total immunity.
The two-strain SVIR model has the following initial conditions:
• τ ∈ [0,D], where D is the duration of the epidemic in days. The case that τ = D is
used to signify that no emergence has taken place during the epidemic. We will
discuss our specific choice for D in the next paragraph.
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• V (0) = c = 0.63 is the proportion of vaccinated individuals in the population.
• I1(0) = 4.8×10−5 is the initial infective seed. It was chosen simply to ensure that
the epidemic would start and finish within D days.
• S(0) = 1− c− I1(0) ≈ 0.37 is the proportion of individuals in the population who
are fully susceptible to the virus at the beginning of the outbreak.
• I2(τ) = I1(0) and I2(t) = 0 ∀t < τ . We model the emergence of the mutant in the
population as the introduction of some proportion of hosts infected by the mutant
strain at time τ , and set this proportion equal to the initial infective seed of the
resident strain.
The parameter values are presented in table 2.1 below and will be referred to throughout
this chapter as the reference values. The mutation rate per infection was chosen as the
value of ε which results in a mutant cumulative emergence probability of 0.9 throughout
the outbreak. The reason for such a high emergence probability is that we are interested
in exploring the competition dynamics when a resident and a newly emerged mutant
co-circulate in a population, so we wanted to facilitate the appearance and growth of a
mutant strain. This is further elaborated in section 2.7.2, where we also show that our
results would have been qualitatively similar had a smaller ε been used.
We note that Public Health England (PHE) reports the following seasonal influenza
vaccine coverages for the winter 2019-2020 season: 60.4% in primary school children
[242], 74.3% in frontline healthcare workers [244], 72.4% in GP registered patients aged
over 65 years old, 44.9% in patients aged six months to under 65 years in one or more
clinical risk groups and 43.8% in patients aged two and three years old (includes both
"healthy" and at risk) [243]. PHE reports that the overall vaccine uptake for the ages of
six months up to 65 years based on GP registered patient data was 13.9% in the winter
2019-2020 season [243]. This is significantly lower than our choice of c = 0.63, but that
does not pose an issue with our model for two main reasons. Firstly, we are interested
in studying the competition dynamics between the two strains when the coverage is
high because that highlights the impact of vaccination. Secondly, we will later vary the
vaccination coverage from 0 to 1 so some of our main results will not depend on our
initial choice of the vaccination coverage. The vaccine efficacy σ1 against the resident
strain was taken from the Influenza Annual Report: Winter 2018 to 2019 published by
Public Health England in 2019 [241]. We note that there is a discrepancy between our
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mathematical definition of vaccine efficacy and the way in which Public Health England
estimates the vaccine effectiveness, and we will address this issue in the Discussion
section (section 5.8) of this chapter.
The transmission rates βi were chosen so that R0,1 = 2 and R0,2 = 1.5, given an average
infectious period 1/νi of 5 days for i = 1,2. The basic reproduction numbers R0,1 and R0,2
of the resident and mutant strains respectively were chosen simply to satisfy reported
values for the R0 of influenza. Specifically Cauchemez et al. report in [55] R0 values
which range from 1.4 to 2.2. The choice to make the mutant strain less fit than the
resident was made so as to underline the effects of the fitness advantage that the mutant
gains from a vaccine which targets only the fitter resident strain. This is further elaborated
in section 2.7.3.
The duration of the outbreak was set at 150 days, which we chose with the usual peak in-
fluenza season in the UK (December through February) in mind, together with the month
leading to it and the month after it ends. The average infection length was chosen as 5
days to be consistent with the infection duration from our within-host model for the evolu-
tion of influenza which will be presented in the next chapter (chapter 3). This is because
ultimately we want to compare the results of our population-level two-strain SVIR model
from this chapter with the results of our cross-scale model which explicitly takes into ac-
count processes that occur at the within host level and will be presented later in chapter 4.
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Parameter Description Value Units Source
β1 transmission rate of
resident strain
2/5 days−1
β2 transmission rate of
mutant strain
3/10 days−1
1/νi average length of


















c fraction vaccinated 0.63 [240]
τ time of emergence of
mutant strain
varies days
ε mutation rate per infection 9.1
D outbreak duration 150 days
Table 2.1 Parameters of the two-strain SVIR model
The model is implemented in Matlab by first running the original, single-strain SVIR
model from section 2.2.2 from time t = 0 until t = τ . This is because until time τ we have
I2(t) = 0. Then from time t = τ until t = D we run our two-strain SVIR model. This is
conceptually equivalent to running the two-strain SVIR model from time t = 0 until time
t = D and switching the value of I2(τ) from 0 to some positive number.
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2.7 Results
2.7.1 The effects of the time of emergence
One of our key questions of interest is how the time of emergence of the mutant strain
affects the competition dynamics between the two strains. Intuitively, it’s logical to expect
that the longer it takes for the mutant to emerge, the smaller its final size will be.
(a) Infectious groups dynamics when τ = 0. This is the case that the outbreak
is initiated by both the resident and mutant strains. This plot underlines the
impact of vaccination, which results in the weaker mutant strain having higher
prevalence than the resident.
(b) Infectious groups dynamics when τ = 15. Contrasting this to plot (a) high-
lights the importance of the time of emergence. The value of τ is the only
difference in the parameters of plots (a) and (b), and we note that a later τ
greatly reduces the prevalence of the mutant strain even though the mutant is
unaffected by the vaccine (σ2 = 0).
(c) Infectious groups dynamics when τ = 80. This is a case where the mutant strain appears but is unable to grow (so we
do not consider this case to be an emergence). This plot illustrates the results of forcing the appearance of the mutant
strain at a time when it cannot survive.
Fig. 2.2 The effects of the time of emergence τ of the mutant strain on the dynamics of the infectious groups I1(t) and
I2(t). The three plots in this figure are the results of three simulations of our two-strain SVIR model, where the only
difference between the simulations is the value of τ . The rest of the parameters were kept at their reference values
from table 2.1. We note that we present the vaccine efficacy against the two strains as σ = [σ1,σ2], and here the
vaccine has no effect against the mutant strain (σ2 = 0).
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Figure 2.2 shows the dynamics of the infectious compartments I1 and I2 in three sce-
narios: when the two strains are introduced in the population at the same time [plot (a)],
when the mutant emerges relatively early in the epidemic and has a chance to spread
[plot (b)], and when the mutant appears so late that it fails to grow [plot (c)]. All other
parameters of the model remain constant at their reference values from table 2.1 and
we further assume that the vaccine has no effect on the mutant strain, signified here by
the fact that σ2 = 0. It is interesting to note that because of that assumption, the vaccine
offers a large enough fitness advantage to the weaker mutant strain that its prevalence
surpasses that of the fitter resident strain when the outbreak is initiated by both the resi-
dent and mutant strains, as plot (a) illustrates. Figure 2.2 provides some initial evidence
that a later τ has detrimental effects on the prevalence of the mutant strain, but only
considers three values for τ . Therefore we will now explore the relationship between τ
and the final sizes of the two strains in more detail.
(a) The final size of the resident strain is computationally a non-decreasing
function of τ .
(b) The final size of the mutant strain is computationally a non-increasing func-
tion of τ .
Fig. 2.3 The final sizes of the resident and mutant strains as a function of the time of emergence τ . Since in this case
the vaccine has no effect on the mutant, the decrease in the mutant’s final size as τ increases can be explained by the
depletion of potential hosts available to the mutant due to infection with the resident strain.
Figure 2.3 illustrates the effects of the time of emergence τ on the final sizes of the two
strains. A later τ means that the resident strain has had more time to circulate and infect
hosts. Under our assumption of full cross-immunity, these infections with the resident
strain lead to the mutant having a smaller number of individuals susceptible to it. As a
result the mutant’s final size is computationally a non-increasing function of τ , as plot
(b) illustrates. Since the two strains are in direct competition for available hosts, the
detrimental effect of a later τ on the mutant strain translates to a beneficial effect on
the resident strain, as it allows it more time to spread without any competition from the
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mutant. This is numerically why the final size of the resident strain is a non-decreasing
function of τ , as plot (a) shows.
So far, figure 2.2(c) with the forced introduction of the mutant strain on day 80 of the
epidemic showed that there exist values of τ for which the mutant strain may appear
but fail to grow. Moreover figure 2.3 showed that the final sizes of the resident and the
mutant plateau after some value of τ , which could imply that emergence is no longer
possible past that value. To explore this we can calculate exactly what the cutoff time for
the mutant’s emergence is using its effective control reproduction number Rce f f ,2, since
as soon as that drops below 1 the mutant’s probability of survival becomes zero and
therefore emergence is no longer possible in our model.
Fig. 2.4 The effective control reproduction number Rce f f ,2(t) of the mutant strain for different values of the
vaccine efficacy σ2 against the mutant strain.
Figure 2.4 illustrates what the window of emergence is for different values of the vaccine
efficacy σ2 against the mutant strain. It is not surprising that as the vaccine-induced
protection against the mutant strain increases, the mutant’s Rce f f ,2(τ) decreases faster,
leading to shorter emergence intervals. We note that even for a relatively small value of
σ2 (here 0.3) emergence becomes impossible for the mutant.
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2.7.2 The probability of emergence
The results we have presented so far are from simulations in which we fixed some value
for τ at the beginning of the simulation. This resulted in cases as the one exhibited in
figure 2.2(c), where the mutant strain appeared very late during the outbreak and failed
to grow. We then used the mutant’s effective control reproduction number Rce f f ,2(t) to
calculate the value of τ after which no emergence can occur. But while Rce f f ,2(t) can
determine the mutant’s window of potential emergence, it does not provide much insight
into how the mutant’s chances of emergence change within that window. To explore this
we examine the mutant’s probability of emergence using the probability density function
for emergence that we derived in section 2.5. We repeat the pdf for emergence f (τ) and
the rate of emergence λ (τ) here for convenience:
λ (τ) = εI1(τ)×
(
1− 1
Rce f f ,2(τ)
)




We note that f (τ) = 0 ⇐⇒ Rce f f ,2(τ) = 1, as our expressions assume that ε > 0 and
Rce f f ,2(τ)≥ 1.
Fig. 2.5 The probability density function for the emergence of the mutant strain during the
outbreak. Here we assume again that the vaccine has no effect on the mutant strain, namely
σ2 = 0. Since f is an improper density, the overall probability of emergence during the
outbreak can be calculated as
∫ D
0 f (τ)dτ . This was calculated numerically in Matlab using
the trapz function to be 0.9.
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Figure 2.5 shows how the probability density function f for the emergence of a mutant
strain changes throughout the epidemic. In the early stages of the outbreak the probabil-
ity of emergence is low due to the small fraction of infected individuals. As that starts to
increase the mutant’s chance to emerge increases as well, until it reaches a maximum.
After that maximum is attained the probability of emergence starts decreasing again
because of the depletion of susceptible individuals available to the mutant due to infection
with the resident strain.
(a) f (τ) for different ε . We note that all the curves drop to zero at τ = 80.9
days.
(b) The cumulative probability of emergence
∫D
0 f (τ)dτ is a non-decreasing
function of the mutation rate per infection ε . The dashed line is at our reference
value ε = 9.1, which leads to a cumulative emergence probability of 0.9.
Fig. 2.6 The effects of the mutation rate ε on the mutant’s probability of emergence.
Figure 2.6 describes the effects of the mutation rate per infection ε on the mutant’s prob-
ability of emergence. It is not surprising that as ε increases, the cumulative probability∫ D
0 f (τ)dτ that the mutant will emerge during the outbreak increases as well, as plot (b)
illustrates. Given our expressions for the emergence density f and the rate of emergence
λ , we may conclude that given any ε > 0 the determining factor of the length of the
potential emergence interval is the control effective reproduction number Rce f f ,2 of the
mutant, which does not depend on ε . This is because, as we mentioned in the beginning
of this section, f (τ) = 0 ⇐⇒ Rce f f ,2(τ) = 1 assuming ε > 0 and Rce f f ,2(τ)≥ 1. This is
illustrated in plot (a) where the different curves, each of which corresponds to a different
mutation rate ε , all become zero at the same τ . Plot (a) further shows that among the four
values of ε we considered, the larger values increase the maximum of the emergence
density f (τ) and also make emergence more likely earlier in the epidemic. This can
be explained by the fact that given some proportion of infected individuals at time τ , a
higher ε implies a larger appearance rate εI1(τ) and a lower probability e−
∫
τ
0 λ (t)dt that
emergence has not occurred before τ . It is important to note that the f (τ) curve does not
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change qualitatively in any fundamental way for the different values of ε considered here.
(a) f (τ) for different σ2 (b) The cumulative probability of emergence
∫D
0 f (τ)dτ is a non-increasing
function of the vaccine efficacy σ2 against the mutant strain. We note that
even given a very high mutation rate of ε = 9.1 relatively small values of σ2 are
enough to ensure that no emergence occurs during the outbreak.
Fig. 2.7 The effects of the vaccine efficacy σ2 against the mutant strain on the mutant’s probability of emergence.
So far our results assume that the vaccine has no effect on the mutant strain. Figure
2.7 describes the effects of the vaccine efficacy σ2 against the mutant strain on the
mutant’s probability of emergence. Given some fixed vaccination coverage c and efficacy
against the resident strain σ1, plot (b) shows that increasing σ2 can reduce the cumulative
probability of emergence down to zero even for relatively small values of σ2 and even
under the assumption of a very high mutation rate. We note that increasing σ2 decreases
the mutant’s effective control reproduction number Rce f f ,2(τ) for any given τ
(
by definition
of Rce f f ,2(τ)
)
. This has a twofold impact on the mutant strain, as illustrated for some
specific values of σ2 in plot (a). Firstly it shortens the potential emergence interval since
the length of the interval is determined by the first τ at which Rce f f ,2(τ) is smaller than 1.
Secondly it decreases the mutant’s probability of survival given appearance at some time
τ , which is
(
1− 1/Rce f f ,2(τ)
)
. Since this is one of the terms which make up the emergence
density f (τ), decreasing it will in turn decrease the density at τ as plot (a) exhibits.
2.7.3 The effects of vaccination
Considering that vaccination is the primary control strategy against influenza epidemics,
it is crucial to understand its effects not only on disease incidence, but also on the
evolutionary dynamics of influenza. Since we model the evolution of influenza as the
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potential emergence and spread of a mutant strain, it is important to explore how the
vaccine efficacy and coverage affect the probability of emergence of a mutant strain and
its expected final size.
(a) The expected final size of the resident strain is a non-increasing function
of the vaccine efficacy σ1 against the resident. We note that E(FS1) > 0 ∀σ1 .
Even when σ1 = 1 and the vaccine offers perfect immunity against the resident
strain there will still be some small proportion that contracts the resident strain
because only 63% of the population is assumed to be vaccinated.
(b) The expected final size of the mutant strain is larger for intermediate values
of the vaccine efficacy σ1 against the resident strain.
Fig. 2.8 The effects of the vaccine efficacy σ1 against the resident strain on the expected final sizes of the resident and
mutant strains.
Figure 2.8 describes the effects of the vaccine efficacy σ1 against the resident strain
on the expected final sizes of the two strains. The left plot shows that the expected
final size of the resident strain decreases as σ1 increases. There are two factors which
can account for this, one direct and one indirect. Firstly it is logical that as the vaccine
efficacy against the resident strain increases its prevalence will decrease because it will
have fewer individuals available to it for infection. Moreover, given some emergence
time τ for the mutant strain, a higher σ1 offers a fitness advantage to the mutant by
lowering the susceptibility of individuals to the resident strain and therefore hindering its
transmission. Because of our assumption of full cross-immunity, this leads to a smaller
final size for the resident strain and in turn to a smaller E(FS1). Plot (b) describes
the relationship between the expected final size of the mutant strain and the vaccine
efficacy σ1 against the resident strain. The increasing portion of the plot can be at-
tributed to the fitness advantage that the mutant strain gains as the vaccine becomes
more efficient in reducing the susceptibility of individuals to the resident strain. This
decreases the resident’s transmission, leaving more potential hosts available to the
mutant. The decreasing portion on the other hand can be explained by the significant
reduction in the number of individuals infected with the resident strain as σ1 becomes
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large, which decreases the mutant’s appearance rate εI1(τ) for any given τ and in
turn decreases its probability of emergence. Therefore there appear to be two conflict-
ing factors which determine the expected final size of the mutant for different values of σ1.
(a) The expected final size of the resident strain is a non-decreasing function
of σ2 due to the detrimental effects of a larger σ2 on the potential emergence
and spread of the mutant strain. We note though that the change in E(FS1) as
σ2 increases is very small.
(b) The expected final size of the mutant strain is a non-increasing function of
the vaccine efficacy σ2 against the mutant. We note that plots (a) and (b) have
different y-axes scales (this was done only for the sake of presentation).
Fig. 2.9 The effects of the vaccine efficacy σ2 against the mutant strain on the expected final sizes of the resident and
mutant strains.
Figure 2.9 describes the effects of the vaccine efficacy σ2 against the mutant strain on
the expected final sizes of the two strains. The left plot shows that the expected final size
of the resident strain increases as σ2 increases. Given the direct competition between
the two strains, this can be attributed to the detrimental effect of a higher σ2 on both
the probability of emergence and the final size of the mutant strain given appearance
at some time τ . We note though that varying σ2 has a very small effect on on E(FS1),
which can be attributed to the fact that the resident strain is assumed to be fitter than
the mutant and also to initiate the outbreak. The right plot shows that the expected final
size of the mutant strain decreases as σ2 increases. Given a mutant emergence at some
time τ , a higher value for σ2 reduces the infection risk of vaccinated individuals from
the mutant strain thereby decreasing its final size. Moreover we have already illustrated
that as σ2 increases both the cumulative probability of emergence of the mutant and the




. Since the final size given some
τ and the emergence density f are the two quantities which determine the mutant’s
expected final size, it is logical then that E(FS2) is a non-increasing function of σ2.
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(a) The expected final size of the resident strain as a function of the vaccine
efficacy against each strain. All parameters except σ1 and σ2 remain at their
reference values.
(b) The expected final size of the mutant strain as a function of the vaccine
efficacy against each strain. All parameters except σ1 and σ2 remain at their
reference values. We note that plots (a) and (b) have different scales.
Fig. 2.10 The effects of the vaccine efficacy on the expected final sizes of the resident and mutant strains.
Figure 2.10 describes the effects of the vaccine efficacy σ1 against the resident and σ2
against the mutant strain on the expected final sizes of the two strains. The left plot
shows how the expected final size of the resident strain changes with σ1 and σ2. We
see that for a given σ1 variations in σ2 appear to have little to no effect on E(FS1). This
is not surprising if we consider that the emergence density is small for any given τ , as
figure 2.5 from section 2.7.2 showed, and that the mutant strain is assumed to be weaker
than the resident. The right plot shows how the expected final size of the mutant strain
changes with σ1 and σ2. We see that for small values of σ2 varying σ1 results in the
same behavior as the one illustrated in plot (b), namely that intermediate values of σ1
are the most beneficial to the mutant strain. For larger values of σ2 though the vaccine’s
improved efficacy becomes the main determinant of E(FS2), while variations in σ1 have
almost no effect on it anymore.
So far we examined how the expected final sizes of the two strains will change as we
vary the vaccine efficacy σ1 and σ2 against the resident and mutant strains respectively,
while keeping the vaccination coverage c constant. We will now investigate the effects of
changing the vaccination coverage on the expected final size of each strain.
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(a) The expected final size E(FS1) of the resident strain decreases as the vac-
cine efficacy σ1 and vaccination coverage c increase.
(b) The expected final size E(FS2) of the mutant strain reaches large values
in three cases: for intermediate values of both c and σ1 , for large values of σ1
and intermediate values of c and for large values of c and intermediate values
of σ1 .
(c) The expected final size E(FS1) of the resident decreases as the vaccination
coverage c increases, and is almost unaffected by variations in σ2 .
(d) Given an intermediate or larger value for σ2 , the expected final size E(FS2)
of the mutant strain is close to zero even for small values of c.
Fig. 2.11 The effects of the vaccine coverage c and the vaccine efficacy σi against the ith strain on the expected final
sizes of the two strains. Whenever a parameter wasn’t explicitly varied it was kept constant at its reference value. The
plots in the left column describe how changes in c, σ1 and σ2 affect the expected final size of the resident strain while
the plots in the right column how they affect the expected final size of the mutant strain.
Figure 2.11 describes how the expected final size of the two strains changes as we vary
the vaccine coverage c and the vaccine efficacy against the ith strain σi.
• Plot (a) shows that the expected final size of the resident strain decreases as the
number of individuals who receive the vaccine increases and as the efficacy σ1
increases.
• Plot (b) shows that intermediate values of vaccination coverage and vaccine efficacy
against the resident strain are among the most beneficial for the emergence and
spread of the mutant strain. Moreover we see that given an intermediate value
of c, large values of σ1 also lead to increases in the expected prevalence of the
mutant. The same holds for intermediate values of σ1 and large values of c. All
these three cases can be explained by the same reasoning: conditions which offer
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a fitness advantage to the mutant (such as an intermediate c and very large σ1,
or an intermediate c and σ1) lead to higher expected final sizes for the mutant
because they hinder the spread of the resident strain. But if the detrimental effect
on the resident strain becomes too large (as is the case with a very large c and σ1),
this will in turn decrease the mutant’s expected final size because it will reduce its
chances of emerging in the population.
• Plot (c) illustrates that changes in the vaccine efficacy σ2 against the mutant strain
have almost no effect on the expected final size of the resident strain even when
c, and therefore the vaccine effectiveness, is large (given that σ1 remains at its
reference value of 0.44). This is in accordance with the results of figure 2.10(c),
which showed that increasing σ2 from 0 to 1 led to less that a 1% increase in
E(FS1) for a vaccination coverage of 0.63.
• Plot (d) shows that the expected final size of the mutant strain attains its largest
values when σ2 is very small or zero, and the vaccination coverage c is large. This
is unsurprising, since it describes a case where the majority of the population is
vaccinated against the resident strain with a vaccine that has little to no effect on
the mutant strain. This offers a significant fitness advantage to the mutant, leading
to a larger expected prevalence. On the other hand given a larger value of σ2
we see again that even very small values of c are enough to ensure a very small
expected final size for the mutant strain. It is important to note that even when
everyone in the population is vaccinated (c = 1), the outbreak still occurs and there-
fore the mutant strain has a chance to emerge. This is because the vaccine offers
only partial protection from the infection, and specifically here the efficacy σ1 is 0.44.
2.7.4 An alternative vaccination model : continuous vaccination
One of the assumptions of our two-strain SVIR model is that individuals cannot be vacci-
nated once the epidemic starts. In this section we will change this and instead assume
that while some fraction of the population received the vaccine prior to the outbreak,
susceptible individuals become vaccinated at a constant rate a throughout the duration
of the epidemic. The only difference then in the formulation of our model is that the
S-equation now includes a −aS term and the V -equation a +aS term. The vaccination
rate a was calculated as the rate which results in an infection prevalence of 25% in an
outbreak with only the resident strain present and with 63% of the population having
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already received the vaccine by the start of the outbreak. This is half the prevalence of a
single-strain epidemic under our previous vaccination program. Our particular choice
for a is not significant though, our only consideration was to not choose a value that
would completely impede the growth of the two strains. Our goal is to simply investigate
whether adding a constant vaccination rate throughout the epidemic will qualitatively alter
our model’s results in some fundamental way. All other parameters of the model are kept
constant at their reference values from table 2.1. We note that the vaccination coverage
c remains at its reference value of 0.63 but now refers to the initial vaccination coverage,
as more individuals receive the vaccine throughout the epidemic.
(a) The expected final size of the resident strain as a function of the vaccine
efficacy against each strain.
(b) The expected final size of the mutant strain as a function of the vaccine
efficacy against each strain. We note that the scale is different between this
plot and plot (a).
Fig. 2.12 The effects of the vaccine efficacies σ1 and σ2 on the expected final sizes of the resident and mutant strains
under the assumption of a constant vaccination rate a = 0.02. All other parameters except σ1 and σ2 remain at their
reference values. Both plots are qualitatively very similar to their corresponding plots from figure 2.10, where no
vaccination occurs after the onset of the epidemic.
Figure 2.12 shows that our continuous vaccination model results are qualitatively similar
to our previous model where we assumed that vaccination occurs prior to the onset of
the outbreak. Therefore our model results are not very sensitive to using a vaccination
program which includes a constant vaccination rate throughout the epidemic as opposed
to using our original assumption that no further vaccination occurs once the outbreak be-
gins. Very importantly, we can still conclude using plot (b) that intermediate values of the
vaccine efficacy σ1 against the resident strain lead to the highest expected prevalences
for the mutant strain.
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2.7.5 Sensitivity to the form of vaccine immunity
The formulation of our two-strain SVIR model in equations (2.8)-(2.13) of section 2.3
depends on the assumption that the vaccine reduces the susceptibility of individuals
to infection. In this section we will change this and instead assume that the vaccine
reduces the transmissibility of the virus from infected individuals to new cases. We will
first motivate the form of our reduced transmissibility model, and then we will present it
and analyze some of its key results.
We now define σi ∈ [0,1] as the proportion by which the vaccine reduces the transmis-
sibility of the ith strain from infected individuals who have received the vaccine to new
cases. Assuming again that vaccination only occurs prior to the onset of the epidemic,
this reduced transmissibility framework necessitates the division of infected individuals
into four categories:
• IS1 : individuals who used to be fully susceptible and became infected with the
resident strain
• IS2 : individuals who used to be fully susceptible and became infected with the
mutant strain
• IV1 : individuals who were vaccinated and became infected with the resident strain
• IV2 : individuals who were vaccinated and became infected with the mutant strain
The key difference between these four categories as far as vaccination is concerned is
that the IS1 and I
S
2 classes will transmit the virus at some β1 and β2 rates respectively,
while the IV1 and I
V
2 classes will transmit it at some reduced (1−σ1)β1 and (1−σ2)β2
rates. Our two-strain SVIR model with reduced transmissibility then becomes:
dS
dt
=−β1SIS1 − (1−σ1)β1SIV1 −β2SIS2 − (1−σ2)β2SIV2 (2.24)
dV
dt
=−β1V IS1 − (1−σ1)β1V IV1 −β2V IS2 − (1−σ2)β2V IV2 (2.25)
dIS1
dt
= β1SIS1 +(1−σ1)β1SIV1 −ν1IS1 (2.26)
dIV1
dt




= β2SIS2 +(1−σ2)β2SIV2 −ν2IS2 (2.28)
dIV2
dt












S(0) = S0 ∈ R+, V (0) = V 0 ∈ R+, ISi (0) = I
0,S
i ∈ R+, IVi (0) = I
0,V
i ∈ R+ and Ri(0) =
R0i ∈ R+
for i = 1,2 and more specifically
V (0) = c ∈ [0,1], ISi (0) = I
0,S
i ∈ [0,1], IVi (0) = I
0,V
i ∈ [0,1], Ri(0) = 0 and S(0) = 1−







where c is the vaccination coverage, namely the proportion of the population that receives
the vaccine.
Here S(t) and V (t) are the fractions of unvaccinated and vaccinated individuals in the
population who are susceptible to either strain at time t, respectively. ISi (t) is the fraction
of individuals infected with the ith strain at time t who used to be fully susceptible and
IVi (t) is the fraction of individuals infected with the ith strain at time t who were vacci-
nated. Ri(t) is the fraction recovered from the ith strain, for i = 1,2, and includes both
individuals who used to be fully susceptible and individuals who received the vaccine.
The parameters βi and νi are the transmission and recovery rates associated with the
ith strain respectively. The parameter σi ∈ [0,1] is the vaccine efficacy, defined here as
the proportion by which the vaccine reduces the transmissibility of the ith strain from an
infected individual to new cases.
Our two-strain SVIR model with reduced transmissibility is based on the same assump-
tions as our two-strain SVIR model with reduced susceptibility from section 2.3, with the
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only exception being that the vaccine now reduces infectiousness instead of susceptibility.
The methods, implementation, initial conditions and parameter values of the two-strain
SVIR model with reduced transmissibility remain exactly the same as those of our
two-strain SVIR model with reduced susceptibility from section 2.3. We only note that
here:
• IS1 (0) = 4.8×10−5. This is the same initial infective seed as the one we used in
section 2.3.
• IV1 (0) = 0. So we assume that the outbreak begins via the infection of individuals
who have not received the vaccine.
(a) The expected final size of the resident strain as a function of the vaccine
efficacy against each strain.
(b) The expected final size of the mutant strain as a function of the vaccine
efficacy against each strain. We note that the scale is different between this
plot and plot (a).
Fig. 2.13 The effects of the vaccine efficacy on the expected final sizes of the resident and mutant strains under
the assumption of reduced transmissibility. All parameters except σ1 and σ2 remain at their reference values. We
emphasize that the two plots have different scales. Both plots are qualitatively very similar to their corresponding plots
from figure 2.10, where no we assumed that the vaccine reduces susceptibility.
Figure 2.13 illustrates the effects of varying the vaccine efficacy σ1 against the resident
strain and σ2 against the mutant on the expected final sizes of the two strains. Plot (a)
shows that varying σ2 has a very limited effect on the expected final size of the resident
strain, while on the other hand varying σ1 has a strong one. We see that reducing
the transmissibility of the resident virus by approximately 60% or more in vaccinated
individuals leads to an expected final size of almost zero for the resident strain. This
happens for every value of σ2, which further highlights the small impact of the vaccine
efficacy against the mutant strain on the spread of the resident. We emphasize though
that our results are merely qualitative and we are not arguing that such a vaccine efficacy
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will guarantee the same results in a real epidemic. Plot (b) shows that intermediate
values of the vaccine efficacy σ1 against the resident strain are the most beneficial for the
potential emergence and spread of a mutant strain in our model. This result is the same
qualitatively as the one given by our two-strain SVIR model with reduced susceptibility
from section 2.3, and can be explained by the same reasoning. As the vaccine efficacy σ1
against the resident strain initially increases, it offers a fitness advantage to an emerging
mutant strain by limiting the transmission potential of its competitor resident strain. But
when σ1 becomes so large that the resident strain cannot spread effectively, then the
emergence potential of the mutant strain decreases. This in turn decreases its expected
final size, accounting for the decreasing portion of plot (b) along the σ1 axis.
This section with the reduced transmissibility and the previous one with the constant vac-
cination rate challenge two important assumptions of our original two-strain SVIR model
with reduced susceptibility from section 2.3. We have shown though that our results
remain the same qualitatively under these different assumptions, and most significantly
that under all three frameworks intermediate values of immunoprotection are the most
inducive to the emergence and spread of a mutant strain.
2.8 Discussion
This chapter examines the emergence and subsequent competition dynamics of a mu-
tant influenza strain drifted from a parent resident strain in a population during a single
influenza epidemic. Of key interest is the impact of a partially effective vaccine on the
epidemiological and evolutionary viral dynamics.
Our most significant and perhaps counter-intuitive result is that antigenic drift, which is
modelled here as the emergence and spread of a mutant strain, appears most likely to
occur at intermediate values of immunoprotection. We use the expected final size of
the mutant strain as an indicator of antigenic drift by assuming that a larger expected
final size increases the chances of the mutant strain reaching fixation. Based on the
results from section 2.7.3, intermediate values for the vaccine coverage and efficacy
against the resident strain maximize the mutant’s expected final size. This adds a new
layer of consideration to influenza vaccination strategies. Traditionally influenza vac-
cination programs aim to control the seasonal outbreaks via vaccination against the
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strains expected to circulate in the current season. But the results of our model imply that
vaccination programs should also consider how likely the current vaccine is to aid the
potential emergence of mutant strains. Such a situation could become very dangerous
especially if the mutant strain is antigenically different enough from its parent resident
strain to be resistant to the effects of a homologous vaccine. In such a case the newly
emerged mutant would be spreading in a population consisting of hosts who have little
natural or artificial immunity to it. Our results emphasize that to prevent such a scenario
it is important for the current vaccine to either be a broad cross-protective vaccine or to
induce a high immune pressure against the resident strain but that it is also critical that a
large proportion of the population is vaccinated. As figure 2.11 shows, the case where
the vaccine efficacy against the resident strain is high but only an intermediate portion
of the population receives the vaccine is actually very inducive to the emergence and
successful spread of a mutant strain.
It is important to emphasize that our prediction that intermediate levels of vaccination
coverage and efficacy against a resident strain would be the most beneficial for the
potential establishment of a mutant strain is not entirely novel. Grenfell et al. argue in
[125] that the highest rate of viral adaptation to host immunity occurs at intermediate
levels of the strength of the immune response. They attribute this to two conflicting factors.
The first is the within-host selection strength, which increases with the strength of the
immune response and therefore leads to a higher adaptation rate. The second is the viral
abundance, which decreases as the level of immunity increases and therefore leads to a
lower adaptation rate. Translating this to our own framework, the equivalent argument
would be that on one hand a larger vaccine efficacy against the resident strain leads to a
higher expected prevalence for the mutant, but if on the other hand the prevalence of the
resident becomes too low then emergence becomes less likely. Therefore our results
extend the argument by Grenfell et al. to the population-level emergence and spread of
mutant strains.
We will now discuss the assumptions and limitations of our model. One of the key
assumptions of our model is that of full cross-immunity, namely that infection with one
strain offers full immunity both to the infecting and to the other strain. If the newly
emerged mutant strain is antigenically similar to its parent resident strain then there is
strong evidence to support our full cross-immunity assumption. Infection with a given
influenza strain results in the generation of long-lived antibodies which are specific to the
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hemagglutinin (HA) and neuraminidase (NA) surface proteins of the infecting strain [222].
The implication of this aspect of the adaptive immune response is that a subsequent
challenge with an antigenically similar strain might not lead to an infection. Even if it does,
the reinfection is often mild because the host should be able to immediately procure
high levels of strain-specific antibodies [295]. A historical example that illustrates the
effects of strain-specific antibodies is when H1N1 re-emerged to cause an epidemic in
1977 after being absent from the human population since 1957, and infected mostly
individuals younger than 20 years. The 1957 and 1977 strains were collected and found
to be antigenically and genetically very similar, which implies that the older individuals
retained their immunity from the first 1957 outbreak [90]. We may conclude then that this
long-lived strain-specific immunity that follows a natural infection by a given influenza
strain makes the full cross-immunity assumption appropriate for our model if the mutant
strain is antigenically similar to the resident.
A scenario of interest arises though when the mutant strain is antigenically distant from
the resident, since that is precisely when the mutant is most dangerous. Even in this case
there is some evidence to support our full cross-immunity assumption. Immunological
[21, 135, 183] and epidemiological [98] studies have shown that infection by a given
influenza strain results in a temporary antigen-nonspecific immunity which can last up
to a few months. This can partially explain why people who become infected once
during a single influenza season have a significantly lower risk of reinfection even by an
antigenically different second strain, as Zarnitsyna et al. report in [319]. It is important
to note that we are only considering mutant strains which arise from the process of
antigenic drift. Pandemic strains, which evidence suggests are primarily the result of
genetic reassortment, exhibit different dynamics [166]. Therefore we may conclude
that even if the co-circulating resident and mutant strains are antigenically different the
assumption of full cross-immunity is still applicable in our single-season influenza model.
Considering that a key question we attempt to answer with this model is how vaccination
affects the evolution and spread of influenza, it is important to address all our assump-
tions regarding vaccination and evaluate their impact on the validity and robustness of
our results. We assume that no vaccination occurs after the onset of the epidemic, which
in our model is in November (a month before the start of peak influenza season in the
northern hemisphere). The CDC reports that for the 2014-2015 up to the 2016-2017
influenza seasons in the US only an approximate further 10% of individuals at most were
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vaccinated after November of the current season [56–58]. Therefore our assumption of a
zero vaccination rate once the epidemic starts is not unrealistic (at least in the case of the
US). But we also considered a different vaccination program in which individuals continue
receiving the vaccine at some constant rate throughout the duration of the epidemic.
Figure 2.12 from section 2.7.4 shows that our results would not differ qualitatively under
this new vaccination strategy. Most importantly, our prediction that intermediate levels of
the vaccine efficacy against the resident strain are the most beneficial for the potential
emergence and spread of a mutant strain would still be valid.
Given any vaccination strategy we need to define how the vaccine affects the virus. This
is a complicated question for a variety of reasons, perhaps most importantly due to the
difficulties in translating experimental results to mathematical quantities. We defined
vaccine efficacy in our model as the proportion by which the vaccine reduces suscepti-
bility to infection, and used the value for the adjusted vaccine effectiveness reported by
Public Health England during the winter 2018-2019 influenza season to inform our model
parameter. The vaccine effectiveness was estimated using a case test-negative design,
which Foppa et al. showed to be valid and unbiased under fairly general assumptions
[103]. But this way to estimate the vaccine effectiveness does not translate exactly to our
definition of vaccine efficacy because it inherently incorporates the effects of the indirect
protection offered to unvaccinated individuals from the reduced infection prevalence in a
population which includes vaccinated individuals. This implies that our reference value for
the vaccine efficacy might overestimate the level of protection that the vaccine offers. This
is not a significant problem in our model though, since our key results come from varying
the vaccine efficacy against each influenza strain and examining the corresponding effect
on each strain’s expected prevalence.
While research suggests that influenza is a rapidly mutating virus [216, 297], most of
our results still use an unrealistically high mutation rate. This was deliberately chosen
so in order to facilitate the emergence and spread of the mutant strain as we are in-
terested in its competition dynamics with its parent resident strain. Our results remain
the same qualitatively when much smaller mutation rates were used, as figure 2.6 il-
lustrated. We emphasize though that all our results in this chapter are qualitative, as
we are not aiming to make accurate quantitative predictions regarding the evolutionary
dynamics of influenza but simply to gain a better insight into how vaccination affects them.
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We assume that only a single mutant strain may emerge during the outbreak. From a
population genetics perspective, it would have been important for the model to account
for the continuous accumulation of point mutations in the hemagglutinin (HA) protein.
Even immune-escape mutants can accumulate too many deleterious mutations after they
emerge in a population and end up disappearing too quickly to establish a viral lineage
[172]. This is a level of complexity that our model does not explicitly consider, although
the survival term in our expression for the probability of emergence from section 2.5 can
partially account for all the mutants that appear but suffer rapid loss without propagating
in the population. Furthermore there is no evidence for the explosive antigenic diver-
sity of circulating strains that influenza’s high mutation rate alone would suggest [236].
This can be partially explained by the competition between antigenically closely related
seasonal strains to spread in a population that often mostly consists of partially immune
hosts. We can imagine that if instead each mutation led to immune escape strains, then
these mutants would take over separate niches and we would observe greater antigenic
diversification [288]. As this is not the case and influenza exhibits constrained diversity, it
should be a justifiable simplification to only allow for a single mutant strain to emerge
during an epidemic. We note though that our model can be extended to include multiple
strains simply by adding more infectious compartments, and also a linear or non-linear
antigenic strain space such as the ones used by Gog and Grenfell in [121].
While our two-strain SVIR model can capture the conflicting factors that appear to
determine the evolutionary dynamics of influenza in a population that utilizes a vaccination
program, we can make a number of changes to facilitate further exploration. These
include:
• Allowing for partial cross-immunity or waning strain-transcending immunity fol-
lowing natural infection with a given strain. We expect this to have a significant
impact on our model’s results, as it will allow for mixed infections or reinfections
following recovery. Currently the only case where an individual might have two
strains circulating within them in our model is if they were initially infected with the
resident strain but then had the mutant emerge within them, though this process is
only implicitly incorporated to our model via our expression for the population-level
probability of emergence. Partial cross-immunity would increase the mutant’s con-
trol effective reproduction number Rce f f ,2 by introducing a new group of individuals
that the mutant could infect following its appearance in the population, thereby
improving its chances of emergence. It would also widen the mutant’s emergence
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window, since as we demonstrated in section 2.7.2 Rce f f ,2 is the main determinant
of the length of the mutant’s emergence interval.
• Adding heterogeneity to the population in the form of age structure. We do not
expect this to alter our model’s results in a fundamental way, as it does not affect the
assumption of total cross-immunity or the key emergence potential of the mutant
strain. Incorporating age structure though would allow us to investigate research
questions such as: how should vaccination of certain age groups be prioritized in
order to minimize the spread of the infection and how does that in turn affect the
emergence dynamics of the mutant strain?
• Incorporating multiple strains via the addition of more infectious compartments.
As we have already discussed in chapter 1, increasing the number of strains can
lead to several analytical and computational challenges. We could start with only
adding a third strain though, which could be either a second resident strain or
a second possible mutant strain. The former could be thought of as modeling a
population where seasonal strains of both the H1N1 and the H3N2 subtypes are
co-circulating, but only one of those strains can give rise to a mutant strain. Such a
model naturally lends itself to the addition of a fourth strain, so that both resident
strains are allowed to mutate. Under our original assumption of total cross-immunity,
we expect such a framework to have a negative impact on the emergence and
spread of mutant strains, as they would have to compete with two strains already
circulating in the population. Under a partial cross-immunity assumption though
we expect the resulting model to exhibit significantly more complicated dynamics,
especially if we assume cross-reactivity between all strains. If instead we consider
a model where two different mutant strains could emerge, we may either assume
that they are both the immediate result of mutations occurring in the resident strain
or that only the first mutant is a direct result of mutations in the resident strain
and then the second mutant can only arise from the first, making the successful
emergence of the first mutant strain a prerequisite for the emergence of the second
one. Under our simplifying assumption of total cross-immunity we do not expect
our model’s results to change in a fundamental way. It would be interesting though
to investigate questions such as under what conditions/ parameter values a strain-
matched vaccine against the resident would provide enough pressure that a weaker
first mutant could emerge in the population and survive long enough to then give
rise to a fitter mutant.
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2.9 Summary
In this chapter we presented a population-level model for the epidemiological and evo-
lutionary dynamics of influenza during a single influenza season. We used it to study
the emergence potential of a mutant strain and the subsequent competition dynamics
with its parent resident strain. We focused on the question of how vaccination affects the
antigenic drift dynamics of influenza, which we modelled here as the potential emergence
and expected growth of a mutant strain. Our results showed that intermediate levels of
immunoprotection are most likely to facilitate the antigenic drift of influenza, and that it is
critical for vaccination programs to aim for a vaccine which exerts high immune pressure
onto the expected current-season strain but also to aim for a large vaccination coverage.
Our model took explicitly into account only processes occurring at the between-host
level, so in chapter 4 we will compare its results to those of a cross-scale model whose




A within-host model for the evolution
of influenza
3.1 Introduction
Our goal in this chapter is to develop a within-host influenza model to describe the
emergence dynamics of a mutant strain during an infection with a resident strain as
well as the consequent competition dynamics between the two strains. We will begin by
extending one of the simplest and most versatile within-host disease models, the TIV
model published by Baccam et al. in [24], to include two strains. Then we will adapt
a slightly more complicated model developed by Saenz et al. in [262] and modify it to
include two strains. Our analysis of the extended Saenz model will initially focus on
the effects of the mutant’s emergence time on the disease dynamics. Then, in order to
investigate the possible times during an infection at which a mutant strain can appear and
survive, we will develop an expression for the emergence density of the mutant. Finally
we will add vaccination to our extended Saenz model.
3.2 Background
3.2.1 The TIV model
In 2006, Baccam et al. published a simple but very influential model of within-host
influenza A kinetics [24]. We refer to it as the TIV model throughout this thesis. It consists
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= βTV −δ I (3.2)
dV
da
= pI − cV (3.3)
Here T (a) denotes the number of uninfected target cells at time a, I(a) the number of
infected cells at time a and V (a) the infectious viral titer at time a, where a denotes the
age of infection. The parameter β is the infectivity rate. Infected cells I produce new
virions at a rate p per cell, and die at a rate δ per cell where 1/δ is the average life-span
of an infected cell. Free virions that are circulating within the host are cleared by the
immune system at a rate of c per day.
The TIV model is based on a number of underlying assumptions:
• Infected cells immediately start shedding virus.
• The binding of free virions with target cells causes only a negligible decrease in
the viral load, which is why there is no −βTV term in (3.3).Since an infected cell
that has reached the virion-producing stage can release 10,000−20,000 progeny
virions per day [211], it is justifiable to ignore the loss of a single virion that is
needed to infect a target cell.
• Infection ends due to the depletion of target cells.
• The innate immune response is included implicitly in the model via the clearance
rate c and the death rate of infected cells δ .
The TIV model has been used extensively in the literature and was often the foundation
on which other within-host disease models were built. It has appeared in the influenza
literature [29, 131], dengue literature [31, 66] and also in the chronic disease literature
[230, 231].
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3.2.2 The Saenz model
While the TIV model is a simple but powerful model, it comes with some potential draw-
backs. The most relevant one to the scope of this thesis is the indirect way in which the
model captures the immune response, namely via the parameters for the clearance rate
of free virions c and the death rate δ of infected cells. This has a negative impact on
exploring the potential emergence of a mutant strain within-host. We will explore this in
detail in section 3.4. To account for this, we will explore a more complicated but better
applicable to the goals of this thesis within-host influenza model published by Saenz
et al. in 2010 [262] which explicitly considers some aspects of the innate immune re-
sponse. For simplicity, we refer to this model as "the Saenz model" throughout this thesis.
A key assumption of the TIV model is that as soon as a target cell becomes infected
it starts releasing progeny virions. Experiments have shown though that the influenza
virus requires some time to replicate within an infected cell [159]. In the Saenz model the
authors assume that when a target cell becomes infected it first enters an eclipse phase,
before it starts releasing progeny virus. We underline that Baccam et al. also studied
the effects of adding an eclipse phase to the TIV model in [24]. This eclipse phase is
important within the scope of this thesis firstly because it slows down viral kinetics and
secondly because the cells which are in it are natural candidates for a potential mutation.
This will be further elaborated in section 3.4.
The Saenz model has the following formulation:
dT
da
=−βV T −φFT (3.4)
dEα
da
= βTV − kαEα (3.5)
dW
da
= φFT −mβVW −awW (3.6)
dEγ
da






= kαEα + kγEγ −δ I (3.9)
dV
da
= pI − cV (3.10)
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dF
da
= nqEγ +qI −dF (3.11)
(3.12)
In this model:
• T (a) is the number of susceptible target cells at time a. T0 is the epithelial cell
population size of the equine respiratory tract (the data used in the Saenz et al.
paper came from experiments in horses).
• V (a) is the viral load at time a, and is expressed as the number of RNA copies per
milliliter of nasal secretion.
• Eα(a) is the number of previously fully susceptible target cells at time a that have
been infected but are not yet releasing progeny virions. This compartment is called
E1 in the Saenz et al. paper [262]. We change the notation here only for the sake
of clarity because we will later introduce a second strain to the model.
• kα is such that 1/kα is the average duration of the eclipse phase of Eα cells.
• F is the IFN that infected cells are secreting.
• β is the rate at which free virions infect available target cells.
• φ is a measure of the efficiency of IFN to induce an antiviral state in target cells, and
is expressed in IFN fold change daily. Moreover, φT is the rate at which susceptible
cells become protected due to the action of IFN.
• W (a) is the number of prerefractory cells at time a, which are target cells which
have been primed by IFN but are not yet fully protected.
• aw is such that 1/aw is the average time that it takes for a prerefractory cell in W to
become fully protected. This was denoted as a in [262], but we changed it here
because we use a to denote the age of infection.
• m is the IFN-reduced infectivity, so that 0 < m ≤ 1, where values close to 0 mean
that IFN greatly reduces infectivity and if m = 1 then IFN has no effect on infectivity.
Prerefractory cells W become infected at a rate mβV .
• Eγ(a) is the number of cells at time a that used to be prerefractory but have been
infected and have the virus replicating within them. Just like Eα cells, they are not
yet releasing any progeny virions. Similarly to Eα , this compartment is called E2 in
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the Saenz et al. paper but we changed it here for the sake of notational clarity in
the extended two-strain Saenz model, which we will present in section 3.4.
• kγ is such that 1/kγ is the average duration of the eclipse phase of Eγ cells.
• R(a) is the number of refractory cells at time a , which are fully immune to the virus.
• I(a) is the number of infected cells at time a that are producing progeny virions.
• δ is the death rate of infected cells.
• p is the production rate of progeny virions by infected cells.
• c is the clearance rate of free virions.
• q is the rate per day at which infected cells I produce IFN.
• n is the IFN-reduced production.
• d is the rate per day of IFN clearance.
All these compartments are illustrated in Figure 3.1, which is taken directly from the
original Saenz et al. paper [262].
Fig. 3.1 Diagram of the infection dynamics in the Saenz model. This figure is taken directly from [262].
The Saenz model is based on the following assumptions:
• The binding of free virions with target cells causes only a negligible decrease in
the viral load, which is why there is no −βV T term in equation (3.10).
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• Once a cell becomes fully immune to infection and enters the R compartment, it
cannot leave.
• Infection leads to death for cells in the I compartment, either due to the detrimental
effects of the virus inside them or due to the action of the immune system.
The Saenz model takes into account some key immunological factors that could poten-
tially affect the evolution of influenza, and given that it consists of a system of ODEs
it is also computationally efficient. This is why we use it here as the basis of our own
within-host model, which we will present in section 3.4 and then build upon in sections
3.5 and 3.6.
3.3 The TIV model with deterministic emergence
3.3.1 Model presentation
Since our goal in this chapter is to develop a within-host model for the evolution as well
as the dynamics of influenza, a useful starting point is to extend the Baccam et al. TIV
model from [24] to include two strains and study the resulting emergence dynamics. This






= β1TV1 −δ1I1 (3.14)
dI2
da
= β2TV2 −δ2I2 (3.15)
dV1
da
= p1I1 − c1V1 (3.16)
dV2
da
= p2I2 − c2V2 (3.17)
Everything is defined in the exact same way as in the original TIV model. Namely, T (a) is
the number of target cells at time a, Vi(a) is the viral load of the ith strain at time a, Ii(a)
is the number of cells at time a that are infected by the ith strain, βi is the infectivity rate
of the ith strain, ci is the clearance rate of the ith strain and pi is the rate of production of
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new virions of the ith strain by a cell in the Ii compartment.
This model is based on all the same assumptions as the TIV model, and furthermore
supposes that:
• Target cells can only be infected once and only with a single strain. No coinfection
can occur at the cellular level.
• There is no competition between strains except for available target cells.
3.3.2 Methods
The aim of the two-strain TIV model is to explore the infection dynamics when a mutant
strain appears within a host sometime during the course of an influenza infection with a
resident strain. Therefore the host is initially infected only with the resident strain (strain
1 in the notation of our model). Infection begins via the introduction of some virions of
the resident strain inside the host. This is in accordance with data that influenza uses
virions to spread among individuals [152]. These virions start entering the host’s target
cells and replicating inside them. While the replication happens instantaneously in this
model, it plays a vital role in the model dynamics. This is because viral replication is an
error-prone process [264], so we assume that at some time α a mutation occurs which
leads to a cell that was originally infected with the resident strain to produce mutant
virions instead. Therefore mutation is modelled here as the introduction of some mutant
viral load inside the host at some time α during the infection. After time α both strains
are circulating inside the host and compete against each other for available target cells
either until the end of the infection or until one of them disappears.
Here the time of appearance of the mutant strain α does not depend on the age of
the infection, the amount of target cells still present or the viral load of the resident
strain. This assumption is oversimplifying and will be changed in section 3.5, where
the emergence of the mutant will happen stochastically and α will be a function of the
host’s current state. But throughout this section α is treated as a fixed parameter of
the model, which means that we are forcing the appearance of a mutant strain. But as
we will demonstrate in section 3.3.3, under certain conditions the mutant viral load only
decreases after its forced appearance. We will not consider this case to be a mutant
strain emergence, merely an appearance. Therefore in this section emergence is defined
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as the appearance of the mutant strain at some time α , after which the mutant viral load
increases (even if that increase is very small and the mutant viral load disappears quickly
after its introduction at α).
Our extended two-strain TIV model has the following initial conditions:
• α ∈ [0,D], where D is the duration of the infection. The case that α = 0 is a
coinfection with two strains instead of a within-host mutant emergence, but we
include it here for the sake of mathematical convenience.
• T (0) = 3.5× 1011. This is the estimate for the number of epithelial cells in the
equine respiratory tract, as given in Saenz et al. [262].
• V1(0) = 0.16. This value comes from [262] as well, but was halved to account for
the appearance of a second strain.
• I1(0) = 0.
• V2(0) = 0. This is because there are no cells infected with the resident strain at
time 0, so no mutation could have taken place.
• I2(0) = 0.
• V2(α)=0.16. This is the same as the initial viral load of the resident strain, and also
includes the case of a coinfection.
• I2(α) = 0.
The parameter values are shown in table 3.1, and they all come from the Saenz et al.
paper [262]. We will refer to the parameter values in table 3.1 as the "reference values".
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Parameter Description Value Units Source












ci Free virus clearance rate
for ith strain
5.2 Rate of virus
clearance day−1
[262]








Table 3.1 Parameters of the two-strain TIV model
We note that the virus shedding data were obtained as daily measures of RNA copies
per milliliter of nasal secretion (NS), as it is reported by Saenz et al. in [262].
We will consider three cases for the relative fitness of the mutant compared to that of the
parent resident strain: a neutral mutant which despite its mutation is functionally identical
to the resident strain (this is the case for many influenza mutations, as stated in [297]), a
weaker mutant which leads to infected cells dying twice as quickly and a fitter mutant
which doubles the lifespan of infected cells. In the notation of the model, δ2 = 2δ1 for the
weaker mutant and δ2 = (1/2)δ1 for the fitter mutant. The biological motivation here is that
the fitter mutant could have a beneficial mutation which interferes with immune signalling
pathways, thus slowing down the immune response. The results of the two-strain TIV
model using this definition for the fitness of the mutant will be presented in section 3.3.3.
But we underline that this is not the only way in which we can defined the relative fitness
of the mutant in this model. The ith strain has four parameters associated with it, namely
the death rate of infected cells δi, the viral clearance rate ci, the transmission rate βi and
and the virion production rate pi. Therefore we could also define a beneficial mutation as
one that leads to a higher rate of production of mutant virions p2 or to a lower clearance
rate c2. The effects of these different definitions on some key infection-related quantities
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will also be presented in section 3.3.3.
The model is implemented in Matlab by first running the original TIV model from section
3.2.2 from time t = 0 until time t = α . That is because until time α both V2 and I2 remain
at zero. Then from time t = α until time t = D we run the full two-strain TIV model.
Conceptually this is equivalent to running the two-strain TIV model from t = 0 until t = D
and switching the value of V2(α) from 0 to 0.16. Various plots in this chapter will be in
log-scale (this will be explicitly stated). Since all plots were generated in Matlab, we note
that Matlab’s log function refers to the natural logarithm.
3.3.3 Results
Results using the reference values
We will begin our analysis of the two-strain TIV model by first assuming that the parame-
ters are fixed at their reference values from table 3.1. We also assume that the relative
fitness of the mutant strain depends only on the choice of the death rate of cells infected
with the mutant, namely δ2.
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(a) The curves for V1 and V2 as well as the curves for I1 and
I2 fully overlap because this plot represents a coinfection with
two functionally identical strains.
(b) Here the mutant is neutral and therefore functionally identi-
cal to the resident strain, but it emerges at time α = 0.3. This
is why the I2 and V2 curves remain below the I1 and V1 curves
respectively. When plotting the log curves of I1 and I2 we be-
gin at some time t > 0 and t > α respectively to avoid plotting
y-values at or around −∞.
(c) I1 and I2 curves fully overlap due to coinfection with iden-
tical strains.
(d) The disadvantage of the neutral mutant strain which ap-
pears here at α = 0.3 means that throughout the duration of
the infection the number of cells it infects is much smaller than
the number of cells that the functionally identical resident cell
infects.
(e) V1 and V2 curves fully overlap due to coinfection with iden-
tical strains.
(f) The later appearance of the mutant strain compared to the
case of coinfection in plot (e) has a very strong impact on its
viral load.
Fig. 3.2 Infection dynamics for a neutral mutation and two different values for the time of emergence α . Here δ2 = δ1 = 2.
The plots in the left column are the result of simulating the model with α = 0. The plots in the right column are the
result of simulating the model with α = 0.3. The two plots in each row describe the same compartments, but for a
different α . A pairwise comparison in each row shows that the later α leads to lower mutant viral load as well as a
smaller number of cells infected by the mutant throughout the duration of the infection.
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Figure 3.2 illustrates the dynamics of the target cells, infected cells and viral loads of the
two strains in the case of a neutral mutation and for two different values of the mutant
appearance time α : the plots in the left column represent the case of a coinfection with a
resident and a neutral mutant strain and therefore assume that α = 0, while the plots in
the right column assume that α = 0.3 days. Given that this difference in α is the only
difference between these two columns, a comparison between them can provide some
initial insight into the effects of the emergence time α on certain key infection dynamics.
More specifically, a comparison between plots (a) and (b) shows that the later α led to a
smaller viral load for the mutant throughout the duration of the infection, as opposed to
its viral load in the case of a coinfection. This is also true for the number of target cells
infected by the mutant strain throughout the infection. Since we used only two different
values for the emergence time α here, we will now investigate this negative effect of a
later α on the mutant’s viral load in more detail.
(a) Deleterious mutation : in the case of α = 0, which is when∫D
0 V2 achieves its maximum, the weaker mutant has a sig-
nificantly smaller cumulative viral load compared to the fitter
resident strain
(b) Neutral mutation : the y-intercept of both curves is the
same because the case α = 0 represents a coinfection with
two functionally identical strains, both of which have the same
initial viral load.
(c) Beneficial mutation : the fitter mutant attains its maximum cumula-
tive viral load at α = 0, and it is larger than the corresponding cumula-
tive viral load of the weaker resident strain.
Fig. 3.3 The cumulative viral load of each strain as a function of the time of emergence α .
3.3 The TIV model with deterministic emergence 83
To further explore the importance of the time of emergence, we can examine how the
cumulative viral load of each strain changes with the emergence time α . The cumula-
tive viral load of the ith strain is defined here as the area under the viral load curve of
the ith strain, namely
∫ D
0 Vi(a)da, where D is the duration of the infection in days. Our
results in figure 3.3 show that for all three types of mutants the cumulative viral load is
computationally a non-increasing function of the emergence time. We observe that in all
three plots there is an initial rapid decrease in the cumulative viral load of the mutant,
which illustrates the strong effect of α on the spread of the mutant. We note though that
after some α the cumulative viral loads of both strains appear to be settling to some
constant value, which suggests that the effect of the emergence time diminishes. This
may be because in these cases the mutant appears so late in the infection that there are
very few or no target cells available to it for infection and therefore it cannot grow its viral
load. To formally assess this though, we will need to investigate the mutant’s window of
emergence.
Fig. 3.4 Example where a fitter mutant appears but fails to establish, as its viral load only decreases after
its forced introduction at α = 1.
Figure 3.4 illustrates the case where a mutant strain appears outside of its emergence
window and therefore fails to grow. We obtained this plot by forcing the appearance of
the mutant at α = 1 day. We emphasize that in our framework this represents a mere
appearance of the mutant strain, but not an emergence.
While figure 3.4 illustrates the viral dynamics when a mutant strain appears too late in
the infection, it does not provide any insight into the width of the mutant’s emergence
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window except that it is shorter than α = 1 day. To investigate this, we can first look into
how many target cells a single cell infected by the mutant can expect to infect before it
dies. If we consider the case of coinfection, namely that α = 0, then this is precisely the
basic reproduction number of the mutant strain Rm0 . A cell infected with the mutant strain
remains infectious for an average of 1/δ2 days before it dies. It releases p2 virions per day
on average, each of which survives for an average of 1/c2 days and can infect any of the
T0 target cells available to it with a success rate β2. Therefore the R0 of the mutant strain







This formula is known and was reported as such by Baccam et al. in their original paper
that first described the TIV model [24]. If the mutant strain appears during the infection
at some time other than α = 0 though then Rm0 might not be a good indicator of the
mutant’s chances of survival. That is because Rm0 assumes that the mutant has the whole
epithelial cell population of the respiratory tract (T0) available to it for infection. But that is
not the case here, as until time a = α the resident strain has been depleting the target
cells. Therefore a more useful measure of the mutant’s window of emergence in this case
is the effective reproduction number Rme f f , which takes into consideration the infection of
target cells by the resident strain and has the following formula:










3.3 The TIV model with deterministic emergence 85
(a) Rme f f (a) of all mutants. The large R
m
0 values of all mutants
are not surprising considering that at time a = 0 there are
3.5×1011 target cells available for them to infect.
(b) Rme f f (a) of weaker mutant. Here the emergence cutoff
time is α∗ = 0.73 days.
(c) Rme f f (a) of neutral mutant. Here α
∗ = 0.74 days. (d) Rme f f (a) of fitter mutant. Here α
∗ = 0.76 days.
Fig. 3.5 The effective reproduction number Rme f f for all types of mutant strains. The values α
∗ were calculated as the
first values of time for which Rme f f < 1.
Figure 3.5 shows how Rme f f changes during the infection for all three types of mutants.
There are two important observations here:
• Rm0 , which is just R
m
e f f (0), can take some high values but this is not surprising given
the abundance of available target cells.
• Rme f f (a) decreases very quickly.
The rapid decrease of Rme f f is due to the reduction in the number of target cells available
to the mutant due to infection by the resident strain. This is why the Rme f f curves follow a
very similar trajectory to that of the target cells, as a comparison between figure 3.5 and
figure 3.2 illustrates. The consequence is that the mutant may only emerge during the
first day of infection in our two-strain TIV model.
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Parameter Sensitivity
We will now investigate the effects of some of the model parameters on the within-host
dynamics, both for the original TIV model and for the extended, two-strain TIV model.
First we will vary some parameters of the original TIV model from section 3.2.1, and
show how these changes affect the viral load during the course of the infection (figure
3.6). Then we will vary some parameters of the two-strain TIV model and illustrate how
they affect some key infection-related quantities (figure 3.7).
For the original, one-strain TIV model we vary the following parameters from 50% up to
150% of their reference values:
• c = 5.2 : the rate of clearance of free virions
• β = 1.4×10−4 : the infectivity rate
• δ = 2 : the death rate of infected cells
• p = 1.4×10−5 : the production rate of new virions by infected cells
• V0 = 0.32 : the initial viral load
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(a) A lower clearance rate c leads to a higher viral load
throughout the infection.
(b) The effect of lowering the death rate of infected cells δ is
similar to that of lowering c, but more pronounced.
(c) Increasing the infectivity rate β speeds up viral kinetics
and leads to an earlier peak for the viral load.
(d) Increasing the rate of virion production p also speeds up
viral kinetics, but unlike increasing β it also leads to a larger
maximal viral load.
(e) Varying the initial viral load V0 does not appear to have a strong effect on the viral load curve.
Fig. 3.6 Parameter sensitivity of the one-strain TIV model. When varying one parameter the rest remain constant at
their reference values.
The following observations can be made from figure 3.6:
• Decreasing the rate of clearance of free virions c and the death rate of infected
cells δ leads to a higher viral load throughout the infection. It also leads to an
increase in the peak viral load.
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• Increasing the infectivity rate β and the virion production rate p speeds up the viral
kinetics.
• Changing V0 does not have a strong effect on the dynamics.
All these observations are unsurprising, but they will provide a useful visual aid in in-
terpreting the effects of the parameters of the slightly more complicated two-strain TIV
model.
As we discussed in section 3.3.2, there are more ways to define the relative fitness of
the mutant other than varying the death rate δ2 of cells infected with it. To study how
a different definition for the relative fitness of the mutant would affect the results of our
two-strain TIV model, we will now vary the strain-specific clearance rate of free virions ci,
infectivity rate βi and the virion production rate pi and explore their effects on some key
infection-related quantities. Specifically, we will study their impact on the cumulative viral
loads of the two strains, the maximal viral loads and the times at which those maxima
were attained.
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(a) The virion production rate pi has the strongest impact on the maximal viral load of the ith strain.
(b) The virion production rate pi and the infectivity rate βi have the strongest effect on the time of the peak viral load of the
ith strain.
(c) Decreasing the clearance rate c1 has the largest positive effect on the cumulative viral load of the resident strain. On
the other hand decreasing p1 and β1 has the largest positive effect on the cumulative mutant viral load, as that provides it
with a significant fitness advantage over the resident strain.
Fig. 3.7 Parameter sensitivity of the two-strain TIV model. Here the mutation is neutral (δ2 = δ1) and α = 0.05 days.
When varying one parameter the rest remain constant at their reference values from Table 3.1.
We can make the following observations based on figure 3.7:
• The results when varying ci and when varying δi are very similar, as their groupings
in all the graphs of figure 3.7 indicate. Though still comparable, changing ci appears
to have a stronger effect on the peak viral load than changing δi for both strains.
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• Increasing pi and βi speeds up the time at which the ith strain achieves its maximal
load. This is not surprising, since a larger pi leads to the viral kinetics happening
more quickly since more virions are produced by each cell infected with the ith
strain. Therefore the time of the peak viral load of the ith strain comes earlier in
the infection. Increasing βi increases the success rate of virions infecting target
cells, thereby also speeding up viral kinetics.
As was the case with the parameter sensitivity analysis of the original TIV model, these
observations are unsurprising. But they indicate that our choice for the relative fitness of
the mutant does not affect the model dynamics in a fundamental way.
3.3.4 Theoretical work
Given the simplicity of the two-strain TIV model, we will follow the work of Hadjichrysan-
thou et al. in [131] to obtain analytical formulas for the cumulative viral load of each strain
and for the number of target cells remaining at the end of infection, which in the notation
of the model are
∫
∞
0 Vi(a)da and T (∞).















To simplify the notation, let AVi =−βi
∫
∞
0 Vida for i = 1,2
Rewriting (3.20) using the new notation, we obtain
β1AV1 +β2AV2 =− lnT (∞)+ lnT (0) (3.21)










I1da = (1/p1)[V1(∞)−V1(0)+ c1AV1 ] (3.23)




I2da = (1/p2)[V2(∞)−V2(0)+ c1AV2] (3.24)










Integrating this we obtain









Viral shedding at the beginning and at the end of an influenza infection is very small, as
various experiments have shown [24, 262]. So we can make the biologically justifiable
assumptions that Vi(∞) =Vi(0) for i = 1,2. We will also assume that Ii(∞) = 0. Under







AV2 = T (∞)−T (0)− I1(0)− I2(0) (3.27)
Considering that T (0), I1(0) and I2(0) are all initial values of the two-strain TIV model and
therefore known, if we had an expression for T (∞) then we could solve for the cumulative
viral loads AV1 and AV2 using equations (3.21) and (3.27). Regrettably I have not been
able to find such an expression from the model equations.
3.3.5 Conclusion
The analysis of our two-strain TIV model with the deterministic emergence of a mutant
strain highlights the biological intuition that the relative fitness of a mutant strain compared
to that of the parent resident strain and the time of appearance of a mutant strain are
critical in determining the mutant’s survival and spread. The model suffers though from
the same limitations as the original TIV model, namely the very rapid near-depletion of
target cells due to infection and the merely implicit inclusion of the immune response. We
expect both of these factors to potentially have a strong impact on emergence dynamics
and on the width of the possible emergence window.
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3.4 The Saenz model with deterministic emergence
3.4.1 Model presentation
The results of the two-strain TIV model show that the time of appearance of the mutant
strain is critical in determining its viability and spread. In the context of the TIV model this
is only because of the depletion of available target cells due to infection by the already
circulating resident strain. Since the goal of this chapter is to build a model that can
capture both the viral and the evolutionary dynamics of influenza within a host, it is
important to investigate if there are other factors that affect the window of emergence of
the mutant strain. A logical next step then would be to explore the effects of the innate
immune response on the emergence dynamics. The biological intuition is to explore how
an infection with a resident strain and its effects on the host immune system impact the
potential emergence of a mutant strain. To this end we extend the Saenz model from
[262], which we have already presented in section 3.2.2, to include two strains. This is
the formulation of our two-strain Saenz model:
dT
da
=−β1V1T −β2V2T −φFT (3.28)
dEα,1
da
= β1V1T − kαEα,1 (3.29)
dEα,2
da
= β2V2T − kαEα,2 (3.30)
dW
dt
= φFT −m(β1V1 +β2V2)W −awW (3.31)
dEγ,1
da
= mβ1V1W − kγEγ,1 (3.32)
dEγ,2
da






= kαEα,1 + kγEγ,1 −δ1I1 (3.35)
dI2
da
= kαEα,2 + kγEγ,2 −δ2I2 (3.36)
dV1
da
= p1I1 − c1V1 (3.37)
dV2
da
= p2I2 − c2V2 (3.38)
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dF
da
= q1Eγ,1 +q2Eγ,2 +q1I1 +q2I2 −dF (3.39)
The definitions of the compartments and the parameters remain as in the original Saenz
model, adjusted only to include a second strain. Here strain 1 refers to the resident
strain and strain 2 to the mutant. Susceptible target cells (T ) become infected by virions
of the resident strain (V1) at an infectivity rate of β1 and by virions of the mutant strain
(V2) at an infectivity rate of β2. They can also become prerefractory to infection due to
the action of type I interferon (F) at a rate φ . While in this prerefractory state (W ), cells
can still be infected by virions of either strain but at a reduced rate mβi. They finally
become refractory and completely immune to infection (R) after they have stayed in this
prerefractory state for an average 1/aw days. Susceptible target cells (T ) that have been
infected by either viral strain but have not yet started releasing progeny virions move
to an eclipse phase (Eα,i) and stay there for an average of 1/kα days until the virus has
finished replicating inside them. Similarly prerefractory cells (W ) that have been infected
by the ith strain first move to an eclipse phase (Eγ,i) and stay there for an average of 1/kγ
days. Cells infected by the ith strain that have reached the virion producing stage (Ii)
die from the infection or as a result of the immune response at a rate δi. They produce
progeny virions at a rate pi and secrete interferon at a rate qi. Cells that have been
infected after they were primed by interferon but have not reached the virion-producing
stage yet (Eγ,1 and Eγ,2) also secrete interferon at a rate of qi, depending on which strain
they were infected by. Circulating interferon decays at a rate d, while free virions of the
ith strain are cleared by the immune system at a rate ci.
The two-strain deterministic Saenz model is based on all the assumptions of the original
Saenz model (section 3.2.2), as well as on the following extension-specific assumptions:
• Cells can only be infected once and only by a single strain.
• There is no competition between strains except for available target cells.
3.4.2 R0 calculation
The basic reproduction number of the resident strain Rr0, and of the mutant strain R
m
0 , can
be derived intuitively from the equations of the two-strain Saenz model. A cell infected
with the resident strain at time a = 0 remains infectious for an average of 1/δ1 days, and
then dies. It produces an average p1 virions per day, each of which survives for 1/c1 days
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on average and can infect any of the T0 available target cells. It is important to note here
that at a = 0 all epithelial cells are target cells. Therefore they are all fully susceptible to
infection at a rate β1 given contact with a virion of the resident strain. This results in the














We can corroborate these formulas using the next generation matrix approach to com-
puting R0 [89]. The infectious subsystem of the two-strain Saenz model associated
with the resident strain consists of the V1, I1, Eα,1, W , Eγ,1 and F compartments. Let
x = (x1,x2,x3,x4,x5,x6)t , where xk ≥ 0, be the number of cells or virions in each compart-
ment of the infectious subsystem. We define x so that its elements correspond to the
order in which the compartments were mentioned, for example x1 corresponds to V1, x2
to I1 etc. The disease free equilibrium of the full two-strain Saenz model is (T0,0,0, ...,0),
so all the compartments except the target cells are at zero. So let x∗ = (0,0,0,0,0,0)t
correspond to the infectious subsystem at the disease free equilibrium. Define F j(x),
where j ∈ {1,2,3,4,5,6}, to be the rate of appearance of new infections in the jth com-
partment of the infectious subsystem. Moreover let V +j (x) be the rate of transfer of cells
into the jth compartment of the infectious subsystem by all other means except a new
infection. Equivalently let V −j (x) be the transfer rate of cells out of the jth compartment.
Finally let V j(x) = V −j −V
+
j . Then using the equations of the two-strain Saenz model,





























Then the Jacobian of F (x) at the disease-free equilibrium x∗ is a 6×6 matrix of all zeros,
with the exception of a single non-zero entry β1T0 in position (3,1). Define F = ∂F∂x
∣∣∣
x∗









c1 −p1 0 0 0 0
0 δ1 −kα 0 −kγ 0
0 0 kα 0 0 0
0 0 0 a 0 −φT0
0 0 0 0 kα 0
0 −q1 0 0 −q1 d

Then the next generation matrix is defined as FV−1, and R0 as its spectral radius [89].







which is the same expression as that given by the intuitive approach. The equivalent
calculations with the infectious subsystem associated with the mutant strain corroborate
the formula for Rm0 shown in equation (3.41).
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3.4.3 Methods
Our approach remains the same as in our two-strain TIV model from section 3.3. We
suppose that infection begins only with the resident strain present, and at some time α
during the infection we force the appearance of a mutant strain.
The time of appearance of the mutant strain α again does not depend on the age of
the infection, the amount of target and prerefractory cells present, the viral load of the
resident strain or the interferon concentration. Similarly to the extended TIV model, α
is treated again as a fixed parameter. Therefore we define emergence again again as
the appearance of the mutant strain at some time α , after which the mutant viral load
increases.
The model has the following initial conditions:
• α ∈ [0,D], where D is the duration of the infection. The case α = 0 represents a
coinfection with two strains and not a mutant strain emergence. It is included here
for the sake of convenience.
• T (0) = 3.5×1011. This is the estimate for the epithelial cell population of the equine
respiratory tract, as given in Saenz et al. [262].
• V1(0) = 0.16. This comes from [262] as well. The authors used an initial viral load
of 0.32, but here it is halved to account for the appearance of a second strain.
• I1(0) = 0.
• V2(0) = 0. Since there are no cells infected with the resident strain at time t = 0
there can also be no mutant virions present.
• I2(0) = 0.
• V2(α) = 0.16. This is the same as the initial viral load of the resident strain.
• I2(α) = 0.
• F(0) = 0. This is because there are no infectious cells at time t = 0.
• Eα,1(0) =W (0) = Eγ,1(0) = R(0) = 0.
• Eα,2(0) = Eγ,2(0) = Eα,2(α) = Eγ,2(α) = 0.
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The parameter values of the model are presented in table 3.2, and almost all come
from the Saenz et al. paper [262]. The only deviation is the value for m, which is the
IFN-reduced infectivity. The authors use m = 1 in [262], but then the susceptibility of pre-
refractory cells to infection is the same as that of the target cells. In order to incorporate
the reduced infectivity of cells primed by interferon in our extended, two-strain Saenz
model, we used m = 0.9 in our simulations. We will explore other possible values for m in
section 3.4.4. We will refer to the parameter values in table 3.2 as the "reference values".
Parameter Description Value Units Source



















ci Free virus clearance rate
for ith strain
5.2 Rate of virus
clearance day−1
[262]
1/ki Average duration of
eclipse phases
1/2 Days [262]
1/aw Average duration of
prerefractory phase
1/4 Days [262]








d IFN clearance 6.8 Rate of IFN
clearance day−1
[262]
φ IFN efficiency 56 (IFN fold change)−1
day−1
[262]
m IFN-reduced infectivity 0.9
α Time of emergence of
mutant strain
Varies Days
Table 3.2 Parameters of two-strain Saenz model
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Initially we will assume that the relative fitness of the mutant strain depends only on
the choice of death rate of cells infected with the mutant. So for a neutral mutation we
assume δ2 = δ1, for a beneficial mutation δ2 = (1/2)×δ1 and for a deleterious mutation
δ2 = 2δ1.
The model is implemented in Matlab by first running the original, one-strain Saenz model
from section 3.2.2 from time a = 0 until time a = α . That is because V2 remains at zero
until time α , which in turn means that all the quantities associated with the mutant strain
are zero. Then at time a = α we run the two-strain Saenz model. Conceptually this is
the same as running the extended, two-strain Saenz model from a = 0 until a = D and
switching the value of V2(α) from 0 to 0.16.
3.4.4 Results
Results using the reference values
(a) The viral load initially decreases due to the inclusion of
the first eclipse phase. We note that the y-axis is in natural-
log scale and that T0 = 3.5×1011 , so ln(T0) = 26.6
(b) The target cells are depleted, but not only due to infection.
A portion of them becomes refractory due to the action of IFN.
(c) The log-trajectories of I1and I2 begin at some time t >
0 and t > α respectively. This is done only for illustration
purposes, as otherwise their y-intercept would be at −∞.
(d) This is the same as plot (c) but is not in log-scale.
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(e) IFN is secreted by cells in the Ii and Eγ,i compartments. (f) The percentages of cells infected with the resident and mu-
tant strains, each normalized by its corresponding average
lifespan.
Fig. 3.8 Within-host dynamics for a neutral mutation (δ2 = δ1) and α = 0.3. All the plots in this figure were generated
in a single simulation of the two-strain Saenz model.
Figure 3.8 illustrates some key disease dynamics for the specific case that a neutral
mutant emerges at time α = 0.3 days. The initial decrease in the viral load that is evident
in plot (a) is due to the effects of the eclipse phase. More specifically, as soon as the
virus is introduced inside the host the virions start entering the host’s target cells. But
that triggers the immune response which starts clearing the free virions (this is captured
by the parameter ci in the model). Moreover the virus requires some time to replicate
within a target cell before new virions can be synthesized and released, specifically an
average of 1/kα = 1/kγ = 1/2 days. Therefore this initial decrease in the viral load can
be attributed to the delay in the production of progeny virions by infected cells, and
to the action of the immune system which is destroying any circulating virions. As we
have already discussed, a potentially problematic aspect of the TIV model with regard
to modeling emergence dynamics is its very rapid near-depletion of target cells. The
two-strain Saenz model rectifies this by incorporating a strong innate immune response
via the anti-viral action of type I interferons, and by including two eclipse phases which
slow down viral kinetics. The result, as shown in plot (b), is that target cells decrease
more slowly compared to the TIV model.
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(a) Deleterious mutation (b) Neutral mutation
(c) Beneficial mutation
Fig. 3.9 The viral loads of both strains during the course of the infection for all three types of mutation. In all cases
the viral load peaks close to a = 2.5 days and then decreases rapidly due to the depletion of the available target cells.
Here α = 0.3.
Figure 3.9 illustrates how the viral loads of both strains change during the course of the
infection for all three types of mutants. We observe that our two-strain Saenz model
appears to capture well the documented peak viral load at around 2 days post-infection
[24, 51, 262]. All three plots show a rapid decline in the viral load following its peak. This
can be explained by the loss of available target cells due to infection and the effects of
interferon, and also by the death of virion-producing infected cells (captured here by the
parameter δi for the ith strain).
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(a) Deleterious mutation : in the case of α = 0, which is when
∫D
0 V2
achieves its maximum, the weaker mutant has a significantly smaller
cumulative viral load compared to the fitter resident strain.
(b) Neutral mutation : the y-intercept of both curves is the same be-
cause the case α = 0 represents a coinfection with two functionally
identical strains, both of which have the same initial viral load.
(c) Beneficial mutation : the fitter mutant attains its maximum cumula-
tive viral load at α = 0, and it is larger than the corresponding cumula-
tive viral load of the weaker resident strain.
Fig. 3.10 The cumulative viral load for each strain as a function of the time of emergence α . For all three mutational
fitness profiles the mutant cumulative viral load is a non-increasing function of α .
Figure 3.10 illustrates the importance of the time of appearance α for the survival and
successful spread of the mutant strain. For all three types of mutation the mutant’s
cumulative viral load is unsurprisingly a non-increasing function of α . More specifically,
for all three cases there is an initial rapid decrease in the mutant cumulative viral load,
followed by its near-settling to some constant value close to zero. This indicates that
after some certain α the effect of the time of appearance on the cumulative viral load
diminishes. It is interesting then to explore if this is because emergence is no longer
possible for the mutant, and what exactly is the associated cut-off value for α . In order
to obtain such exact values for the value α∗ after which the mutant strain can no longer
emerge we can follow the same approach as in section 3.3.3 and use the mutant’s
effective reproduction number Rme f f , which takes the following form:
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where mW (a) are the prerefractory cells at time a that can be infected and Rm0 is known
since it was already calculated in section 3.4.2.
(a) Rme f f for all types of mutation (b) Deleterious mutation : Rm0 = 33 and α
∗ = 1.81
(c) Neutral mutation : Rm0 = 66 and α
∗ = 1.88 (d) Beneficial mutation : Rm0 = 132 and α
∗ = 1.94
Fig. 3.11 Rme f f for neutral, deleterious and beneficial mutations. The value α
∗ is defined as the first value of α for
which Rme f f falls below 1. Despite the considerable differences in the R
m
0 of the three types of mutation, their associated
values of α∗ are very similar.
Figure 3.11 shows how Rme f f changes during the course of the infection for all three types
of mutation. While Rme f f can initially take some very high values, it decreases very quickly.
This is unsurprising given its dependence on the amount of target cells available, which
also explains why the Rme f f trajectories resemble the trajectory of the target cells. This
dependence on the number of target cells available may also explain why, despite the
significant differences in the basic reproduction numbers of the three mutant types, their
associated α∗ values are still very similar. In all three cases, the mutant strain can only
emerge during the first two days of infection.
The two-strain TIV model from section 3.3 has a stricter window for emergence, as a
comparison between figures 3.5 (from section 3.3.3) and 3.11 shows. More specifically,
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the cut-off values α∗ are earlier for the two-strain TIV model for all three types of mutation.
This can be attributed to the very rapid depletion of target cells due to infection in the
TIV model. In the two-strain Saenz model on the other hand, target cells are still being
depleted due to infection but many of them also become prerefractory. This means that
they can still be infected by the already circulating resident strain, but at a reduced rate.
Moreover, in the Saenz model infected cells do not immediately start shedding virus. This
leads to a slower decrease in the number of cells available to the mutant strain compared
to the TIV model, and allows it to successfully appear and spread at later times during
the infection.
Parameter sensitivity analysis
So far we have only used the death rate of infected cells to define the relative fitness of
the mutant strain in our extended Saenz model. We will now investigate how the within-
host dynamics are affected if we use a different definition for the fitness of the mutant.
Moreover the majority of the reference values of our model’s parameters were taken
from the Saenz et al. paper [262], with the exception of the value for the IFN-reduced
infectivity m. We will now also vary some of the extended Saenz model’s parameters and
study their effects on certain key infection-related quantities. The parameters explored
are the following:
• pi : the production rate of virions of the ith strain.
• βi : the infectivity rate of the ith strain.
• φ : IFN efficiency. The rate at which target cells become primed by IFN and move
to the prerefractory class is φF .
• qi : the rate of production of IFN. The cells which secrete IFN are in the Ii and E2,i
compartments.
• ci : the rate of clearance of free virions of the it strain.
• δi : the death rate of cells infected with the ith strain.
• m : IFN-reduced infectivity. Cells in the prerefractory state W have been primed by
interferon and are infected at a reduced rate mβiW .
• kα : 1/kα is the average duration of the eclipse phase Eα .
• kγ : 1/kγ is the average duration of the eclipse phase Eγ .
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The parameters are varied by 50% up to 150% of their reference values. When one
parameter is varied all others remain constant at their reference values.
(a) p1 and c1 have the strongest effect on the maximum of V1
(b) p2 and c2 have the strongest effect on the maximum of V2
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(c) Increasing pi , βi and kα speeds up viral kinetics the most and results in an earlier resident peak viral load.
(d) Increasing pi , βi and kα speeds up viral kinetics the most and results in an earlier mutant peak viral load.
(e) Decreasing c1 and δ1 and increasing p1 has the strongest effect on
∫D
0 V1 .
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(f) Increasing p2 has the strongest effect on
∫D
0 V2 , followed very closely by decreasing c2 and then by decreasing δ2 , p1
and β1 .
(g) Increasing m and decreasing φ , pi and βi have the strongest positive effect on the maximum IFN concentration.
(h) The cell death percentage is defined here as the sum of the integrals of the I1 and I2 percentages during the infection,
each normalized by the corresponding average lifespan of an infected cell. Decreasing δ1 has the strongest effect on cell
death.
Fig. 3.12 Parameter sensitivity analysis for the two-strain Saenz model. Each plot explores the effects of the parameters
on one specific infection-related quantity. Here the mutation is neutral and α = 0.05 days.
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The following observations can be made from figure 3.12:
• The rate of production of virions of the resident strain p1 has an intermediate to
strong effect on all quantities studied. Increasing p1 greatly increases the maximum
and cumulative viral loads of the resident strain, and therefore increases the total
amount of cells infected as well. Increasing p1 speeds up viral kinetics and leads
to an earlier time of peak viral load both for the resident and the mutant strain.
Since the two strains are in competition against each other for available target and
prerefractory cells, a higher p1 leads to lower maximum and cumulative viral loads
for the mutant. The equivalent effects are also observed for p2, though slightly less
pronounced. This is because the mutant strain appears here at α = 0.05, which is
very early but still means that the resident strain has a small advantage over the
mutant.
• Varying the infectivity rate of the resident strain β1 yields very similar results to
varying p1. The same holds for β2 and p2. This similarity is not surprising since pi
and βi have a strong impact on the speed of viral kinetics.
• Decreasing the rate of clearance of free virions of the resident strain c1 has a strong
positive effect on the maximum and cumulative viral loads of the resident strain.
This is not surprising, since a lower c1 implies a less efficient immune system
response with regard to killing off circulating virions. Due to competition between
the strains decreasing c1 has a deleterious effect on the mutant strain, such as
reducing the mutant maximum and cumulative viral loads. The rate of clearance of
virions of the mutant strain c2 has the analogous effects.
• The death rate of cells infected with the resident strain δ1 has very similar effects to
that of c1, namely decreasing it greatly increases the maximum and cumulative viral
loads of the resident strain. But unlike c1, δ1 naturally has a significant impact on
the cell death percentage too. Again due to the competition between the resident
and mutant strains, decreasing δ1 has detrimental effects on the mutant strain. The
equivalent effects are observed for δ2.
• The average duration of the first eclipse phase 1/kα has a strong effect on the time
of the peak viral load both for the resident and the mutant strains. This is because
a larger kα means that fully susceptible target cells move more quickly into the
virion producing stage, thus speeding up viral kinetics. The parameter kα also has
an intermediate effect on the maximum IFN concentration. Cells in the first eclipse
phase do not secrete IFN. It is only infected cells (Ii) and cells in the second eclipse
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phase (Eγ,i) which secrete IFN, but a smaller kα means that cells stay in the first
eclipse phase longer.
• The parameter qi affects only the peak IFN concentration and the cell death. Since
qi is the rate of production of IFN by cells in the Ii and Eγ,i compartments it is
unsurprising that it has an effect on the maximum IFN concentration. Moreover,
since higher amounts of IFN mean that more target cells become prerefractory
and then completely immune to infection, it is not surprising that increasing qi
decreases the cell death throughout the infection.
• The IFN efficiency φ has a significant effect on the maximum IFN concentration.
This is expected as increasing it leads to target cells becoming prerefractory at
a faster rate, which in turn decreases the amount of IFN-secreting infected cells
throughout the infection.
• The IFN-reduced infectivity of prerefractory cells m has unsurprisingly a significant
effect on the peak IFN, as well as a weak effect on cell death.
Fig. 3.13 The effects of varying some key mutant-specific parameters on the cut-off time for emergence α∗. The
parameters explored here are the ones which appear in the Rm0 formula. None of them appear to have a significant
effect on α∗, as its values only range inside [1.85,2.03]
Our default definition for the relative fitness of the mutant assumes that mutation affects
only the death rate δ2 of cells infected by the mutant strain. The biological intuition
here is that a fitter mutant could have a beneficial mutation that interferes with immune
signalling pathways, thus slowing down the immune response. Some other strain specific
parameters which could have been used to define the mutant’s relative fitness are pi, ci
and βi. We could think of a beneficial mutation as one that increases the accuracy and
reliability of the viral RNA replication, leading to more viable virions being synthesized
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and therefore to a larger p2. Or as one that improves the virions’ efficiency in binding
with target cells and therefore leads to a higher β2. Or finally as one that improves the
virions’ evasion of the host immune response and in turn leads to a lower c2. We can use
figures 3.12 and 3.13 to conclude that the within-host dynamics of the two-strain Saenz
model would be similar had any of these possible definitions been used instead of the
default, which depends only on δ2. Firstly, we have already been demonstrated using
figure 3.12 that the effects of δ2 and c2 are very similar. If the relative fitness depended
instead on the production rate of virions p2 or the infectivity rate of the mutant strain β2,
the main difference would be that the viral loads would peak slightly earlier during the
infection. That peak would still occur sometime between the second and third days of
infection though (figures 3.12c and 3.12d), thus not affecting the within-host dynamics in
a substantial manner. Therefore we may conclude that the results of our extended Saenz
are not highly sensitive to the definition of the relative fitness of the mutant strain.
3.4.5 Conclusion
Our two-strain Saenz model with deterministic emergence appears to be a good basis
for a within-host model that describes the dynamics and evolution of influenza. Some of
its most significant advantages for the scope of this thesis are its computational efficiency
and its inclusion of the innate immune response and of the two eclipse phases. The
analysis of our extended Saenz provided some valuable insight into the importance
of the time of emergence for the spread of the mutant strain. So far though we have
forced the appearance of a mutant strain by choosing a specific value for α and using it
as one of the model’s fixed parameters. But as we demonstrated in section 3.4.4, if α
comes very late in the infection then the mutant will fail to grow. Therefore a next step in
understanding the emergence dynamics of a mutant strain would be to consider in more
depth the factors which affect its viability at different appearance times and incorporate
them into our extended Saenz model.
3.5 The Saenz model with stochastic emergence
3.5.1 The probability of emergence
When considering an infection with only the resident strain, at time α there are Eα(α)+
Eγ(α) cells which have been infected by the resident strain but have not yet started
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releasing progeny virions. Since we are assuming that influenza mutations are the
results of mistakes occurring during the error-prone viral replication phase, an eclipse
cell infected originally by a virion of the resident strain could produce virions of the mutant
strain instead. The mutation rate ε̂ of influenza, expressed as substitutions per nucleotide
per cell infection (s/n/c), has been estimated in various published studies [264, 297]. But
not all nucleotide mutations result in antigenic changes. We restrict our calculations
only to the nucleotides which code for the hemmagglutinin (HA) and neuraminidase
(NA) proteins. This is because various analyses have shown that mutations in these
two influenza surface proteins are the main drivers of antigenic drift [200, 207, 291].
Most substitution mutations do not result in functional or antigenic changes in the in-
fluenza proteins [312]. Therefore we will further assume that only 10% of the HA-coding
and NA-coding nucleotides can potentially generate an antigenic change and that only
0.05% of the substitution mutations in these nucleotides will successfully result in an
antigenic change. This probability that a substitution mutation in the HA- and NA-coding
nucleotides will result in an antigenic change is chosen by us and is semi-arbitrary. We
will address this at length in the Discussion section of this chapter.
Continuing towards our expression for the probability of emergence, it is important to
also account for the fact that substitution errors often result in lethal mutations [200],
while we are only interested in viable ones. Moreover experimental studies have shown
that different types of mutation occur at different frequencies [297]. Using a deleterious







where the multiplication by kα and kγ is because at time α only a portion of cells in the
two eclipse phases will to move to the I2 class and start releasing progeny virions. Here
ε is the mutation rate when restricting only to the HA- and NA-coding nucleotides that
could lead to antigenic mutations and ρw is the probability that mutation leads to a viable,
weaker mutant.
As we have previously demonstrated in section 3.4.4, not all viable mutants can grow
following their appearance. To account for this, an approach used in models of mutant
strain emergence at a population level is to calculate the mutant’s probability of survival
using results from branching processes [307], while also accounting for the loss of
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available hosts due to infection by the resident strain [143]:
P(survival |appearance at α) = 1− 1
Rme f f (α)
where Rme f f (α) is the effective reproduction number of the mutant strain. This term
however does not take immunological feedbacks, such as the size of the resident strain
and its impact on the mutant viral load, into account. If a mutant strain survives but
remains at a very small viral load throughout the infection or only infects very few target
cells then its impact on the infection dynamics could be negligible compared to that of the
resident strain. Therefore we will only consider that a mutant strain successfully emerges
within a host if it reaches a certain threshold in its total number of virions. That threshold
will be explored in section 3.5.2. Using again a deleterious mutation as an example, our
expression for the probability of survival and adequate growth of a weaker mutant strain
is then:
Pw(survival & growth |appearance at α) =
(
1− 1








where 1 is the indicator function and s∗ is the aforementioned size threshold. It is impor-
tant to note that
∫ D
α
V2(a)da depends on the time of appearance α but also on the fitness
of the strain.
Using equations (3.43) and (3.44), we can express the rates of appearance, survival and











































Emergence at some time α inherently assumes that before α either no mutant appeared
or some mutant appeared but failed to establish. Using results from survival analysis
and treating λ (α) as a hazard function, we can express the probability that no mutant
strain has emerged up to time α as e−
∫
α
0 λn(a)da, using the case of a neutral mutation
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as an example. Therefore using the rate of emergence at α and the probability that no
emergence has occurred before α , we may express the probability density function f for
the emergence of a mutant strain at time α as:








f f (α) = λ f (α)× e−
∫
α
0 λ f (a)da
This formulation depends on the following underlying assumptions:
• An infected cell can only produce virions of a single strain.
• The duration of the infection at the cellular level is exponentially distributed and
contacts follow a Poisson process. This is necessary for the probability of survival
being
(
1− 1/Rme f f
)
[75].
The parameter values are in table 3.3. The values of ρw, ρn and ρ f all come from [297],
where Visher et al. generated 128 viruses from an influenza A strain (A/WSN/33/H1N1),
each with a single nucleotide mutation, and then performed a competitive fitness assay to
measure their fitness against that of the parent strain. The percentage of lethal mutations
was found to be 30%. It is important to note that the authors grouped weakly deleterious
and neutral mutations together in their analysis, because the fitness values they derived
for their weakly deleterious mutants were not statistically different from the fitness value
of the parent strain. Since in this chapter we are not differentiating between weakly and
strongly deleterious mutations, we use the results of the authors’ "weakly deleterious
and neutral mutations" group to inform only the parameters of our neutral mutant. A
similar analysis by Lyons & Lauring in [200] resulted in very similar probabilities for lethal,
deleterious, neutral and beneficial mutations.
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Parameter Description Value Units Source
Nuc Number of nucelotides in
influenza genome
13588 n [44]
NucHA Number of nucelotides
coding for HA
1778 n [44]
NucNA Number of nucelotides
coding for NA
1413 n [44]
ε̂ Mutation rate (all
nucleotides)
2.3×10−5 s/n/c [264]
ε Mutation rate (given 10%







ρw Probability that mutation







ρn Probability that mutation







ρn Probability that mutation







Table 3.3 Parameters for the extended Saenz model with stochastic emergence
In this section the three types of mutation are defined again by the choice of the death
rate δ2 of cells infected by the mutant strain. As a result, the effective reproduction
numbers Rme f f for all three mutants are known from section 3.4.4.
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3.5.2 Results
(a) The emergence density of a mutant strain for all types of mutation.
Using Matlab’s trapz function we calculated the cumulative within-host
probability as 0.71 for a weaker strain, 0.91 for a neutral and 0.37 for
a fitter.
(b) The trajectory of cells in the two eclipse phases Eα and Eγ to-
gether.
(c) The rate of appearance for each type of mutant strain. The plot
indicates that mutants can appear on most days of the infection. Given
the definition of app(α) it is not surprising that its curve resembles that
of the eclipse cells in plot (b).
(d) The total viral load for each type of mutation given a forced appear-
ance at α . The cut-off value s∗ is the minimum growth condition from
equation (3.44), which a mutant needs to meet in order to emerge
successfully. Here s∗ = 1.
Fig. 3.14 Stochastic emergence of all three types of mutants in the two-strain Saenz model. Here s∗ = 1.
Figure 3.14 shows how the emergence density of a mutant strain changes during the
course of the infection for each type of mutation [plot (a)]. Initially there are very few
eclipse cells [plot (b)], resulting in small chances of emergence. As the number of the
eclipse cells increases so does the density of emergence, until it reaches a maximum
and then drops to and remains at zero. This is because of the survival probability term
in our expression for the emergence density, which requires that the mutant’s effective
reproduction number Rme f f is larger than 1 at the time of emergence. Moreover the cut-off




that any mutant which appears at some time α must meet in order to emerge successfully
[plot (d)]. These two conditions force the possible emergence window to be early in the
infection, specifically within the first two days for all mutants when s∗ = 1, as is the case
in figure 3.14. It should be noted however that mutants can keep appearing through most
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of the infection, as plot (c) illustrates. The within-host emergence probability in the cases
of a neutral and a weaker strain is very high (0.91 and 0.71 respectively), while for a fitter
mutant it is significantly smaller (specifically 0.37). This is due to the findings of Visher et
al. in [297], according to which very few mutations lead to a viable, fitter mutant. It can
still be argued though that the cumulative emergence probabilities are very high in our
model for all three types of mutation. We will investigate the reasons behind this in the
next section (section 3.5.3) and also address them at length in the Discussion section of
this chapter (section 3.7).
Fig. 3.15 The cutoff value α∗ after which no successful emergence can occur as a function of s∗. This




V2(a)da drops below the given s∗. For a mutant to reach a higher total viral load it needs to emerge
earlier in the infection, which is why α∗ is a non-increasing function of s∗.
Figure 3.15 shows the sensitivity of the stochastic emergence model to the choice of
the sufficient growth cutoff value s∗. By definition as s∗ increases our condition for the
minimum total mutant viral load given emergence at some time α becomes stricter. As a
result the latest time α∗ after which no mutant could reach the minimum size s∗ comes
earlier in the infection. This is why α∗ is a non-increasing function of s∗. Since a very
small value for the growth cutoff would allow for a wider window of emergence, it is
useful to calculate what is the smallest value that s∗ could take. For analytical purposes
we suppose D = ∞ throughout this calculation. If we introduce some mutant viral load
V2(0) at time α = 0 and only allow it to decrease until it reaches zero, then its virion
production rate p2 must be zero. Then from the dV2/da equation of the extended Saenz
model (equation 3.38 in section 3.4) it follows that:
V2(a) =V2(0)× e−c2a
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Therefore mathematically the minimum value that s∗ could take is the mutant initial viral
load V2(0), but that corresponds to a mutant strain which dies off very quickly. So to
ensure sufficient growth we will require that at least s∗ ≥ 2V2(0).
3.5.3 The mutant’s window of emergence
As we discussed in the previous section, our within-host emergence density results in a
very narrow emergence window for the mutant strain for all three types of mutation. In
this section we will try to identify the factors that lead to such a small potential emergence
interval. For the sake of simplicity we will only consider the case of a neutral mutant strain.
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(a) The emergence density for a neutral mutant. Here f (α) = 0 ∀α ≥
1.68 because any α > 1.68 does not satisfy our final size requirement
s⋆ = 1 (though it does satisfy Rme f f (α) > 1 until α = 1.88). We note
that f reaches its peak at αpeak = 1.39 days.
(b) The population of Eα cells peaks earlier than that of the Eγ cells.
We note that there are 2 y-axes in this plot and they have different
scales.
(c) The number of target cells remains relatively constant until the viral
load approaches a value close to its peak, and then it decreases very
rapidly. We note that there are 2 y-axes in this plot and they have
different scales.
(d) The same plot as (c) but not in log-scale. We note that there are 2
y-axes in this plot and they have different scales.
Fig. 3.16 The window of emergence of a neutral mutant strain in our within-host model when the parameters are fixed
at their reference values from Tables 3.3 and s⋆ = 1. All plots are the result of a single simulation of our within-host
model.
Figure 3.16 shows how the emergence density of a neutral mutant strain changes
throughout the infection [plot (a)], along with some relevant within-host quantities. Plot
(b) shows how the number of target cells, refractory cells and eclipse cells changes
throughout the infection. We focus on the eclipse cells Eα and Eγ because they are the
candidates for mutation. We see that Eα cells are more prominent compared to Eγ cells
earlier in the infection. This is not surprising, since Eγ cells are cells which started as
target cells, then moved into the prerefractory W compartment via the action of interferon
and then became infected at a reduced rate mβ . Eα cells on the other hand are simply
target cells which have been infected but have not reached the virion-producing stage yet.
Since the Eα cells increase and reach their peak numbers earlier than the Eγ cells, we
may conclude that their contribution to the potential emergence of the mutant is higher
than that of the Eγ cells. We note that the numbers of refractory cells begin to take off
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in the middle of the second day of infection, and can account for some of the decrease
in T . Plot (c) shows how the numbers of target cells and virions change in log-scale
throughout an infection with the resident strain. We observe that the population of target
cells remains relatively constant in the initial stages of the infection until the viral load
approaches its peak, and then it depletes very rapidly. Since the number of target cells
T makes up part of our expression for the effective reproduction number Rm,we f f of the
mutant, this drastic decrease in T also leads to a rapid decrease in Rm,we f f . As a result,
if the mutant had appeared under these circumstances it would not be able to spread
efficiently due to the lack of target cells available to it. The minimum final size condition
in our expression for the emergence density accounts for such mutants and ensures that
they cannot emerge. This explains why the window of emergence cannot extend past
α⋆ = 1.68, which is the first α that fails our s⋆ = 1 condition. We underline that plot (c)
also illustrates the log-linear phase of rapid virus growth followed by the log-linear phase
of slower virus decay. Plot (d) depicts the same quantities as plot (c), namely the number
of target cells and virions, but not in log-scale. We include it in this figure because it
highlights the small interval from the time that the viral load starts to grow until the time
that emergence is no longer possible in our model. It further highlights the two phases
of exponential growth and decay of the virus. Using these four plots, the shape of the
emergence density can be explained as following:
• Eα cells start to increase towards the end of the first day of infection. Eγ cells
and virions start to increase later in the infection. Therefore for α < 1, Eα cells
appear to contribute the most to the potential emergence of the mutant. Since their
population is still very small though, the probability of emergence is also very small
during the first day of infection.
• From the beginning of the second day of infection and until time αpeak = 1.39 (which
corresponds to the maximum of f ) the population of Eα cells grows considerably,
while the population of Eγ cells starts to grow but is still rather small. The viral load
has also increased considerably from its initial size, which is not surprising given
the rapid viral expansion displayed in plot (c). Moreover, by the time α = αpeak the
number of target cells has already started to decrease but is still very large. This
abundance of eclipse cells, virions and target cells can account for the increase in
f during the second day of infection until it reaches its peak at αpeak = 1.39 days.
• Between α = 1.39 and α = 1.68, which corresponds to the cut-off value for emer-
gence in our model given s⋆ = 1, the number of virions and eclipse cells keeps
increasing. On the other hand though the population of target cells has decreased
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rapidly to approximately 1% of its original size. This can explain the quick decrease
of the emergence density following its peak.
We may conclude that the main determinant of the width of the emergence window is the
decrease in the number of target cells. A rapid depletion in the population of target cells
entails a narrow emergence window.
3.5.4 Rederiving the probability of survival
In order to further explore the emergence potential of a mutant strain we limit our attention
only to the early stages of the mutant’s appearance at some time α and investigate its
probability of survival in a stochastic setting. We follow a method presented by Pearson
et al. in [227] to obtain a formula for the probability of extinction by transforming our
two-strain Saenz model into its equivalent multi-type branching process. The key differ-
ence between our work and the results published in [227] is that the authors considered
a coinfection with two strains instead of a mutant strain appearance and focused on
the populations of target cells, infected cells and virions. We on the other hand also
include eclipse cells and consider the potential effect of the host immune response via
the inclusion of prerefractory cells. This accounts for the fact that the later a mutant strain
appears the fewer cells are available to it either due to infection by the resident strain or
due to the action of type I interferon.
Since we are only interested in the very early stages of a mutant strain appearance at
some time α , we assume as in [227] that there are no variations in the number of target
and prerefractory cells, namely T (α) = T and W (α) =W are constants. For the sake
of clarity we combine the two eclipse phases Eα,2 and Eγ,2 into a single eclipse phase
E2 with duration 1/k, where the subscript 2 is because we are interested specifically
in the mutant strain (strain 2). This last simplification does not alter the model in any
fundamental way since we have been assuming so far that the duration of the two
eclipse phases Eα,2 and Eγ,2 are actually equal. The relevant equations adapted from
the two-strain Saenz model are:
dV2
dt
= p2I2 − c2V2
dE2
dt
= β2V2T +mβ2V2W − kE2




Then our system can be fully described by a state vector m⃗ = (nV2,nE2,nI2), where nV2 is
the number of virions, nE2 the number of eclipse cells and nI2 the number of infectious
cells.
Event Description Rate Transition
vector
V2 → E2 Virion infects cell r1 = (β2T +mβ2W )V2 (0,1,0)
E2 → I2 Eclipse cell becomes
infectious
r2 = kE2 (0,−1,+1)
I2 →V2 Infectious cell releases
virion
r3 = p2I2 (+1,0,0)
V2 → /0 Virion dies r4 = c2V2 (−1,0,0)
I2 → /0 Infectious cell dies r5 = δ2I2 (0,0,−1)
Table 3.4 Two-strain Saenz model: the discrete time multi-type branching process





where Z(m⃗) = ∑5i=1 ri(m⃗). Since we can obtain the probability of survival from the
probability of extinction, we define extinction as the state 0⃗ = (0,0,0) and, using the
same notation as Pearson et al. in [227], we express the probability of extinction as:
E (m⃗) = ∑
i
Pi(m⃗)E (m⃗+dm⃗i) (3.45)
where dm⃗i refers to the ith transition vector from table 3.4. The reasoning behind this
expression is as follows: if the system starts at some state m⃗ then it will transition to some
state m⃗+dm⃗i with probability Pi(m⃗). Then the probability of extinction from state m⃗ is the
sum of the extinction probabilities of all states which differ from it by a single transition,
weighted by the probability of these transitions. Then substituting in the expressions for
Pi(m⃗) and E (m⃗+dm⃗i) we obtain:



















































where PV2 , PE2 and PI2 are the probabilities of extinction when starting from a state
where only a single virion, a single eclipse cell or a single infected cell is present
respectively. We now assume as in [227] that the processes of virion, eclipse cell and
infectious cell extinction are independent. Then we may express







Substituting equation 3.47 into 3.46, we then solve for PV2 by setting E2 = 0 and I2 = 0,
for PE2 by setting V2 = 0 and I2 = 0 and finally for PI2 by setting V2 = 0 and E2 = 0.
















V2 and substituting for Z(nV2 ,0,0) we obtain
PV2 =
(β2T +mβ2W )
β2T +mβ2W + c2
PV2PE2 +
c2
β2T +mβ2W + c2
(3.48)
Similarly assuming V2 = 0 and E2 = 0, dividing the resulting expression by P
nI2−1
I2 and
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Finally by setting V2 = 0 and I2 = 0 and following the exact same method we conclude
that
PE2 = PI2 (3.50)
Solving equations 3.48-3.50 we obtain
PV2 = min
( (p2 +δ2)c2





( (β2T +mβ2W + c2)δ2




Fig. 3.17 The probability of survival of a mutant strain given appearance at some time α . P(survival) is
calculated here as 1−PV2 (α) using equation 3.51. The curve resembles the trajectory of the target cells
during the infection.
Since we are modeling the appearance of a mutant as the introduction of some initial
mutant viral load, we can use equation 3.51 to calculate the probability of the mutant’s
survival given appearance at some time α . The result is presented in figure 3.17. The
probability of survival follows a trajectory very similar to that of the target cells. Initially it
is very high and then declines very rapidly until it reaches zero.
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3.5.5 Conclusion
In this section we developed a probability density function for the emergence of a mutant
strain within a host that is initially infected by a resident strain. Our emergence density
takes into consideration the mutant’s effective reproduction number and also includes
a minimum final size requirement for the mutant viral load so as to avoid situations in
which the mutant arises within-host but fails to replicate effectively. Our emergence
density depends on influenza’s mutation rate, which we restricted for our purposes to the
substitution mutations in the NA- and HA-coding nucleotides that specifically result in
an antigenic change. Plotting the emergence density using the reference values for our
two-strain Saenz model parameters showed that the cumulative emergence probability
throughout the host’s infection is high. It also showed that the window of emergence is
very narrow, which our analysis suggests can be attributed mainly to the rapid depletion
of target cells in our model.
3.6 The Saenz model with vaccination
3.6.1 Adding vaccination
There are various different ways to incorporate vaccination in a within-host influenza
model. We will first list four adaptive immune responses to a natural influenza infection
or influenza vaccination and for each one we will suggest a simple way that we could
include it in our model.
• Antibodies targeted against the HA protein block the ability of the receptor binding
site of HA to interact with the host cell surface, thereby preventing attachment
and entry. A simple way to incorporate this in our within-host model could be via
a decrease in the transmission rate βi, as βi captures the successful binding of
virions to target cells.
• Antibodies generated against the NA protein limit the release of virus from infected
cells [180]. This could be added to our model as a decrease in the virion production
rate pi.
• Antibodies targeting the highly conserved external domain of the M2 protein inter-
fere with virus assembly [180]. We could also add this to our model as a decrease
124 A within-host model for the evolution of influenza
in the virion production rate pi, as an inefficient virus assembly would lead to fewer
fully functional infectious progeny virions being produced.
• Cytotoxic T-cells enhance viral clearance, which does not confer protection but is
important for illness recovery [69]. We can capture this in our model as an increase
in the viral clearance rate ci.
We will capture the effects of vaccination simply via an increase in the clearance rates c1
and c2 of the resident and mutant strains respectively. We emphasize that increasing
ci is not the only way in which we could incorporate this aspect of the cellular immune
response (or vaccination in general) to our within-host model. We could also explicitly
add new compartments for antibodies or T-cells, but our aim is to capture the within-host
effects of vaccination in a very simple way. This is because later in chapter 5 we will
combine our within-host vaccination model with a between-host model to investigate
the epidemiological and evolutionary dynamics of influenza across both scales. Since
such cross-scale models can easily become very complicated and computationally in-
tensive, we believe that incorporating vaccination simply as an increase in one of the
strain-specific within-host model parameters provides a good starting point. Furthermore
we argue that our decision to incorporate the effects of vaccination by varying specifically
the viral clearance rates ci as opposed to varying the transmission rates βi, the viral
production rates pi or the death rate of infected cells δi should not have a significant
impact on our model’s results. This is because in section 3.4.4 we performed a parameter
sensitivity analysis of our extended Saenz model and found that varying each one the
strain-specific parameters βi, ci, δi and pi had similar effects on our model’s results.
We will assume that the vaccine is homologous to the resident strain and examine its
impact on some key strain-specific dynamics in three different cases: the case that the
vaccine offers no cross-protection from the mutant strain, the case that the vaccine offers
partial cross-protection from the mutant strain and finally the case that the vaccine offers
full cross-protection from the mutant strain. The case of full cross-protection does not
entail that the vaccine offers full immunity to the mutant strain, only that the effect of the
vaccine is exactly the same on both strains.
We further assume that the host is already vaccinated before the infection begins. Given
our definition of vaccination this means that we implement our extended Saenz model
3.6 The Saenz model with vaccination 125
exactly as it appears in section 3.4, but with a different value for the clearance rates
c1 and c2. We vary c1 and c2 to explore how vaccine efficacy, defined here as the
vaccine-induced increase in the clearance rate c1, affects the dynamics of the two strains.
3.6.2 Results
(a) The viral load of the resident strain becomes smaller throughout
the infection as c1 increases, based on the four values of c1 tested
here.
(b) The viral load of the mutant strain becomes larger throughout the
infection as c1 increases, based on the four values of c1 tested here.
Fig. 3.18 The viral loads of the resident and mutant strains for certain values of the clearance rate c1. Here we assume
that the vaccine has no effect on the mutant strain. The mutant strain is weaker (δ2 = 2δ1) and α = 0.1 days.
Figure 3.18 shows the effects of four different values of the clearance rate c1 on the viral
loads of the resident and mutant strains throughout the infection. Since we assume that
vaccination acts merely by increasing c1, we may think of increasing c1 as the vaccine
having an increasingly stronger effect on the resident strain and becoming more efficient
in clearing it. For the purposes of this figure we assume that vaccination has no effect on
the mutant strain. Plot (a) shows that higher values of c1 correspond to lower viral loads
for the resident strain throughout the infection, while plot (b) shows that the reverse holds
true for the mutant. This is not surprising given our assumption that the vaccine acts
only on the resident but has no impact on the mutant. As the vaccine becomes more
efficient in clearing the resident the mutant strain gains an increasingly larger competitive
advantage, allowing it to grow more effectively and reach higher concentrations.
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(a) The maximum of V1 is computationally a non-increasing function
of c1 . When the vaccine has no effect on the mutant strain then the
mutant gains an advantage in the competition for target cells. This is
why the blue curve remains below the curves corresponding to partial
and full cross-protection.
(b) In the case of no cross-protection the maximum of V2 is compu-
tationally a non-decreasing function of c1 . This is because as c1 in-
creases the host immune system becomes more efficient in clearing
the resident strain, offering an advantage to the otherwise weaker mu-
tant strain.
(c) The percentage of cells infected by the resident strain is computa-
tionally a non-increasing function of c1 .
(d) In the case of no cross-protection, the percentage of cells infected
by the mutant is computationally a non-decreasing function of c1 .
Fig. 3.19 The effects of a vaccine homologous to the resident strain. The left column illustrates the vaccine’s effects
on the resident strain and the right column on the mutant. No cross-protection means that the vaccine has no effect on
the clearance rate c2 of the mutant, full cross-protection that it has the same effect on c2 as it does on c1 and partial
cross-protection that it increases c2 by half the amount that it increases c1. Here the mutant strain is weaker (δ2 = 2δ1)
and α = 0.1 days.
Figure 3.19 illustrates the effects of a vaccine that is homologous to the resident strain
on the maximum viral load of the two strains and on the cell death attributed to each
strain. We focus on varying only the clearance rate c1 against the resident strain because
we assume that the infection is initiated only by the resident strain and that the mutant
strain is the result of random errors that occur during the replication of the resident within
eclipse cells. We investigated the effects of vaccination under three different assumptions
regarding the efficacy of the vaccine on the emerging mutant strain: full cross-protection
which means that the vaccine has the exact same effect on the clearance rate c2 as it
does on c1, no cross-protection in which case the vaccine has no effect on c2 and finally
partial cross-protection for which we assume that the increase in c2 due to vaccination is
half that of c1. We make the following observations:
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• The maximum viral load of the resident strain is computationally a non-increasing
function of the clearance rate c1. This is illustrated in plot (a) and is not surprising
since increasing c1 has an adverse effect on the growth of the resident.
• The impact of vaccination on the growth of the resident strain is most detrimental
when the vaccine has no effect on the mutant strain. This is shown in plot (a) where
the blue curve that corresponds to the no cross-protection assumption remains
below the partial and full cross-protection curves for all values of c1 that we tested.
This can be attributed to the fitness advantage that the mutant strain gains by a
vaccine that is clearing out its competitor resident strain while having no effect on
the mutant.
• When the vaccine does not have an effect on the mutant strain, the maximum viral
load of the mutant is computationally a non-decreasing function of the clearance
rate c1 as plot (b) indicates. This may again be attributed to the fitness advantage
that the mutant gains from a vaccine that is increasingly efficient in clearing the
resident strain while at the same time having no effect on the spread of the mutant.
• Our conclusions regarding the effects of the vaccine on the maximum viral load
of the two strains still apply when we investigate the cell death attributed to each
strain, as plots (c) and (d) illustrate.
(a) After c1 = 10.5, indicated here by the vertical blue line, the maxi-
mum viral load of the weaker mutant remains above that of the resi-
dent.
(b) After c1 = 12.8, indicated here by the vertical blue line, the cell
death attributed to the weaker mutant remains above that of the resi-
dent.
Fig. 3.20 The total cell death percentage and the maximum viral loads of the two strains as the vaccine efficiency against the
resident increases. Here the vaccine has no effect on the mutant strain. The mutant strain is weaker (δ2 = 2δ1) and α = 0.1 days.
Figure 3.20 shows the effects of vaccination on the maximum viral load of the two strains
and the cell death attributed to each strain specifically under the assumption that the
vaccine offers no protection from the weaker mutant strain. While we have already
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explained the trajectories of both max viral load curves in plot(a) during our analysis of
figure 3.19, we chose to present them in the same plot to highlight the beneficial impact
on the weaker mutant strain of a vaccine that becomes increasingly efficient in restricting
the growth of the resident while having no effect on the mutant. We note that such a
vaccine provides such a fitness advantage to the otherwise weaker mutant strain that
after a value of c1 = 10.5 the maximum viral load of the mutant remains consistently
higher than that of the resident. The equivalent holds for the death of cells infected by
either the resident or the mutant strains as plot (b) illustrates.
3.7 Discussion
The main goal of this chapter was to build a within-host influenza model to explore some
key factors that affect the potential emergence of a mutant strain within a host and the
subsequent competition with its parent resident strain. We began by investigating the
emergence dynamics of a mutant strain using as a foundation a very simple within-host
model, the TIV model which Baccam et al. published in 2006 [24]. Our first step was
extending the TIV model to include two strains and then using it to explore the within-
host dynamics while forcing the appearance of a mutant strain at some time during the
infection with a parent resident strain. Our analysis focused on the effects of the time
of appearance and of the relative fitness of the mutant compared to that of the parent
resident strain. We showed that, as expected, the later a mutant strain appears during
the infection the smaller its viral load and its impact on the infection dynamics. As we
illustrated, even a fitter mutant can fail to grow after its forced introduction if it appears
too late during the infection. Naturally a quantity of interest was the latest time at which a
mutant of some given relative fitness can appear and successfully grow. To study this
window of possible emergence we calculated the effective reproduction number of the
mutant strain as a function of the age of the infection and discovered that in our two-strain
TIV model no mutant can emerge after at most 0.76 days. We attributed this to the very
rapid depletion of target cells due to infection by the already circulating resident strain. In
order to mitigate this we proceeded to explore the Saenz model published by Saenz et al.
in 2010 [262], which explicitly incorporates the innate immune response via the action of
type I interferon and also includes an eclipse phase and can therefore slow down viral
kinetics. We extended the Saenz model to include two-strains, and then performed the
same analysis on the extended Saenz model as we did with the extended TIV model.
Our results showed that including the effects of interferon and the eclipse phase extended
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the window of emergence as expected. Using the extended Saenz model we also derived
an expression for the within-host emergence density of a mutant strain and demonstrated
that it is significantly affected by the still rather quick depletion of target cells. Finally we
investigated the effects of vaccination on our within-host model and showed that even
a weaker mutant strain might dominate the infection if the vaccine-induced pressure
against the fitter resident strain is large enough.
The use of experimental research findings for data fitting and estimating model parame-
ters has been a very insightful technique for the within-host modelling of influenza. It is
important to emphasize though that obtaining an accurate model where all parameters
are identifiable is a significant challenge. In target cell limited models such as the TIV, the
TEIV and the Saenz models, some of the parameters that often appear and need to be
estimated are the infectivity rate β , the virus production rate p, the free-virus clearance
rate c, the infected cell death rate δ , the initial viral inoculum V0 and the initial target cell
population T0. As Smith and Perelson report in [274], the most commonly used methods
to estimate these parameters are nonlinear least squares or the maximum likelihood
analog. But since not all parameters are identifiable, it has been necessary for modellers
to fix some parameters or restrict the ratios of parameters to ensure that they will result
in biologically relevant values. A common assumption is that βT0c ≤ 1, so that on average
each virion infects at most one cell. Moreover, since the basic reproduction number R0
is given by the product of βT0c and
p
δ
(section 3.4.2), and because reported values of the
within-host R0 for influenza are significantly larger than one [24], another restriction is
that p
δ
>> 1. We note that T0 and the eclipse phase duration k are most often fixed, while
p, β and V0 are estimated [24, 29, 140, 141, 262, 274]. Another significant difficulty in
estimating the parameters is the wide variety of experimental systems used in various
studies. Differences in the type of host (human, ferret, pony, mouse), the virus strains
used and the cell types used in in vitro experiments (MDCK cells, A549 cells) make it
difficult to generalize parameter estimates to all influenza infections. As Handel et al.
argue in [141] it is especially hard to estimate β and p since different studies express
the virus load in different units. While most parameters of our two-strain Saenz model
and its various expansions are taken directly from the paper published by Saenz et
al. in 2010 [262], we still performed a parameter sensitivity analysis in section 3.4.4 to
investigate how different parameters values would have impacted the results of our model.
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While forcing the appearance of the mutant strain at some specific time during the infec-
tion yielded some insightful results, in section 3.5.1 we further developed an expression
for the within-host emergence density of a mutant strain. In developing this expression
we made some assumptions regarding the amount of HA- and NA-coding nucleotides
that can potentially generate an antigenic change (and set it to 10%) and the percentage
of substitution mutations in these nucleotides which will successfully result in antigenic
change (and set it to 0.02%). While research has shown that not all substitution muta-
tions result in antigenic changes [168, 312], we emphasize that the specific values we
chose were semi-arbitrary and were chosen so that the resulting within-host cumulative
emergence probability is high enough to facilitate the emergence of the mutant but not so
high that every single infection will result in the mutant emerging. More specifically, our
choices resulted in a within-host cumulative emergence probability of 0.78 for a weaker
mutant, 0.92 for a neutral and 0.36 for a fitter mutant. Therefore there is a high chance
that the mutant strain will emerge during a host’s infection, but this is not problematic for
two main reasons. Firstly we are interested in investigating the competition dynamics
between a newly emerged mutant and its parent resident, so facilitating the emergence
of the mutant is helpful in this regard. Secondly we do not aim to make quantitative
predictions regarding the emergence potential of a mutant strain during a single-strain
infection with a resident strain. We are interested in identifying patterns in the emer-
gence and subsequent competition dynamics between the two strains from a qualitative
perspective. Larger values for the percentage of substitution mutations that will result
in antigenic change (which we set at a very low 0.02%) would lead to the mutant strain
emerging in every infected individual, which would be problematic when we couple our
within-host model with a population-level model in chapters 4 and 5 because it would
give the mutant a significant advantage over the resident under our total cross-immunity
assumption. We emphasize though that some of our cross-scale model’s main results
will come from varying model parameters such as the within-host mutation rate ε .
Our final step in the analysis of our within-host model was to include vaccination into our
two-strain Saenz model, as one of our key research goals is to describe how vaccination
affects the epidemiological and evolutionary dynamics of influenza. We incorporated
vaccination to our model simply as an increase in the viral clearance rates ci. We chose to
only capture the effects of vaccination implicitly instead of explicitly adding compartments
to our model to describe the action of vaccine-generated antibodies because later in
chapter 5 we will combine our within-host vaccination model with a between-host model
for the spread of influenza. Such cross-scale models can easily become complicated
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and computationally intensive, and as a result we wanted to incorporate the effects of
vaccination in the simplest way, by varying the values of one of our within-host model
parameters (specifically ci).
Throughout this chapter we explored the effects of the relative fitness of the mutant
strain compared to that of the parent resident strain both on the infection and emergence
dynamics. Our definition of relative fitness depended on choosing one of the strain-
dependent parameters of the model and assigning to it some value different than its
reference value. When the new value would have a positive effect on the mutant’s growth
we referred to the new strain as a fitter strain, always in comparison to the resident.
Similarly if it would have a negative effect then we called the new strain a weaker mutant
and if it would have no effect at all then we referred to the resulting new strain as a
neutral mutant. In section 3.5 we used the findings of an experiment by Visher et al.
[297] to inform our probability density function for the emergence of a mutant strain of
some specified relative fitness. But Visher et al. use a different definition of relative
fitness compared to ours. They generated mutant variants from an influenza parent
strain, each of which differed from the parent by a single nucleotide substitution, and then
had each variant directly compete against the parent strain in vitro. They then measured
the change in relative frequencies between the parent strain and the variant, used that
value as the difference in growth rate and defined relative fitness as the exponent of that
value. Therefore there is no direct correspondence between their definition and ours.
Moreover there is no experimental guidance that we could find on how exactly a relative
fitness such as the one used by Visher et al. would inform the parameters which we use
to define a mutant strain, such as the mutant virion production rate or the death rate of
cells infected by the mutant. The parameter sensitivity analysis that we performed in
sections 3.3.3 and 3.4.4 can partially mitigate this uncertainty, since it illustrated that the
results of our model are not highly sensitive to changes in the different strain-specific
parameters and therefore to the exact definition of relative fitness.
In both our two-strain TIV and Saenz models we assume that no coinfection can occur
at the cellular level. While this simplifies the model dynamics substantially, it also raises
some concerns. Experimental data indicates that cellular coinfection is common in
influenza. Fukuyama et al. in [110] generated four distinct, color-coded influenza viruses
and injected mice with a mixture of them. Their experiments showed that approximately
20% of the bronchial epithelial cells were infected with more than one color-coded virus
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at the second day postinfection. Allowing mutant virions to enter cells that are already
infected by the resident strain would increase the number of cells available to them,
potentially leading to a wider window of emergence for a mutant strain. We expect though
that cellular coinfection might not have a very significant effect on the models presented
in this chapter, as they both assume that the virus spreads evenly among all available
cells [111]. The same reasoning applies to our assumption that infected cells release
virions of only a single strain. Throughout this thesis the only mechanism studied for the
evolution of influenza is antigenic drift. If we wanted to extend our model to include a
different mechanism such as reassortment, then incorporating cellular coinfection might
have a strong impact on the model dynamics. The first within-host ODE model of multiple
infection at the cellular level was developed by Dixit and Perelson in 2004 [82]. The
authors investigated how often drug-resistant recombinant genotypes emerge during HIV
infection but assumed that cellular coinfection does not affect the phenotype of infected
cells. Koelle et al. developed a model of cellular coinfection in 2019 which explicitly took
into account the effects of a cell’s multiplicity of infection (MOI) [170]. Koelle et al. based
the structure of their model on epidemiological "macroparasite" models, first described by
Roberts, Smith and Grenfell in 1995, whereas the TIV and Saenz models mirror instead
the structure of epidemiological "microparasite" models. The authors initially kept track
of the total number of target cells (which included both uninfected and variably infected
cells as they can be targets of further infection), free virus and internalized virus across
all target cells. They assumed that the viral production and the cell mortality rates both
scale linearly with cellular MOI and that the distribution of cellular MOIs is given by a
negative binomial. With these simplifying assumptions they were then able to extend their
model to include the action of interferon and to keep track of the reassortants present
in the within-host viral population under the assumption that all viruses coming out of
a coinfected cell are reassortants. While their model provides significant insights into
the effects of cellular coinfection, it is structurally very different to our within-host models
presented in this chapter. In 2015 Phan and Wodarz reviewed the challenges of modeling
cellular coinfection and reassortment using ODE models, which generally divide the
population of infected cells into subpopulations infected with one, two, three etc viruses
[233]. The authors referred to this as the "multiple infection cascade" and demonstrated
that truncating the cascade to simplify the model can lead to pathological outcomes.
More specifically, they showed that for identical model parameters (and therefore com-
petitively neutral strains) shorter infection cascades can lead to competitive exclusion
while longer cascades will lead to coexistence. The authors also investigated whether
multiple infection can promote the coexistence of two virus strains with different fitness
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and concluded that in general, related strains of the same virus are unlikely to coexist in
the context of multiple infection. Their analysis highlights the analytical and computational
challenges of incorporating multiple infection to an ODE model efficiently, even when the
model does not explicitly take into the account eclipse cells or the host immune response.
We also note that influenza (along many other viruses) has been shown to also spread
via direct cell-to-cell transmission [64, 256]. This is another way that multiple infection
may be generated, but modelling it requires very different approaches to what we have
described so far in this chapter [173].
The original Saenz model in [262] as well as the extension we developed in this chapter
are target-cell limited models, which entails that infection ends due to the lack of available
target cells. This is also true for the TIV model, but a key difference is that in the TIV
model target cells are depleted only because they are lost to infection, while in the Saenz
model target cells are depleted either because they become infected or because they
become refractory to infection due to the action of type I interferon. In sections 3.4 and
3.5 we showed that the rapid decline of available target cells has a strong impact on
emergence, by forcing the mutant’s window of emergence to be very narrow and early
in the infection. We argued that this rapid decline is a structural issue of our extended
Saenz model and can be primarily attributed to the free mixing of virions and target
cells. Therefore we believe that a spatial within-host model such as the one developed
by Reperant et al. in [253], where the respiratory system was broken down into three
distinct compartments and infection began in one compartment and could then slowly
move to the other two, might result in the slower decline of target cells and therefore
in a wider emergence window. We note though that while emergence needs to occur
early in our model, we showed that the rate of appearance of a mutant strain remains
high throughout most of the infection. This is in accordance with experiments which
have shown that novel variants can appear and reach a detectable size even five days
post-infection [208].
3.8 Summary
In this chapter we developed a within-host model to study the emergence dynamics of a
mutant strain during an infection with a parent resident strain. We began by extending
the simple TIV model published by Baccam et al. in 2006 [24] to include two strains and
studied the effects of the mutant’s emergence time on the disease dynamics. Our analysis
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showed that the very rapid decline of target cells in the two-strain TIV model only allows
for a very narrow emergence window early in the infection. In an attempt to mitigate
this and slow down the viral kinetics, we then adapted a within-host model that also
includes an eclipse phase as well as an innate immune response. Our extended Saenz
model, based on a model published by Saenz et al. in 2010 [262], slowed down the
disease dynamics considerably compared to the two-strain TIV model but also resulted
in a narrow emergence window early in the infection. In order to investigate how the
chances of a mutant strain appearing and growing within that emergence window change,
we then developed a probability density function for the emergence of the mutant. Finally
we added vaccination to our extended Saenz model and showed that even a weaker
mutant strain might dominate the infection if the vaccine-induced pressure against the
fitter resident strain is high.
Chapter 4
A cross-scale model for the evolution
of influenza
Author Contributions
The work presented in this chapter is my own under the guidance of my supervisor Julia
Gog, unless it is explicitly stated otherwise. Figure 4.1 in section 4.5.1 describes the
grid implementation of our cross-scale model which was suggested by Robin Thompson
from the University of Oxford during a two-day discussion between him, myself and my
supervisor Julia Gog. Moreover equation (4.30) in section 4.5.1 was developed by both
myself and my supervisor, but with significant input from my supervisor.
4.1 Introduction
In this chapter we will develop a cross-scale model to describe the epidemiological and
evolutionary dynamics of influenza within a single season. Our model will take explicitly
into account dynamical processes that occur at the within-host level. Specifically we
will assume that the between-host transmission rates are linear functions of the within-
host viral load. The structure of this chapter is as follows: first in section 4.2 we will
present a cross-scale model developed by Coombs et al. in 2007 [68], which we will
use as the foundation of our own cross-scale model. In section 4.3 we will present our
cross-scale model by first separating it into its two tiers, the between- and within-host,
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and then discussing how to link them. Then in sections 4.4 and 4.5 we will derive some
basic properties of our model and describe how to implement it in a computationally
efficient manner. Finally in section 4.6 we will present our cross-scale model’s results
and investigate their sensitivity to the assumed form of the within-host emergence density.
4.2 Background
We will base our model for the cross-scale evolution of influenza on a model published by
Coombs et al. in 2007 [68], where they examined the within- and between-host selection
pressures on the evolution of chronic pathogens with a specific emphasis on HIV. In their
publication they studied the competition dynamics between two strains using an SI model
that allows the internal state of infected hosts to vary with the age of the infection. We
refer to the resulting model as the original Coombs model throughout this thesis. The



























with the following notation:
• S(t) represents the number of susceptible hosts in the population at time t. Individ-
uals in the class S can be infected by either strain and coinfection is possible.
• The variable x0 ∈ [0,1] denotes the fraction of viruses of strain 1 in an initial
inoculum that consists of a mix of strains 1 and 2.
• I(t,a,x0) denotes the density of infected individuals that were infected with an
inoculum given by x0 at time t −a.
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• The parameter b is the rate at which new individuals are added the population via
birth or immigration.
• The parameter δ is the natural death rate.
• The parameter β (a,x′0,x0) is the transmission rate from individuals who were
infected with a strain mix x0 a time units ago to new infections with initial inoculum
x′0.
• The parameter α(a,x0) is the death rate due to infection, and depends both on the
age of infection a and the initial strain mix x0.
Equation (4.1) describes how the number of susceptible individuals in the population
varies over time. It needs to account for new infections generated by infected individuals
of all possible infection ages a ∈ [0,∞) who were initially infected with all possible strain
mixes x0 ∈ [0,1] and who are now infecting new cases with all possible mixes x′0 ∈ [0,1].
This explains the presence of the triple integral in the S-equation of the Coombs model.
We note that this formulation pre-supposes that susceptible individuals are shared among
all strains. Equation (4.2) describes how the density of infected individuals changes both
with time and with the age of infection a. This takes into account both individuals who
are infected but die due to natural causes via the parameter δ and individuals who are
infected and die due to the infection via the parameter α(a,x0). Finally equation (4.3)
describes the rate at which new infections are generated at time t with an initial inoculum
defined by x′0. Equation (4.3) needs to take into account new infections generated by
infected individuals of all possible infections ages a who were initially infected with all
possible initial strain mixes x0, which explains the presence of the double integral in the
equation.
We note that the authors in [68] simplified their original model by considering a term for
the survivorship probability of an infected individual. More specifically, given an individual
who was infected by some strain mix x0 a time units ago, then the probability that they
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where α(a,x0) is the death rate due to infection. This allowed the authors to express the
density I(t,a,x0) of infected individuals who were infected with strain mix x0 at time t −a
as
I(t,a,x0) = I(t −a,0,x0)σ(a,x0)
Using this new expression for I(t,a,x0) the authors then reformulated their original model


















β (a,x′0,x0)I(t −a,0,x0)×σ(a,x0)dx0da (4.5)
We will refer to equations (4.4)-(4.5) simply as the Coombs model throughout this thesis.
This is because we will use this simplified version as the basis of our own cross-scale
model, instead of the slightly more complicated original Coombs model that includes
partial differential equations.
In the Coombs model the transmission rate β and the infection-related death rate α
depend on the age of infection a, and are therefore the link between the within-host and
population dynamics of the infection. The authors used a TIV within host model to inform
the parameters β and α in the following way:




0,x0)], where b1 is a scaling factor. Therefore
the transmission rate depends linearly on the viral load of the host.
• α(a,x′0) = a1δ [T0−T (a,x′0,x0)], where a1 is a scaling factor. Therefore the infection-
related death rate at some age of infection a is defined by the number of epithelial
target cells lost to infection up to time a.
The Coombs model is based on the following underlying assumptions:
• The transmission rate β (a,x′0,x0) depends linearly on the viral load of the host at
some age of infection a.
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• The inocula that initiate new infections are fixed in size and their composition
depends only on the strain mix of the infected host at the time at which the inocula
were produced.
• The infection-related mortality rate α(a,x′0) at some age of infection a depends
linearly on the cumulative loss of epithelial target cells up to time a.
4.3 Model presentation
Having presented the Coombs model, we will now use it as the foundation of our own
cross-scale model, which we will use to study the emergence dynamics of a mutant
influenza strain in a fully susceptible population. Similarly to the Coombs model, our
cross-scale model is defined by a different set of dynamical equations for the between-
and the within-host tiers. We will first present the equations that describe the spread of
the infection between hosts. As the two scales are linked explicitly in our model, these
between-host equations will depend on processes that occur within infected individuals,
so we will then present our within host model of viral kinetics. Having presented our
two-tiered model and defined the link between its two scales, we will then discuss its
various assumptions.
4.3.1 The between-host tier
Using as a foundation the reformulated Coombs model [equations (4.4)-(4.5)] from













βi j(a)Ii(t −a,0)da (4.6)







βi j(a)Ii(t −a,0)da (4.7)
with the following notation:
• S(t) denotes the number of susceptible individuals at time t of the epidemic.
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• Ii(t − a,0) represents the density (in a) of individuals who became infected with
strain i at time t −a.
• The constant k is such that da = kdt. This accounts for the fact that Ii(t,a) is a
density in a whereas the right hand side of equation (4.7) is a number.
• The parameter βi j(a) is the transmission rate from individuals who were infected
with the ith strain a time units ago to new infections with strain j.
• N denotes the number of strains.
Equation (4.6) is an integro-differential equation that describes how the number of sus-
ceptible individuals in the population varies over time. It needs to account for the new
infections generated by individuals of all possible infection ages a ∈ [0,∞) who initially
were infected with the ith strain and are now infecting new cases with the jth strain,
where i and j vary over all possible N strains. Equation (4.7) is a renewal condition which
describes how new infected cases of the jth strain are generated. It takes into account
the contact of susceptible individuals with infected hosts of all possible infection ages
who were initially infected with any of the possible N strains, but are now transmitting
specifically the jth strain. It is important to emphasize that while these two equations
describe the population disease dynamics, they depend on the viral dynamics within
infected hosts via the transmission rate βi j(a).
We highlight the similarities and differences between our cross-scale SI model defined
by equations (4.6) and (4.7) and the Coombs model given by equations (4.4) and (4.5)
that we presented in the previous section:
• Our model consists of an integro-differential equation and a renewal condition,
because we used the Coombs model as its foundation.
• There is no birth and natural death rate in our model, unlike the Coombs model.
This is a justifiable simplification given that we are studying the dynamics of an
acute infection over a relatively short period (here 150 days), whereas Coombs et
al. were interested in the dynamics of chronic infections such as HIV.
• We are assuming that a new infection can be initiated by exactly one strain, while
Coombs et al. assume that new infections are initiated by inocula that consist of a
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fraction x0 of viruses of strain 1 and 1− x0 of strain 2, where x0 ∈ [0,1].
Since in this chapter we will only consider a parent resident strain and a mutant strain,
we present the equations of our cross-scale SI model for only two strains, a resident
(strain 1) and a mutant (strain 2), and under the assumption that backwards mutation is
























4.3.2 The within-host tier
In the presentation of our cross-scale SI model we underlined the dependence of the
population-level transmission rates βi j(a) on the within-host viral kinetics but we did not
specify how these between-host transmission rates will vary with the host’s internal state.
To this end we now present a within-host model for the dynamics of influenza which we
will use to inform our cross-scale SI model. The within-host model we use in this chapter
is our extended Saenz model, which was presented in chapter 3 (specifically 3.4). For
two strains, a resident and a mutant, it has the following formulation:
dT
da
=−β wh1 V1T −β wh2 V2T −φFT (4.11)
dEα,1
da
= β wh1 V1T − kαEα,1 (4.12)
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dEα,2
da
= β wh2 V2T − kαEα,2 (4.13)
dW
da
= φFT −m(β wh1 V1 +β wh2 V2)W −awW (4.14)
dEγ,1
da
= mβ wh1 V1W − kγEγ,1 (4.15)
dEγ,2
da






= kαEα,1 + kγEγ,1 −δ1I1 (4.18)
dI2
da
= kαEα,2 + kγEγ,2 −δ2I2 (4.19)
dV1
da
= p1I1 − c1V1 (4.20)
dV2
da
= p2I2 − c2V2 (4.21)
dF
da
= q1Eγ,1 +q2Eγ,2 +q1I1 +q2I2 −dF (4.22)
Here strain 1 refers to the resident strain and strain 2 to the mutant. Susceptible target
cells (T ) become infected by virions of the resident strain (V1) at an infectivity rate of β wh1
and by virions of the mutant strain (V2) at an infectivity rate of β wh2 . They can also become
prerefractory to infection due to the action of type I interferon (F) at a rate φ . While in
this prerefractory state (W ), cells can still be infected by virions of either strain but at a
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reduced rate mβ whi . They finally become refractory and completely immune to infection
(R) after they have stayed in this prerefractory state for an average 1/a days. Susceptible
target cells (T ) that have been infected by either viral strain but have not yet started
releasing progeny virions move to an eclipse phase (Eα,i) and stay there for an average
of 1/kα days until the virus has finished replicating inside them. Similarly prerefractory
cells (W ) that have been infected by the ith strain first move to an eclipse phase (Eγ,i)
and stay there for an average of 1/kγ days. Cells infected by the ith strain that have
reached the virion producing stage (Ii) die from the infection or as a result of the immune
response at a rate δi. They produce progeny virions at a rate pi and secrete interferon
at a rate qi. Cells that have been infected after they were primed by interferon but have
not reached the virion-producing stage yet (Eγ,1 and Eγ,2) also secrete interferon at a
rate of qi, depending on which strain they were infected by. Circulating interferon decays
at a rate d, while free virions of the ith strain are cleared by the immune system at a rate ci.
In chapter 3 we also derived an expression for the within-host basic reproduction numbers














Our cross-scale model is based on all the assumptions of our extended Saenz model
from 3.4, as well as on the following assumptions:
• Infection leads to recovery. This is why there is no disease-related mortality rate in
our model, as opposed to the Coombs model. This is not a surprising differentiation
between our model and the Coombs model, since we are considering the dynamics
of seasonal influenza while Coombs et al. applied their model to HIV.
• The transmission rate depends linearly on the viral load of the host. More specifi-
cally we assume as Coombs et al. in [68] that:
βi j(a) = bVj(a) (4.25)
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where b is a scaling constant, and i, j ∈ 1,2. This is a very important assumption
in our model because the population-level transmission rates are the links between
the two scales of our model. We emphasize that the linear dependence we assume
here is one of various different ways that we could relate the within-host viral load
to the between-host transmission rates. We will discuss these at length in the
Discussion section of this chapter (section 4.7).
• Each individual can be infected by exactly one strain. No co-infection can occur.
The only case where more than one strains may co-circulate within a single host is
if the host was initially infected with the resident strain and then had the mutant
strain emerge within them.
For the sake of clarity, we repeat here the assumptions of our extended Saenz model.
These are the same as they appear in 3.4:
• The binding of free virions with target cells causes only a negligible decrease in
the viral load, which is why there is no −βiViT term in equations (4.20) and (4.21).
• Once a cell becomes fully immune to infection and enters the R compartment, it
remains immune.
• Infection leads to death for cells in the Ii compartments.
• Cells can only be infected once and by only one strain.
• The competition between strains is mediated purely through the availability of target
cells.
4.4 Basic properties
The population-level basic reproduction number Rr,p0 of the resident strain in our cross-





where β11(a) is the rate at which individuals who were initially infected with the resident
strain a time units ago and never had the mutant strain emerge within them infect new
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individuals. Here Dwh denotes the duration of the infection within a host. Similarly, we





Both these expressions are dependent on infected individuals being infectious for a fixed
amount of Dwh days. In other words the recovery rate of infected individuals is a Dirac
delta function concentrated at Dwh. We note though that an equivalent formulation would
be to simply define that βi j(a) = 0 ∀a > Dwh.
4.5 Methods
As we are interested in the emergence dynamics of a mutant strain in a population,
we assume that initially there is only a resident strain causing an epidemic. When an
individual becomes infected with the resident strain we keep track of the age of their
infection because variations in their within-host viral load will affect their population-level
transmission rate. Similarly to the implementation of our extended Saenz, we assume
that when an individual is infected with the resident strain there is a chance that errors
will occur during the within-host viral replication process which will lead to the emergence
of a mutant strain within that host. At the between-host level the consequence of this
within-host emergence is that the host may transmit either the resident or the newly
emerged mutant whenever they infect a new host, with a probability that depends on
each strain’s viral load at the time of transmission. This in turn can lead to two strains,
a mutant and its parent resident, circulating in the population and competing for hosts
either until the end of the epidemic or until one of them disappears.
We assume as Coombs et al. in [68] that the transmission rate βi j(a) is a linear function
of the host’s viral load. As a result, βi j(a) depends implicitly on the time of emergence α
of the mutant strain within the host. This is because as we have demonstrated in 3.4.4,
the emergence time α has a strong effect on the viral loads of both strains. To emphasize
this dependence on α , we will use the notation βi j(a,α) to refer to the transmission rate
from someone who was infected with the ith strain a time units ago and had the mutant
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strain emerge within them at time α to new cases of strain j. More specifically:
βi j(a,α) = bVj(a,α)
where b is a scaling constant. We note that in the case of an infection initiated by the
mutant strain there is no dependence on α because we do not allow for backwards
mutation (from mutant to resident) in our model. We define α = /0 as the case that no
emergence occurs during a host’s infection with the resident strain. If we consider such
an infection with only the resident strain present, then using equation (4.26) for Rr,p0 we





Our model has the following initial conditions:
• N = 1 is the size of our population and we assume it remains fixed throughout the
outbreak.
• I1(0) = 10−5 individuals.
• I2(0) = 0. This is because we assume that the outbreak is initiated only by resident
strain.
• Dp = 150 days. This is the duration of the outbreak, and we set it as 150 days to
cover the main winter season of influenza in the Northern hemisphere, namely
December-February, together with a month leading up to it and a month right after
it.
• Dwh = 5 days. This is the duration of the infection within a host.
• Rr,p0 = 2. This was chosen simply to satisfy reported values of the population-level
R0 of influenza. More specifically Cauchemez et al. report in [55] that R0 ranges
from 1.4 to 2.2.
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Within-host model
Parameter Description Value Units Source



















ci Free virus clearance rate
for ith strain
5.2 Rate of virus
clearance day−1
[262]
1/ki Average duration of
eclipse phases
1/2 Days [262]
1/aw Average duration of
prerefractory phase
1/4 Days [262]








d IFN clearance 6.8 Rate of IFN
clearance day−1
[262]
φ IFN efficiency 56 (IFN fold change)−1
day−1
[262]
m IFN-reduced infectivity 0.9
α Time of emergence of
mutant strain
Varies Days
Dwh Infection duration 5 Days
Table 4.1 Parameters of the within-host tier of the cross-scale model.
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Between-host model
Parameter Description Value Units Source










Table 4.2 Parameters of the between-host tier of the cross-scale model.
4.5.1 Implementation
We will now describe the implementation of our cross-scale SI model. Unlike the imple-
mentation of our models in chapters 2 and 3, here we will go into detail because as Gog
et al. discuss in [122], one of the significant challenges that cross-scale models present
is to implement them with computational efficiency. Towards this end we will pre-calculate
the between-host transmission rates and the within-host emergence density so that in
our implementation we can use them as parameters of our cross-scale model instead of
having to compute them in every simulation of our model.
First we discretize the age of infection a. We assume that a ∈ [0,da,2da, ...,Dwh]
such that da = 0.5 days. Moreover we assume that the within-host emergence time
α ∈ [da,2da, ...,Dwh] and use α = /0 to denote that no emergence occurs. We note that
α = 0 is not possible, since the resident strain needs to start replicating within a host
before emergence can occur. We also note that da does not need to be constant and
a and α do not need to have the same discretization, both choices were made for the
sake of simplicity. Since a and α are discrete variables, we define â and α̂ as their
continuous analogues. We underline though that in our Matlab implementation â and α̂
are not truly continuous. In the discretized version of our cross-scale SI model we will use
emergence at some time α = α⋆ to denote that in the continuous analogue the mutant
strain emerged sometime between α⋆−da and α⋆. Therefore we need to modify both
our between-host transmission rates βi j(a,α) and the within-host emergence density
f (α), which so far have been defined with a and α being continuous variables.
Starting with the probability density function f (â), we obtain the following probability of







We assume that P( /0) denotes the probability that no emergence occurs within the host.
For the discrete version of the transmission rates we need to consider that if the mutant
emerges at some time α = α⋆, which in the continuous analogue means that α̂ ∈
(α⋆−dα,α⋆], then it might be the case that emergence is significantly more likely for
certain values of α̂ inside that window depending on the form of the emergence density

















where the first term is a normalizing constant.
From equations (4.29) and (4.30) we see that in order to pre-calculate P(α) and βi j(a,α)
we require f (α̂) and βi j(â|α̂) for every value of â and α̂ . We note that given our assump-
tion that the population-level transmission rates are linear functions of the within-host
viral load, in order to calculate βi j(â|α̂) we simply need to know Vi(â|α̂). We can obtain
these by simulating our within-host model using the time of emergence α̂ as a parameter.
We underline again that while we defined â and α̂ as the continuous analogues of a and
α , they are not truly continuous in our Matlab implementation.
We will now describe how to implement efficiently the between-host tier of our cross-
scale model using what we will refer to as the grid implementation. First we discretize
real time, so that if t̂ refers to the continuous time between the start of the outbreak
and its end after Dp = 150 days, then t is its discrete analogue. Therefore we have t
∈ [0,dt,2dt, ...,Dp] where we set dt = 1 day. We note that the difference dt between any
two consecutive time points can vary, we chose it as constant in our simulations only for
the sake of simplicity. This leads to a discrete time SI model for the between-host tier of
150 A cross-scale model for the evolution of influenza
our cross-scale model. This additional discretization of the real time t combined with our
previous discretization of the age of infection a allow us to simulate our cross-scale SI
model efficiently in the following way. Let It1(a,α) denote the number of individuals at time
t who were originally infected with the resident strain a time units ago and had the mutant
strain emerge within them at time α (including α = /0 for the case that no emergence
has occured yet). Similarly for It2(a), where the absence of α is because we do not allow
for backwards mutation in our model. Keeping track of these for every t, we may use
our pre-calculated values of βi j(a,α) to numerically solve the discrete SI equations of
the between-host tier. We note that an individual who has both the resident and the
mutant strain within them can transmit either strain with a probability that depends on
the strains’ within-host viral load, which we have pre-calculated for every a and α in our
discretization. Furthermore keeping track of It1(a, /0) for all possible values of a allows us
to perform at each time point a binomial random test for the within-host emergence of
the mutant strain where for any given a the number of trials is It1(a, /0) and the probability
of success depends in some way on the pre-calculated viral load V1(a, /0).
Fig. 4.1 Schematic of the grid implementation of our cross-scale model. This figure represents the possible infection paths of a
single infected individual, where we keep track of the age of their infection as well as the time of emergence of the mutant strain
within them. Here I1(a,α) denotes an individual who just finished the ath day of their infection and had the mutant emerge within
them at time α . The first row represents the case of an infected individual who did not have the mutant strain emerge within them at
any point during their infection. We note that after the 5th day of infection the individual recovers. For the sake of illustration a value
of da = 1 day was used for this schematic, whereas in our simulations used da = 0.5 days.
Figure 4.1 offers a schematic of the grid implementation and describes the possible
infection paths of an infected individual. More specifically, we start with an individual
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that is infected with the resident strain. If the mutant strain emerges within them by
the end of their first day of infection then we save the information that α = 1 and the
individual moves along the last row of the diagram in figure 4.1 until they recover. No
further stochastic tests are needed because we only allow for a single mutant strain to
emerge during an individual’s infection. If on the other hand the mutant does not emerge
during the first day, we save this information by having the individual move to the I1(1, /0)
node in the first row of the diagram, which denotes that their age of infection is 1 day and
the mutant has not emerged within them yet. We then follow a similar procedure during
the individual’s second day of infection, where no emergence will have them continue to
the I2(2, /0) node in the first row while emergence will lead them to the I2(2,2) node in
the second row of the diagram. We note that in this schematic we assumed for the sake
of simplicity that da = dt = 1 day, which is not true in our simulations as we wanted a
finer discretization for the age of infection a. This is because the analysis of our extended
Saenz model in chapter 3 suggested that there is only a small window for the potential
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within-host emergence of the mutant strain early in the infection.
Algorithm 1: Pseudocode for grid model
Initialization : da, dt > da, Dp, P(a) ...
for time = da : da : Dp do
day= ⌊time⌋
if day=time then








check for emergence :
∀a NumTrials(a) = Iday1 (a, /0)
NumEmergencies(a) = Binomial(NumTrials(a),P(a))
compute new infections :
r1 = ∑a ∑α I
day
1 (a,α), r2 = ∑a I
day
2 (a)
S(day) = exp(−(r1 + r2))S(day−dt)
numNewIn f s = S(day−dt)−S(day)




numNewI2 = numNewIn f s−numNewI1
else
update the ages of infection
check for emergence
Algorithm 1 shows the pseudocode for a single simulation of our cross-scale model. In
our simulations the real clock time needs to account for the difference in the time scales
of the real time t and the age of infection a. Since we set our discretization of a as finer
than that of t, we increment time by da to check whether the mutant has emerged within
infected individuals between time−da and time. When time takes one of the values in
our discretization of t, which happens when time and day are equal in algorithm 1, we
additionally compute the new infections that arose between time− dt and time. This
formulation depends on setting dt = k⋆×da, where k⋆ > 1 ∈ Z.
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4.6 Results
We will now present the results and analysis of our cross-scale model. The structure of
this section is as follows:
• In the first subsection we will investigate how varying some of the within-host
model’s parameters affects the population-level basic reproduction number of
mutant strain.
• In the second subsection we will study our cross-scale model’s transmission rates
and how they are affected by the age of infection and the within-host time of
emergence.
• In the third subsection we will present our cross-scale model’s results using the
within-host derived emergence density from 3.5 to inform the mutant’s within-host
probability of emergence.
• In the fourth subsection we will perform a similar analysis of our cross-scale model
but instead of the within-host derived emergence density we will assume that the
emergence density remains constant throughout an individual’s infection. While
this means that emergence no longer depends on the results of our within-host
model, the resulting framework resembles our population-level model from chapter
2, with the key difference that we have not yet incorporated vaccination to our
cross-scale model.
• Finally in the fifth subsection we will study our cross-scale model under the assump-
tion that the within-host emergence follows a scaled Weibull distribution, which we
will argue results in emergence dynamics that we originally expected our extended
Saenz model to produce. This will further test the sensitivity of our model’s results
to the assumed form of the within-host emergence density.
4.6.1 The effects of the within-host fitness
In chapter 3 we defined the fitness of the mutant strain, always in relation to the fitness of
the parent resident strain, in terms of the death rate of cells infected by the mutant. More
specifically we defined a weaker mutant strain as one which results in infected cells dying
twice as quickly compared to cells infected with the resident strain, or δ2 = 2δ1 in our
notation. Equivalently we defined a fitter mutant strain by setting δ2 = (1/2)×δ2. Here we
review our choice for the fitness of the mutant by varying some of the parameters of our
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within-host model and evaluating their impact on the population-level basic reproduction
number of the mutant strain Rm,p0 . As we showed in section 4.4, we have the following





Therefore by simulating a single-strain infection that is initiated with the mutant strain
we can vary all the relevant within-host parameters and examine how they affect Rm,p0
via their effect on the within-host viral load. Since there is no backwards mutation in
our model, this process involves no stochastic elements. We note that in order to solve
equation (4.27) it is necessary to set a value for the population-level basic reproduction
number of the resident strain Rr,p0 , as this is necessary to obtain the scaling constant b.
Fig. 4.2 The effects of varying the relevant within-host parameters on the mutant’s population-level Rm,p0 . When one
parameter is varied the rest are kept constant at their reference value from table 4.1. The population-level basic
reproduction number of the resident strain is set as Rr,p0 = 2.
We can make the following observations based on figure 4.2:
• Doubling the death rate δ2 of cells infected by the mutant results in R
m,p
0 ≈ 0.88,
which makes it impossible for the mutant to spread in the population. Halving the




• Decreasing the clearance rate of free virions c2 has the largest positive effect
on Rm,p0 , followed by increasing the production rate of progeny virions p2 and
decreasing the death rate δ2 of infected cells.
• Varying the IFN production rate q2, the IFN efficiency φ , the IFN clearance d, the
IFN-reduced infectivity m and the duration of the eclipse phases 1/kα and 1/kγ have
only a small impact on Rm,p0 .
• Increasing the duration of the prerefractory state 1/aw has a significant positive
impact on Rm,p0 , surpassing that of increasing the mutant’s within-host transmission
rate β wh2 .
This analysis suggests that we should alter our choice for the fitness of the mutant
strain in the context of our cross-scale model. Our previous choice of δ2 = 2δ1 for a
deleterious mutation leads to a mutant that has no chance of spreading in the population
(Rm,p0 ≈ 0.88), but we are interested in studying the competition dynamics of an emerging
mutant strain both within- and between-host. Therefore, given a resident strain with
Rr,p0 = 2, we need to choose a value for δ2 such that in the case of a deleterious mutation
we still have δ2 > δ1, but also R
m,p
0 > 1.
In chapter 3 we studied the resulting within-host viral competition dynamics when varying
the mutant’s within-host transmission rate β wh2 , the production rate of new virions p2, the
death rate of infected cells δ2 and the clearance rate of free virions c2. These are the
four mutant-specific within-host parameters that determine the mutant’s within-host basic
reproduction number Rm,wh0 [equation (4.24)]. We will now further investigate their impact
on the mutant’s between-host basic reproduction number Rm,p0 .
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(a) Increasing the within-host transmission β wh2 has the smallest posi-
tive effect on Rm,p0
(b) Varying the virion production rate p2 has an intermediate effect on
Rm,p0
(c) Decreasing the viral clearance rate c2 has the largest positive effect
on Rm,p0 . We note that this plot has a different y-axis scale compared
to plots (a),(b) and (d). This was chosen only for the sake of illustration.
(d) Varying the death rate δ2 of infected cells has an intermediate ef-
fect on Rm,p0 .
Fig. 4.3 The effects of varying the mutant-specific within-host parameters on the mutant’s population-level basic repro-
duction number Rm,p0 . The parameters were varied between 25% and 200% of their reference values from table 4.1.
Whenever the within-host death rate of infected cells δ2 wasn’t varied, we used δ2 = δ1 = 2. The green dashed lines
in plots (a)-(d) correspond to a beneficial mutation with Rm,p0 = 2.5, the black dashed lines to a neutral mutation with
Rm,p0 = 2 and finally the red dashed lines to a deleterious mutation with R
m,p
0 = 1.5. We picked these values in relation
to the population-level fitness of the resident strain, for which we set Rr,p0 = 2.
Figure 4.3 shows how the mutant’s population-level basic reproduction number Rm,p0 is
affected when we vary the four mutant-specific within-host parameters: the transmission
rate β wh2 , the virion production rate p2, the viral clearance rate c2 and the death rate δ2
of infected cells. We observe that increasing the mutant’s within-host transmission rate
β wh2 leads to the smallest increase in R
m,p
0 , while decreasing the clearance rate of free
mutant virions c2 leads to the largest increase in R
m,p
0 . We therefore expect our model to
be more sensitive to changes in c2 compared to the other within-host parameters studied
here. The dashed lines in plots (a)-(d) are at our chosen values for the Rm,p0 of a fitter,
a neutral and a weaker mutant strain, always in relation to the fitness of the resident
strain for which we set Rr,p0 = 2. We note that our choices of R
m,p
0 = 2.5 for a beneficial
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and Rm,p0 = 1.5 for a deleterious mutation are semi-arbitrary, as our only criterion was to
avoid giving either a very significant advantage or disadvantage to the mutant.
Fig. 4.4 The relation between the mutant’s within-host basic reproduction number Rm,wh0
and between-host basic reproduction number Rm,p0 . This plot was obtained by varying
the mutant-specific within-host parameters and evaluating their impact on Rm,wh0 and R
m,p
0 .
Specifically, he parameters β wh2 , p2, c2 and δ2 were varied between 25% and 200% of their
reference values from table 4.1. When one parameter was varied the rest remained constant
at their reference value.
Figure 4.4 illustrates how the relation between the mutant’s within-host basic reproduction
Rm,wh0 and between-host basic reproduction number R
m,p
0 changes as we vary the within-
host mutant-specific parameters. The parameters we varied here are the ones which
appear in our expression for Rm,wh0 [equation (4.24)]: the within-host transmission rate
β wh2 , the virion production rate p2, the viral clearance rate c2 and the death rate δ2 of
cells infected with the mutant. We may make the following observations:
• Varying β wh2 has the smallest impact on the mutant’s relative fitness on both the
within- and between-host levels.
• The within-host death rate of infected cells δ2, which has only an intermediate
effect on the mutant’s population-level fitness, appears to have the most significant
impact on its within-host fitness.
• The relation between Rm,wh0 and R
m,p
0 appears to be almost linear as we vary c2,
convex as we vary p2 and concave as we vary δ2 and β wh2 . Regrettably I have not
been able to find a satisfactory explanation for these relations.
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Throughout the rest of this chapter we will use the death rate δ2 of cells infected with the
mutant strain to define the within-host fitness of the mutant, which allows us to remain
consistent with our standard definition from chapter 3. Moreover, we will use Rm,p0 = 2.5
for a fitter strain and Rm,p0 = 1.5 for a weaker strain, unless stated otherwise, while a
neutral mutant strain will have Rm,p0 = 2 which is the same as the resident strain. From
figure 4.3(d) we see that the values of δ2 which lead to our desired values for R
m,p
0 are
δ2 = 1.6, δ2 = δ1 = 2 and δ2 = 2.6 for a fitter, a neutral and a weaker strain respectively.
4.6.2 The transmission rates
The population-level transmission rates β11(a,α), β12(a,α) and β22(a,α) are very signifi-
cant for our cross-scale model because they provide the link between the within-host and
the population tiers. Therefore they are what differentiates our cross-scale model from
population models with constant values for the transmission rate β , such as the model
we developed in chapter 2. Considering that one of the principal goals of this thesis is to
evaluate the usefulness of a more complex cross-scale model against that of a standard
population model in the context of the evolution of influenza, it is crucial to examine the
transmission rates of our model very closely.
(a) Resident-only infection. (b) Mutant-only infection.
Fig. 4.5 The transmission rates for single strain infections in our cross-scale model. Their trajectory resembles the
within-host viral load curves, which is expected given our assumption that the transmission rates are linear functions of
the within-host viral loads. The curve in plot (a) and the black curve in plot (b) are the same because a neutral mutant
strain is defined by the same strain-specific parameters as the resident (here δ2 = δ1).
Figure 4.5 shows the transmission rates for single strain infections. Plot (a) describes
an infection with only the resident strain present, while plot (b) with only a mutant but
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also takes into consideration all three cases for the fitness of the mutant. The blue curve
in plot (a) is the same as the black curve in plot (b) because the resident strain and the
neutral mutant strain are defined by the same strain-specific within-host parameters. We
observe that the trajectories of the transmission rates resemble those of the within-host
viral loads. This is expected since we defined the transmission rates to be linear func-
tions of the within-host viral loads, scaled only by a constant. The result is that a host’s
transmissibility increases as their viral load increases and reaches a peak around the
third day of infection, after which the host becomes less infectious. We note that there is
no mentioning of the emergence time α in figure 4.5 because we are only considering
single strain infections. We also note that in our simulations of the cross-scale model we
set the transmission rate equal to zero at the end of the infection (here at a = 5 days),
but we did not show this here for the sake of illustration.
(a) The transmission rate β11(a|α) to new infections with the resident
strain for three different values of the emergence time α .
(b) The transmission rate β12(a|α) to new infections with the mutant
strain for three different values of the emergence time α .
Fig. 4.6 The transmission rates β11(a|α) and β12(a|α) of a host who was initially infected with the resident strain for
three different values of the within-host emergence time α . We note that α = 0 describes a coinfection rather than
a mutant strain emergence, but we included it here to highlight the positive effects of earlier emergence times on the
transmission rate of the mutant. The mutant here is neutral, so we have δ2 = δ1.
Figure 4.6 shows the transmission rates for an individual who was initially infected with
the resident strain and had the mutant strain emerge within them at some specified
time α during their infection. Plot (a) describes the host’s transmission rate to new
cases with the resident strain while plot (b) to new cases with the mutant. We observe
that a later emergence time has a large negative impact on the transmission rate of
the mutant strain, as when α = 1 the host transmits almost none of the mutant to new
cases [as shown in plot (b)]. This is expected since we assume that the transmission
rates are linear functions of the within-host viral load, and as we have demonstrated
in chapter 3 a later emergence time significantly hinders the mutant’s growth. Given
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the within-host competition of the two strains for available resources, it is not surprising
that a later emergence time has the opposite, beneficial effect on the transmission rate
of the resident strain as plot (a) illustrates. We note that the case α = 0 represents a
coinfection with two strains rather than a mutant strain emergence, but we included it
here to highlight the strong effect of the emergence time on the transmission rates of the
two strains.
(a) The transmission rate β11(a|α) to new infections with the resident
strain is almost unaffected by the emergence time α , except when α
is very small.
(b) The transmission rate β12(a|α) to new infections with the mutant
strain attains its largest values when α is very small and is almost 0
for all other values of α .
Fig. 4.7 The transmission rates β11(a|α) and β12(a|α) of a host who was initially infected with the resident strain
functions of the age of infection a and the within-host emergence time of the mutant strain α . The mutant strain is
chosen as neutral here, therefore δ2 = δ1 = 2. Here α = 5 represents the case that no emergence has taken place
during the host’s infection. We note that the scale is different between these two plots.
Figure 4.7 shows how the transmission rates vary with the age of infection a and the
emergence time α for the specific case of a neutral mutation. Plot (a) describes the
transmission rate from an individual who was originally infected with the resident strain,
had the mutant emerge within them at some time α , and is now transmitting to new
cases with the resident strain. Plot (b) describes the same host’s transmission rate to
new cases with the mutant strain. We note that in the simulations of our cross-scale
model a host at any given time can transmit either the resident or the mutant strain to a
new individual, with some probability that depends on the within-host viral loads at the
time, but not both. We emphasize that in the context of this figure the emergence of the
mutant strain is not stochastic, rather α was used as fixed parameter of our within-host
model. As a result, we force a mutant to appear within the host even at times when it
cannot grow or survive. The importance of α is evident from plot (b), which shows that
the host’s transmission of the mutant strain is very close to zero for any emergence time
that is not very early in the host’s infection. This can also be seen in plot (a), where the
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host’s transmission rate of the resident strain appears to remain unaffected as α varies,
except for very small values of α . We can attribute this to the competition dynamics
between the two strains, since as we have shown in chapter 3 even very small increases
to α can give a significant disadvantage to the mutant. This is because a later α implies
that the resident strain has had more time to circulate within the host and infect target
cells, therefore decreasing the pool of target cells available to the mutant. This leads
to restricted growth for the mutant, and therefore to smaller viral loads and in turn to
smaller transmission rates. We note that this result is dependent on our assumption that
a cell may only be infected once and by only one strain. While figure 4.7 illustrates the
importance of the within-host emergence time α for the mutant’s chances of spreading in
the population, it is useful to further examine the relationship between the transmission
rates and α .
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(a) Total conditional transmission potential for a deleterious mutation : δ2 = 2.6 (b) Total conditional transmission potential for a neutral mutation : δ2 = δ1 = 2
(c) Total conditional transmission potential for a beneficial mutation : δ2 = 1.6




a β12(a|α)da of hosts who were initially infected
with the resident strain as a function of the within-host emergence time α . In all plots the blue curve represents the total
conditional transmission potential
∫
a β11(a|α)da to new cases with the resident strain while the red curve represents
the total conditional transmission potential
∫
a β12(a|α)da to new infections with the mutant strain. Here α = 5 describes
the case that no emergence has occurred throughout an individual’s infection with the resident strain. The case α = 0
describes a co-infection, which we do not allow for in our simulations of the epidemic, but we included it here for
graphical purposes.
Figure 4.8 shows how the integrals of the conditional transmission rates, which we will
refer to as the total conditional transmission potentials, vary with the emergence time α
for all three cases for the fitness of the mutant. Due to our choice of the transmission
rates being a linear function of the viral load, the total conditional transmission poten-
tials are simply the integral of the conditional viral load multiplied by a scaling constant,
namely
∫
a β11(a|α)da = b
∫
aV1(a|α)da using the conditional transmission of the resident
strain to new hosts as an example. We note that the emergence of the mutant here
is deterministic, as we are treating α as a parameter of our model for the purposes of
this figure. All three plots show that computationally the total conditional transmission
potential
∫
a β11(a|α)da to new cases with the resident strain is a non-decreasing function




to new cases with the mutant strain is a non-increasing function of α . This is not surpris-
ing given our findings in 3.4.4, which showed that the integrals of the viral loads follow
the same trajectories as the ones described here. The reasoning remains the same
too: a later α gives an increasingly larger disadvantage to the mutant strain because
the resident is depleting its pool of available target cells. After a certain α though, the
only factor that contributes to the total viral load of the mutant is the initial number of
mutant virions which we introduce to the model at α . This is why the total conditional
transmission potential to new cases with the mutant initially decreases but then plateaus
as α increases, and equivalently why the total conditional transmission potential to new
cases with the resident initially increases but then plateaus with α .
4.6.3 Results using the within-host derived emergence density
In this section we will present our cross-scale model’s results under the within-host
emergence density function fWH that we derived in section 3.5. We repeat our expression
for fWH here:




where λ (α) is the rate of appearance, survival and adequate growth of a mutant strain
and is given by:
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Fig. 4.9 The within-host emergence density function fWH for all three types of mutants.
Figure 4.9 shows how the emergence density fWH changes during an individual’s infec-
tion. We have already discussed the shape of fWH in 3.5, but we will summarize our
relevant conclusions here:
• The mutant’s emergence window is very narrow and very early in the infection.
This can be attributed to the fast depletion of target cells in our extended Saenz
model.




fWH(α)dα , can be considered high for all three types of
mutants. Specifically, the cumulative within-host emergence probability is 0.73 for
a weaker mutant, 0.91 for a neutral and 0.34 for a fitter mutant. The reason for the
much smaller cumulative emergence probability for a fitter mutant is that according
to Visher et al. only 5% of viable mutations lead to a fitter mutant strain [297]. We
addressed the large cumulative emergence probabilities in 3.5, and we concluded
that they can be attributed to the free mixing of the target cells and virions and to
the large number of target cells within the host.
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(a) The average portions of individuals originally infected with the resident and
mutant strains in 500 simulations of our model. Here the mutant is assumed to
be weaker, so we have δ2 = 2.6 for the within-host death rate of cells infected
with the mutant, and δ1 = 2. At the between-host level this translates to R
r,p
0 =
2 for the resident and Rm,p0 = 1.5 for the weaker mutant strain.
(b) The average portions of individuals originally infected with the resident and
mutant strains in 500 simulations of our model. Here the mutant is assumed to





(c) The average portions of individuals originally infected with the resident and mutant
strains in 500 simulations of our model. Here the mutant is assumed to be fitter, so we
have δ2 = 1.6, and again δ1 = 2. At the between-host level this translates to R
r,p
0 = 2
for the resident and Rm,p0 = 2.5 for the fitter mutant strain.
Fig. 4.10 The infectious groups dynamics under the within-host derived fWH . We note that the I1 compartment refers
to the portion of individuals in the population who were originally infected with the resident strain, but could also have
had the mutant strain emerge within them. The I2 compartment refers to hosts who were infected with the mutant
strain.
Figure 4.10 shows how the mean portions of individuals originally infected by the resident
and mutant strains vary throughout the epidemic for the three cases of a deleterious,
neutral and beneficial mutation. We can make the following observations:
• The largest variability in the portion of individuals initially infected with the mutant
happens in the case of a neutral mutation [plot (b)]. On the contrary we observe
very little variability in the cases of a deleterious mutation [plot(a)] and a beneficial
mutation [plot (c)]. For a weaker mutant this can be attributed to the fitness
disadvantage that it has compared to the resident strain both at the within- and
the between-host levels. For a beneficial mutation we refer back to figure 4.9,
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which shows that the fitter mutant’s emergence probability attains its maximum
and then drops to zero very quickly. Moreover we note that the mutant’s chances
to emerge during the first day of infection are very small (and lower compared to
those of a weaker and a neutral strain). Therefore we expect the fitter mutant to
emerge most often around a time when its available resources will be very limited,
though still enough for it to survive and reach a minimum final size within-host
(by construction of our fWH). This restriction to the mutant’s available resources
hinders its within-host growth and therefore its transmission to new hosts, even
despite the mutant’s fitness advantage.
• The peak as well as the duration of the epidemic are affected by the relative fitness
of the mutant strain. The case of a neutral mutation leads to the slowest epidemic
and the smallest, latest peak. This may be explained by the strong competition
between the two strains for available hosts in the population, which allows neither
of them to spread quickly. Our assumption of full cross-immunity entails that hosts
originally infected by the mutant strain become fully immune to the resident. We
also assume though that the mutant strain may emerge within any host that is
infected with the resident. These two assumptions, combined with the lack of a
fitness disadvantage, the very narrow emergence window early in the infection
and the large within-host cumulative emergence probability, can explain why on
average the mutant strain dominates the epidemic as plot (b) illustrates. Among
the three plots the second slowest epidemic occurs in the case of a deleterious
mutation [plot (a)]. Given a weaker strain’s fitness disadvantage, it is unsurprising
that despite its large within-host cumulative emergence probability, the mutant
cannot compete efficiently against the fitter resident strain at either the between-
or within-host levels. We note that the case of the beneficial mutation led to the
shortest epidemic and the largest peak for the resident strain, suggesting that the
fitter mutant’s smaller cumulative within-host emergence probability and slightly
later emergence window inhibit its within-host growth so much that the mutant has
a very small impact on the spread of the resident both within- and between-host .
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(a) The final sizes of the resident and mutant strain in 500 simulations of our
cross-scale model. Here the mutation is assumed to be deleterious. We em-
phasize that for illustration purposes this plot has a different y-axis scale com-
pared to the other two plots.
(b) The final sizes of the resident and mutant strain in 500 simulations of our
cross-scale model. Here the mutation is assumed to be neutral. We emphasize
that for illustration purposes this plot has a different y-axis scale compared to
the other two plots.
(c) The final sizes of the resident and mutant strain in 500 simulations of our cross-scale
model. Here the mutation is assumed to be beneficial. We emphasize that for illustration
purposes this plot has a different y-axis scale compared to the other two plots.
Fig. 4.11 The population-level final sizes of the resident and mutant strains in 500 simulations of our cross-scale model
for the three different cases of the mutant’s relative fitness. We emphasize that for illustration purposes the three plots
have different y-axis scales.
Figure 4.11 shows the population-level final sizes of the resident and mutant strains in
500 simulations of our cross-scale model for the three cases of a deleterious, neutral
and beneficial mutation. We may make the following observations:
• The final size of the epidemic, defined here as the sum of the final sizes of the
resident and mutant strains, is affected by the emergence of a mutant strain at
the within-host level. Firstly, we may use Kermack and McKendrick’s epidemic
final size formula R1(∞) = 1− exp(−Rr,p0 ×R1(∞)) from [163] to calculate the final
size of a single-strain epidemic with only the resident strain present. We may
simulate such an epidemic by assuming that the within-host emergence density
of the mutant remains constant at 0, and in that case the epidemic final size is
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0.8. All three plots show though that the epidemic final size does not remain at 0.8
when a mutant strain is added to the model. This is true even in cases where the
mutant has a very small presence at the between-host level as for instance plot
(a) illustrates, where the weaker mutant strain had a final size close to 0 in some
of our simulations but the resident never achieved a final size larger than 0.52.
Kermack and McKendrick’s final size formula assumes a constant between-host
transmission rate. But in our model the between-host transmission rate of the
resident strain is a function of the resident’s within-host viral load and is therefore
negatively affected by the within-host emergence of a mutant strain, even if the
mutant never transmits to a new host in the population.
• The resident strain achieved larger final sizes when competing against the fitter
mutant than the weaker one, as a comparison between plots (a) and (c) shows.
This may be attributed to the significantly larger cumulative within-host emergence
probability of the weaker mutant strain and the fact that its emergence window
comes slightly earlier in the infection. More specifically, a weaker mutant has
more chances to emerge during an individual’s infection so we expect it to emerge
considerably more often than the fitter mutant in our simulations. Moreover the
weaker mutant’s narrow emergence window comes slightly earlier in the infection
and therefore ensures not only that the mutant can grow within-host despite its
fitness disadvantage compared to the resident, but also that it has higher chances
than the fitter mutant to emerge earlier in the infection and have more resources
available to it. As a result we expect the weaker mutant’s negative effect on the
within-host growth of the resident strain to be more prominent than that of the
fitter mutant. Given our assumption that the between-host transmission rates are
linear functions of the within-host viral load, this implies a larger decrease in the
transmission rates of the resident when it has to compete against a weaker mutant
compared to a fitter one. This in turn can account for the smaller population-level
final sizes of the resident strain in plot (c) compared to plot (a).
• The most variability in the final size of the mutant occurs in the case of a neutral
mutation, as plot (b) illustrates. We can see that in many of our simulations the
final size of the mutant strain was significantly larger than that of the resident strain.
This can be explained not only by the large cumulative emergence probability of
a neutral mutant but also by the narrow and early emergence window that fWH
imposes, which guarantees that if the mutant appears it will have enough target
and prerefractory cells available to it for infection and its viral load will have the
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opportunity to grow within-host. This leads to better chances for the mutant to
transmit to new hosts and spread in the population. We note that our use of the
word "chances" is because in the implementation of our cross-scale model the
decision of which strain transmits to a new host is a random event that depends on
the within-host viral load of the two strains at the time of transmission.
4.6.4 Results using a constant emergence density
We will now change our approach regarding the emergence density and instead of
deriving it from our within-host model we will assume that it remains constant throughout
an individual’s infection. This approach has the significant disadvantage that it weakens
the link between the two scales of our cross-scale model. As we discussed in chapter 3
though, our within-host derived emergence density comes with the potential drawback
that it only allows for a very short emergence window early in the infection. Therefore
we want to assess how sensitive our cross-scale model’s results are to the assumed
form of the within-host emergence density. We choose a constant within-host emergence
density because it results in a framework that most closely resembles our between-host
model for the evolution of influenza from chapter 2.






where p is the cumulative emergence probability of the mutant during an infection, and is
chosen by us.
We will initially use the cumulative emergence probability
∫
α
fWH(α)dα from the pre-
vious section to inform the value of p. We underline though that this initial choice is
not particularly important, as later in this section we will vary p and study its impact
on our cross-scale model’s results. We are interested in contrasting the results of our
cross-scale model from this section with the equivalent results from the previous section,
where we used the within-host derived emergence density fWH . For this reason we will
first assume that the mutation is deleterious and compare how the infectious groups
dynamics and the population-level final sizes of the two strains differ between this section
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that assumes a constant within-host emergence density and the previous section where
the emergence density was informed by our within-host model. We will then repeat the
same analysis for the cases of a neutral and a deleterious mutation.
(a) The average portions of individuals originally infected with the resident and
mutant strains in 500 simulations of our model.
(b) The final sizes of the resident and mutant strains in 500 simulations of our
cross-scale model.
Fig. 4.12 Some key results from 500 simulations of our cross-scale model in the case of a deleterious mutation. Here
we assume that the within-host emergence density is constant and the within-host cumulative emergence probability
p is 0.73.
Figure 4.12 shows some key results of our cross-scale model under the assumptions
that the mutation is deleterious, the within-host emergence density remains constant
throughout an individual’s infection and the within-host cumulative emergence probability
is 0.73.
• Plot (a) shows that the weaker mutant’s population-level prevalence throughout the
epidemic is very low. Comparing this to the equivalent plot under the within-host
derived fWH [figure 4.10(a)], we observe that in the case of fWH the weaker mutant
again had a very low population-level prevalence throughout the epidemic but
that the epidemic lasted longer and peaked considerably later. It is interesting
then that while in both cases the mutant did not spread in the population, in the
previous section it still had a considerable impact on the between-host dynamics
of the resident strain. Under the assumption that the emergence density remains
constant throughout the infection, the mutant’s emergence window spans the whole
duration of the infection. Therefore there can be many cases where the mutant
emerges late in the infection and cannot grow efficiently (or potentially cannot
grow at all) because the resident strain has been circulating longer within the
host and infecting the target cells. In such cases the mutant’s viral load remains
so small that the mutant has very low chances of transmitting to new individuals.
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Moreover, since the two strains are in competition both within- and between-host,
a smaller viral load for the mutant implies a larger viral load (and therefore stronger
between-host transmission) for the resident. So the result under fconst is a quick
epidemic that peaks around 50 days. Contrasting this to the previous section where
the emergence density was derived from our within-host model, we first note that
fWH imposes a very narrow emergence window early in the infection. This means
that whenever the weaker mutant emerges within-host, it emerges early enough to
still have available target cells left to it for infection. As a result it can grow more
efficiently compared to a weaker mutant strain that appears late in the infection
under fconst . Therefore the early emergence window under fWH allows the weaker
mutant to better compete against the resident within-host, thereby weakening the
resident’s transmission to new hosts due to our assumption that the between-host
transmission rates are linear functions of the within-host viral load. This is why
the epidemic is slower under the within-host derived emergence density fWH and
peaks later (close to 80 days).
• Plot (b) shows that the weaker mutant never achieved a final size larger than 0.08
at the between-host level, while in the previous section (figure 4.11(a)) it did so for
a few of our simulations. This could be again attributed to the fact that a constant
emergence density allows for the appearance of a mutant strain throughout the
whole duration of a host’s infection. As a result the mutant might often appear
very late in the infection and be unable to grow efficiently (or at all), which would
significantly lower its chances of transmitting to new hosts and therefore decrease
its final size in the population.
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(a) The average portions of individuals originally infected with the resident and
mutant strains in 500 simulations of our model.
(b) The final sizes of the resident and mutant strain in 500 simulations of our
cross-scale model.
Fig. 4.13 Some key results from 500 simulations of our cross-scale model in the case of a neutral mutation. Here we
assume that the within-host emergence density is constant and the within-host cumulative emergence probability p is
0.91.
Figure 4.13 shows some key results of our cross-scale model under the assumptions that
the mutation is neutral, the within-host emergence density remains constant throughout
an individual’s infection and the within-host cumulative emergence probability is 0.91.
• Plot (a) shows that the neutral mutant strain has a very strong prevalence through-
out the epidemic, and on average even dominates it. A comparison with the
equivalent plot under the within-host derived fWH [figure 4.10(b)] shows that, again,
under the narrow and early emergence window of fWH the epidemic lasts con-
siderably longer and peaks much later. This is the same observation as in the
case of a weaker mutant strain, and can be attributed to similar factors. Under the
constant emergence density fconst the mutant may appear at any time during a
host’s infection, even very late in the infection. Such a late emergence impedes the
within-host growth of the mutant since it means that there are fewer cells available
to it for infection. This offers an advantage to the resident strain, allowing it to
spread more efficiently within-host and in turn in the population compared to cases
where the mutant emerges early in the infection. The end result is a short epidemic
that peaks close to 50 days. Under the within-host derived fWH , the narrow and
early emergence window facilitates the within-host growth of the neutral mutant
strain and therefore its between-host transmission as well, since that depends
linearly on the strain’s within-host viral load. The result is an epidemic with two
strains which can heavily compete against each other at both the within- and
between-host scales, which increases the epidemic’s duration as well as the time
of its peak (which occurs close to 120 days).
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• Plot (b) shows that the neutral strain often achieved larger final sizes than the
resident. This is in agreement with the final size results under the within-host
derived fWH [figure 4.11(b)].
(a) The average portions of individuals originally infected with the resident and
mutant strains in 500 simulations of our model. Here the mutant is assumed to
be fitter and the within-host emergence density is constant.
(b) The final sizes of the resident and mutant strain in 500 simulations of our
cross-scale model. Here the mutation is assumed to be beneficial.
Fig. 4.14 Some key results from 500 simulations of our cross-scale model in the case of a beneficial mutation. Here
we assume that the within-host emergence density is constant and the within-host cumulative emergence probability
p is 0.34.
Figure 4.14 shows some key results of our cross-scale model under the assumptions
that the mutation is beneficial, the within-host emergence density remains constant
throughout an individual’s infection and the within-host cumulative emergence probability
is 0.34.
• Plot (a) shows that the fitter mutant strain has a strong prevalence in the population
throughout the epidemic. It is interesting to compare this to the results under the
within-host derived fWH [figure 4.10(c)], where the fitter mutant had a very low
prevalence in the population. We may attribute the much higher prevalence of the
mutant under fconst to the fact that it offers equal chances to the fitter mutant to
emerge very early in the infection, while under fWH the fitter mutant is expected to
emerge most often very close to its emergence cut-off time. Moreover under fWH
no emergence can occur past the second day of infection due to the conditions it
imposes, namely that the mutant cannot emerge once its effective reproduction
number Rm,whe f f falls below 1 or if it cannot satisfy the minimum within-host final size
requirement. On the other hand under fconst the mutant may emerge even late in
the infection and while that ensures that it will not grow efficiently (or at all), it will
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still have a very small but non-zero chance to transmit to new hosts as long as its
viral load is positive.
• Plot (b) shows that the fitter mutant often achieved larger final sizes than the
resident. This is in contrast with the equivalent results under fWH [figure 4.11(c)],
where the fitter mutant reached very small final sizes in the vast majority of our
simulations. We may again attribute this difference to the higher chances of the
mutant to arise very early in the infection (during the first day) under fconst and to
the stricter conditions for emergence that our within-host derived fWH imposes.
(a) The mean portion of individuals originally infected with the resident strain
throughout the epidemic for four different values of the cumulative within-host
emergence probability p. For each value of p, the averages were taken over
100 simulations of our cross-scale model.
(b) The mean portion of individuals originally infected with the mutant strain
throughout the epidemic for four different values of the cumulative within-host
emergence probability p. For each value of p, the averages were taken over
100 simulations of our cross-scale model.
Fig. 4.15 The mean portions of individuals originally infected by the resident and mutant strains throughout the epidemic
for four different values of the cumulative emergence probability p. The averages were calculated over 100 simulations
of our cross-scale model for each value of p. All other values remained fixed at their reference values from tables 4.1
and 4.2 for all simulations, and we assumed that the mutant is neutral.
Figure 4.15 provides some insight into the effects of varying the cumulative within-host
emergence probability p on the between-host disease dynamics. It is not surprising
that as emergence becomes more probable the prevalence of the mutant strain at the
population increases [plot(b)] and equivalently that of the resident strain decreases [plot
(a)]. It is interesting that the larger values of p slightly shift the peak of the epidemic later.
By peak here we refer to the maximum portion of individuals originally infected with either
the resident or the mutant strain (as opposed to the maximum total portion of infected
individuals between both strains). This small delay can be attributed to the increasing
competition between the two strains at both the within-host and population levels as the
cumulative within-host emergence probability of the mutant increases. More specifically,
as p increases so does the probability of the mutant strain to emerge within-host at
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every time-point of an individual’s infection. As a result the mutant has better chances
of emerging earlier during a host’s infection and achieving larger viral loads. This in
turn has a twofold impact: firstly it increases the mutant’s chances of transmitting to
new hosts due to our assumption that the population-level transmission rates are linear
functions of the within-host viral loads, and secondly it hinders the within-host growth
of the resident strain due to our assumption that cells can only be infected once and
by a single strain. Therefore as the within-host cumulative emergence probability p
increases we expect both the within-host viral loads and the population-level prevalence
of the mutant strain to increase as well. This results in higher competition between
the two strains for available cells at the within-host level and for available hosts at the
between-host level, and therefore to the slower spread of the resident strain due to our
full-cross immunity assumption. The result is the later epidemic peak that we observe in
plot (a).
(a) A small within-host cumulative probability, specifically p =
0.1 here, has almost no effect on the epidemic final size over
100 distinct simulations of our cross-scale model. We note
that the y-axis in plot (a), along with all other plots in this
figure, ranges from 0.7 to 0.9
(b) A within-host cumulative probability p = 0.5 has a very
small effect on the population-level final size.
(c) A within-host cumulative probability p = 0.5 has a very
small effect on the population-level final size, but larger that
in the cases of p = 0.1 and p = 0.5.
(d) A within-host cumulative probability p = 0.5 has a very
small effect on the population-level final size, but once again
larger that in the cases of p = 0.1 and p = 0.5.
Fig. 4.16 The epidemic final size in the case of a neutral mutant strain in 100 simulations of our model for four different
values of the within-host cumulative emergence probability p under fconst . We note that the y-axis in each plot ranges
from 0.7 to 0.9, which was done simply for illustration purposes. All other values remained fixed at their reference
values from tables 4.1 and 4.2 for all simulations.
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Figure 4.16 shows the final size of the epidemic in the case of a neutral mutant strain
in 100 distinct simulations of our cross-scale model and for four different values of the
within-host cumulative emergence probability p. Here we define the epidemic final size
as the sum of the population-level final sizes of the resident and the mutant strains. We
observe the following:
• For a very small value of p, specifically p = 0.1 in plot (a), there is almost no
variability in the epidemic final size among different simulations. A very small p
together with our assumption of a uniform distribution for emergence in this section
implies that the mutant emerges only rarely within individuals infected with the
resident, and even in the cases where it emerges it often does so too late in the
infection to efficiently compete with the already circulating resident strain. As a
result the resident’s within-host growth is hardly impeded by the mutant, which in
turn allows its between-host transmission rate to not be affected by the within-host
emergence of the mutant. This can explain why in plot (a) we see almost no
variability in the epidemic final size, as it is determined almost in its entirety by the
spread of the resident strain.
• On the other hand the larger values of p we tested here (specifically p = 0.8 and
p = 1) resulted in some slight variability in the epidemic final size, even though
the mutant is assumed to be neutral. We underline though that the y-axis in all
plots of figure 4.16 ranges only from 0.7 to 0.9. A larger p implies a higher chance
for the neutral mutant to appear within-host early enough that it can compete with
the resident for available target cells and grow. Given our assumption that the
strain-specific between-host transmission rates are linear functions of the strain-
specific within-host viral loads, the within-host spread of the neutral mutant will
have a negative impact on the resident’s population-level transmission rate. The
magnitude of this impact is determined mainly by the within-host appearance time
of the mutant, since as we demonstrated in chapter 3 an earlier appearance time
implies a larger spread for the mutant and consequently a more inhibited growth for
the resident. We may therefore attribute the simulations where the epidemic final
size varied (and mostly decreased) in plots (b)-(d) to the neutral mutant growing
within a large enough number of hosts originally infected with the resident so as
to decrease the resident’s between-host transmission rates, but still not growing
efficiently enough that its population-level spread can offset the decrease in the
epidemic final size that the slower spread of the resident alone would imply. We
highlight that this decrease in the resident’s transmission rates to new hosts would
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still occur even when the neutral mutant only ever managed to attain a very small
presence at the population or even if it never transmitted to a new host.
(a) The average final sizes of the resident and mutant strains as a function
of the within-host cumulative emergence probability p. Here the mutation is
deleterious.
(b) The average final sizes of the resident and mutant strains as a function
of the within-host cumulative emergence probability p. Here the mutation is
neutral.
(c) The average final sizes of the resident and mutant strains as a function of the within-
host cumulative emergence probability p. Here the mutation is beneficial.
Fig. 4.17 The effects of varying the within-host cumulative emergence probability p on the population-level mean final
sizes of the resident and mutant strains in 100 simulations of our cross-scale model and for all three types of mutants.
In all cases Rr,p0 = 2, while R
m,p
0 = 1.5, 2 and 2.5 for a weaker, neutral and fitter mutant respectively.
Figure 4.17 illustrates the effects of varying the cumulative within-host emergence prob-
ability p on the population-level mean final sizes of the resident and mutant strains for
all three types of mutation. For all three cases as the cumulative emergence probability
increases so does the mean final size of the mutant strain. In the cases of a neutral
and beneficial mutation there is a value of the cumulative emergence probability after
which the mean final size of the mutant strain is larger than that of the resident. This
happens despite the fact that in all our simulations the outbreak begins only with the
resident strain present. It can be attributed though to our assumptions of no coinfection
and full cross-immunity. In our model we allow two strains to co-circulate within a single
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host only if the host was originally infected with the resident strain and then had the
mutant emerge within them. Such a host may then transmit the mutant strain to other
susceptible individuals, who will subsequently gain full immunity from the resident as well
as the infecting mutant strain. As a result while both the mutant and the resident may
only infect fully susceptible individuals at the point of transmission, the mutant has an
advantage because it can emerge within several individuals who were originally infected
with the resident strain. When the within-host emergence probability is high enough,
plots (b) and (c) shows that this advantage can lead to the epidemic being taken over by
the mutant strain.
4.6.5 Results using the Weibull distribution
In this section we will present the results of our cross-scale model using a Weibull proba-
bility density function for the within-host emergence of the mutant strain. This is because
as we will show, a Weibull distribution appears to capture well the emergence dynamics
that we expected our within-host model to produce.










where η is a scale parameter, ζ a shape parameter and p is the cumulative within-host
emergence probability of the mutant strain. For the remainder of this chapter we will
assume that η = 2 and ζ = 2.5 unless explicitly stated otherwise.
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Fig. 4.18 The emergence density fWB throughout the infection for p = 0.1.
Figure 4.18 shows how the Weibull within-host emergence density fWB changes through-
out an individual’s infection. Our reasoning for choosing a Weibull distribution with these
specific parameters is that the resulting pdf captures the emergence dynamics that we
originally expected our within-host model to produce. We see that under fWB emergence
is more likely in the early stages of the infection and becomes very difficult after the third
day of infection. This agrees well with the trajectories of the viral load, the eclipse cells
and the target cells in our within-host model. Moreover we observe that the window of
emergence under fWB is much wider compared to the window of emergence under our
within-host derived fWH , which was only a single day. So now we would like to test how
the results of our cross-scale model differ when the emergence density is given by a
Weibull distribution with these specific shape and scale parameters that allow for such
an emergence window.
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(a) The mean portions of individuals originally infected with the resident and
mutant strains throughout the epidemic over 500 simulations of our cross-scale
model.
(b) The final sizes of the resident and mutant strains over 500 simulations of
our cross-scale model.
Fig. 4.19 Some key results of our cross-scale model under the assumptions that the within-host emergence density is
given by fWB and the mutation is deleterious. We assume that the cumulative within-host emergence probability p is
0.73 to facilitate a comparison with our model’s results under the within-host derived fWH and the constant fconst .
Figure 4.19 shows some of our cross-scale model’s results under the assumptions that
the within-host emergence of the mutant strain follows a scaled Weibull distribution fWB,
the mutation is deleterious and the within-host cumulative emergence probability p is
0.73. We can make the following observations:
• The weaker mutant has a very low prevalence in the population [plot (a)]. This is in
agreement with our cross-scale model’s results under both the within-host derived
fWH and the constant fconst .
• The epidemic peak under the fWB shifts earlier compared to fWH [figure 4.10(a)].
The earlier peak under the scaled Weibull emergence density fWB may be explained
by the following reasoning: the larger within-host emergence window of fWB allows
for the emergence of the mutant later during a host’s infection. In such a case the
mutant is at a larger disadvantage compared to the resident and cannot grow its
viral load as efficiently. As a result, the mutant has lower chances of transmitting to
new hosts in the population and also has a smaller negative effect on the within-
host viral load of the resident strain. Therefore, the larger emergence window of
fWB leads to lower competition between the two strains both at the within- and
the between-host levels. The resident strain then can spread more rapidly in the
population, leading to the observed earlier epidemic peak in plot (a).
• The epidemic peak under fWB shifts later compared to fconst [figure 4.12(a)]. This
can be explained by the exact same reasoning as the comparison between fWB and
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fWH , since under the constant emergence density fconst the window of emergence
spans the whole duration of the infection. We may conclude then that between
the three forms of the within-host emergence density that we investigated in this
chapter, in the case of a deleterious mutation a larger emergence window facilitates
the faster spread of the resident strain both within-host and in the population.
• Plot (b) shows that the weaker mutant appeared at the population in all of our simu-
lations, but only reached small final sizes. Despite the large within-host cumulative
emergence probability of the mutant (p = 0.73), this is not surprising given the
fitness disadvantage it has compared to the resident strain. The results illustrated
in plot (b) are in agreement with the equivalent results under the within-host derived
fWB [figure 4.11(a)] and the constant fconst [figure 4.12(a)].
(a) The mean portions of individuals originally infected with the resident and
mutant strains throughout the epidemic over 500 simulations of our cross-scale
model.
(b) The final sizes of the resident and mutant strains over 500 simulations of
our cross-scale model.
Fig. 4.20 Some key results of our cross-scale model under the assumptions that the within-host emergence density is
given by fWB and the mutation is neutral. We assume that the cumulative within-host emergence probability p is 0.91.
Figure 4.20 shows some of our cross-scale model’s results under the assumptions that
the within-host emergence of the mutant strain follows a scaled Weibull distribution fWB,
the mutation is neutral and the within-host cumulative emergence probability p is 0.91.
We may make the following observations:
• Plot (a) shows that the neutral mutant strain has on average a larger prevalence
throughout the epidemic compared to the resident strain. A comparison between
plot (a) and the equivalent plots under the within-host derived fWH and the constant
fconst shows that in the case of a neutral mutation a larger emergence window
offers an advantage to the resident strain and facilitates its population-level spread,
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resulting in an earlier epidemic peak. This is the same outcome as in the case of a
deleterious mutation that we discussed in the previous figure and can be attributed
to the same reasons.
• Plot (b) shows that the neutral mutant strain appeared in the population in all
500 simulations of our cross-scale model and often dominated the epidemic and
achieved larger final sizes than the resident. This is in agreement with the equiva-
lent results under fWH and fconst .
(a) The mean portions of individuals originally infected with the resident and
mutant strains throughout the epidemic over 500 simulations of our cross-scale
model.
(b) The final sizes of the resident and mutant strains over 500 simulations of
our cross-scale model.
Fig. 4.21 Some key results of our cross-scale model under the assumptions that the within-host emergence density
is given by fWB and the mutation is beneficial. We assume that the cumulative within-host emergence probability p is
0.34.
Figure 4.21 shows some of our cross-scale model’s results under the assumptions that
the within-host emergence of the mutant strain follows a scaled Weibull distribution fWB,
the mutation is beneficial and the within-host cumulative emergence probability p is 0.34.
We may make the following observations:
• Plot (a) shows that the fitter mutant strain has an intermediate prevalence in
the population despite its small within-host cumulative emergence probability. A
comparison between plot (a) and the equivalent plot under fWH [figure 4.10(c)]
highlights the negative effects of the very small emergence chances during the
first day of infection and of the strict emergence conditions under our within-host
derived fWH on the population-level spread of the mutant. We also observed this
when we compared the between-host level prevalence of the fitter mutant strain
under fWH and fconst .
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• Plot (b) shows that the fitter mutant strain appeared in the population in all 500
simulations of our cross-scale model and in a few cases even dominated the epi-
demic and achieved larger final sizes than the resident. This result is in agreement
with the equivalent result under fconst [figure 4.14(b)] but is in contrast with the
equivalent result under fWH [figure 4.11(c)], where in the majority of our simulations
the fitter mutant strain only achieved small final sizes.
(a) The scaled Weibull distribution fWB for five different values of the scale
parameter η . Here p = 0.91. We observe that higher values of η lead to a
wider emergence window for the mutant.
(b) The average final sizes of the resident and mutant strains as a function of
η . Here the mutation is deleterious and the within-host cumulative emergence
probability p is 0.73.
(c) The average final sizes of the resident and mutant strains as a function of
η . Here the mutation is neutral p = 0.91.
(d) The average final sizes of the resident and mutant strains as a function of
η . Here the mutation is beneficial and p = 0.34.
Fig. 4.22 The effects of varying the Weibull scale parameter η from 0.1 to 5 on the population-level average final
sizes of the resident and the mutant strains. In all plots the mean final sizes were calculated as the average of 100
simulations of our cross-scale model for each value of η . All other parameters remained fixed at their reference values
from tables 4.1 and 4.2.
Figure 4.22 illustrates the effects of varying the Weibull scale parameter η on the
population-level mean final sizes of the resident and the mutant strains for all three cases
of mutant fitness. From plot (a) we can see that varying η may also be thought of as vary-
ing the width of the possible emergence window while keeping the cumulative emergence
probability constant. For all three types of mutation a short emergence window early in
184 A cross-scale model for the evolution of influenza
the infection appears to be more beneficial than a wider window. This can be attributed to
the fact that a mutant which arises early in the infection when there is already a resident
strain circulating within the host has more resources still available to it compared to a
mutant which arises at a later time. This allows for more efficient viral growth within-host
and therefore leads to a better chance of being transmitted to new hosts. It is interesting
that for very small η , which translates to a very short emergence window very early in
the infection, even a weaker mutant can end up taking over the epidemic as plot (a)
illustrates. We note that under the within-host derived fWH and the constant emergence
density fconst the weaker mutant never achieved a higher population-level final size than
the resident, despite its high cumulative within-host emergence probability of 0.73. This
hightlights the significant advantage of a short and early emergence window, as it allows
for more efficient within-host viral growth and therefore better chances of transmission to
new hosts.
(a) The small value of η = 0.5 appears to have almost no
effect on the variability of the epidemic final size in 100 distinct
simulations of our cross-scale model. We note that the y-axis
ranges from 0.65 to 0.9 in plots (a)-(d), which was done purely
for illustration purposes.
(b) The value of η = 1 appears to have very little on the vari-
ability of the epidemic final size in 100 distinct simulations of
our cross-scale model.
(c) The value of η = 1.5 appears to have a more prominent ef-
fect on the variability of the epidemic final size than the values
of η = 0.5 and η = 1.
(d) The value of η = 2 appears to have a more significant
effect on the variability of the epidemic final size compared to
the values tests in plots (a)-(c), though we highlight that the
range still remains between 0.66 and 0.82
Fig. 4.23 The epidemic final size in 100 distinct simulations of our cross scale model for four values of the Weibull scale
parameter η and under the assumption of a neutral mutation. The cumulative within-host probability p of the neutral
mutant is 0.91. All other parameters remained fixed at their reference values from tables 4.1 and 4.2. We note that the
y-axis in all plots ranges from 0.65 to 0.9 for illustration purposes.
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Figure 4.23 shows how the epidemic final size varies in 100 distinct simulations of our
cross-scale model for four different values of the Weibull scale parameter η , assuming
the mutation is neutral. The within-host cumulative emergence probability p here is 0.91
so as to remain consistent with our findings in section 4.6.3. We note that the y-axis in
all plots of figure 4.23 ranges from 0.65 to 0.9 for illustration purposes. Plot (a) of figure
4.22 illustrated how the Weibull distribution changes for the same values of the scale
parameter η studied here. We observe that for these four values of η , the variability
in the final size of the epidemic increases as the value of η increases. We considered
the reference value of our Weibull scale parameter to be η = 2 in this section, which
corresponds to plot (d) here. It is then interesting to try and understand why smaller
values of η lead to smaller variability in the epidemic final size.
• When η = 0.5 the window of emergence is very narrow and occurs very early
in the infection. This, combined with the high cumulative within-host emergence
probability of p = 0.91 for the neutral mutant, implies that the mutant emerges very
often within hosts originally infected with the resident and it emerges early enough
in the infection that it can grow efficiently and transmit to new hosts. Therefore
the reduction in the transmission rate of the resident strain to new hosts due to
the within-host competition with the neutral is accompanied in this case by the
efficient transmission of the mutant to new hosts. Even though within-host the
resident has a competitive advantage over the mutant since we do not allow the
time of emergence to be α = 0, our assumption of total cross immunity gives the
mutant a competitive advantage at the population-level. This is because any host
originally infected with the mutant is completely immune to the resident, while
any host originally infected with the resident may have the mutant emerge within
them and then transmit both strains to new hosts. Therefore, the case of η = 0.5
describes an epidemic where the mutant strain emerges within the majority of
hosts infected with the resident, and it emerges early enough in the infection that
it can efficiently transmit to new hosts and then spread in the population, thereby
contributing significantly to the epidemic final size.
• As η increases in plots (b)-(d) (while p remains constant at 0.91), the window of
emergence becomes wider and the chances of the mutant appearing at some
later time in the infection where it cannot efficiently grow and then transmit to new
hosts increase as well. We emphasize that even in such cases the mutant can
still compete with the resident within-host, and therefore reduce the resident’s
between-host transmission rates. Therefore, the variability in the epidemic final
186 A cross-scale model for the evolution of influenza
size which is especially apparent in plots (c) and (d) may be explained by the
variability in the mutant’s within-host emergence time, where in some cases the
mutant emerges early enough within-host that it can grow efficiently and infect new
hosts (thereby contributing efficiently to the epidemic final size) while in others the
mutant can only have a negative impact on the resident’s transmission rate to new
hosts but cannot efficiently spread in the population.
4.7 Discussion
In this chapter we developed a two-strain cross-scale model for the epidemiological
and evolutionary dynamics of influenza that explicitly links the within- and between-host
scales. The links were the population-level transmission rates of two strains, which we
assumed are linear functions of each strain’s within-host viral load. One of our main
goals was to investigate the emergence and subsequent competition dynamics between
a mutant strain and its parent resident strain both at the between- and within-host scales.
We first studied the results of our cross-scale model using the within-host emergence
density that we originally derived from our within-host model in section 3.5.1, which
imposes a very narrow window of emergence early in the infection. Our analysis showed
that under these conditions a neutral mutant strain has the best chances of emerging
within-host and subsequently spreading in the population. On the contrary a weaker
mutant strain had a significant fitness disadvantage which limited its spread at both
scales due to the competition with the resident, while a fitter mutant strain had a very low
prevalence in the population because of its significantly smaller within-host cumulative
emergence probability and its slightly later emergence window (in comparison to the
neutral and weaker strains). In order to test the sensitivity of our model’s results, we then
repeated the analysis of our cross-scale model first by assuming that the within-host
emergence density remains constant throughout an individual’s infection and then by
assuming that it follows a scaled Weibull distribution. Our results highlighted the im-
portance of the within-host emergence window for the population-level spread of the
mutant, as extending the width of the emergence window while keeping the within-host
cumulative emergence probability fixed had a negative effect on the between-host final
size of the mutant strain in all cases. On the contrary, our analysis showed that a very
narrow emergence window early in the infection provides the best opportunity for the
mutant to emerge and grow within-host and then spread in the population.
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One of the most important assumptions of our cross-scale model is that the between-host
transmission rates are linear functions of the within-host viral load. Considering that
these transmission rates provide the explicit link between the two tiers of our model,
we need to carefully consider the multi-faceted impact of this assumption. In a paper
published in 2019, Almocera and Hernandez-Vargas report that an acceptable form for
the population transmission rate as a function of the within-host viral load is still open
to discussion due to insufficient empirical data [7]. We will expand on this in the next
paragraph by first discussing some papers that assumed a linear relation between host
infectiousness and viral load, then by presenting a paper which assumed a logarithmic
relation and finally by discussing a paper that compared several approaches.
In 2009 Chen et al. published a paper in which they investigated the effects of within-host
viral kinetics and exhaled droplet size on the indoor transmission of influenza [63]. Using
empirical data on the amount of a host’s exhaled virus-carrying bioaerosol droplets per
time, the authors found that a linear dependence on the within-host viral load captured
the dataset well. As they pointed out though, their results are difficult to validate due
to the scarcity of experimental data on the amount of exhaled virus-carrying droplets
in indoor environments. A similar breath plume model published by Halloran et al. in
2012 also found that a linear relation between the viral load and the concentration of
exhaled pathogens per unit volume of air could capture well a different empirical dataset
[134]. In 2007 Handel et al. published a paper in which they investigated the generation
and spread of neuraminidase inhibitor (NI) resistance in influenza [140]. Part of their
modelling framework included developing a function for the amount of viral shedding
that depended on the within-host viral load. The authors used viral load and nasal dis-
charge weight data from previously published volunteer studies and found that a sigmoid
relation between viral shedding and the logarithm of the viral load provided the best fit.
To connect this with infectiousness, the authors then assumed a direct proportionality
relation between the total amount of shedding and the basic reproduction number R0.
Finally, Tsang et al. published a paper in 2015 in which they mapped influenza A vi-
ral shedding to infectiousness in households [294]. The authors studied four different
models based on the assumed relation between viral shedding and infectivity: infectivity
being proportional to the viral load V , to log(V ) and to a power of these variables. Their
results showed that the model which assumed that infectivity was proportional to the
viral load V gave the worst fit to the household data because it led to most transmission
occurring very early in the infection. The rest of the models resulted in better fits, but
still overestimated the proportion of transmission occurring more than three days since
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symptom onset. Our main conclusion after reviewing these published studies is that there
is not enough empirical data to inform the exact nature of the relationship between the
within-host viral load and the population-level transmission rate of influenza. Therefore
an important future research project would be to repeat the analysis of our cross-scale
model assuming different functional relations between the population-level transmission
rates and the within-host viral load.
The analysis of our model highlights the significant advantage of cross-scale models to
allow for the direct comparison of competing selection pressures from different scales. In
section 4.6.3 we demonstrated that even a fitter mutant strain may fail to spread in the
population if it consistently emerges during a time in a host’s infection that it can survive
and grow but still has relatively limited resources available to it. More specifically, under
our within-host derived emergence density fWH we showed that the fitter mutant strain is
expected to emerge most often very close to its emergence cut-off value. As a result its
pool of available target and prerefractory cells is limited due to depletion by the already
circulating resident strain. This inhibits the within-host growth of the fitter mutant and
has a large negative impact on its transmission to new hosts, even despite the mutant’s
fitness advantage.
Special consideration needs to be given to the case of a neutral mutant strain. Even
though a neutral strain is characterized in our cross-scale model by the same values
for the strain-specific within-host parameters as the resident, the two strains are not
structurally indistinguishable. We may attribute this to the combined effect of some
key assumptions of our model. The first is the total cross-immunity assumption, which
dictates that an individual infected with either strain gains full immunity not only to the
infecting strain but to the other one as well. As a result, individuals originally infected with
the mutant strain have complete protection against the resident strain. But we further
assume that any individual originally infected with the resident strain might have the
mutant strain emerge within them, making it possible for the host to then transmit either
strain to new hosts. We note that in the implementation of our model the decision of
which strain is transmitted at every transmission event is made stochastically, with a
probability based on the viral loads of the two strains at the time of transmission. We
further emphasize that when the mutant strain emerges within-host it competes with the
resident for target and prerefractory cells, which has a negative effect on the growth of
the resident within-host and in turn on its between-host transmission (since we assume
4.7 Discussion 189
that the strain-specific between-host transmission rates are linear functions of the strain-
specific within-host viral load). Therefore by construction of our model we can make the
following observations:
• The mutant strain has an advantage over the resident because it may emerge
within individuals originally infected with the resident, while individuals originally
infected with the mutant have total immunity to the resident strain.
• The emergence of a mutant strain within a host infected with the resident can slow
down the within-host growth of the resident and therefore decrease its transmission
rate to new hosts. This is independent of whether the mutant successfully transmits
to new hosts. The asymmetry between the neutral mutant and its parent resident
strain then also lies in the fact that in a host originally infected with the mutant
strain, the transmission rate to new cases with the mutant cannot be affected in
any way by within-host processes involving the resident strain.
These observations together lead to a problematic scenario in the case of a neutral mutant
strain, which could be the result of a silent mutation and biologically indistinguishable
from the parent resident. In that case we would expect the strains to be competitively
neutral, and the existence of the neutral mutant to have no impact on the epidemic final
size. But in figures 4.16 and 4.23 we have shown that a neutral mutant can indeed have
an effect on the final size of the epidemic. The conditions we have identified for such
an outcome are that the within-host cumulative emergence probability should be high
enough that the neutral mutant emerges within a large portion of the hosts infected with
the resident, and that the mutant should arise late enough in the infection that it cannot
grow and spread to new hosts efficiently. The mere presence of the mutant within-host
though will still have a negative impact on the resident’s transmission to new hosts due to
the within-host competition of the two strains for available target and prerefractory cells.
Therefore these conditions create an epidemic where the mutant emerges within many
hosts, fails to have a significant presence at the population-level (and therefore fails to
contribute efficiently to the epidemic final size) but still slows down the transmission of
the resident strain to new hosts. In contrast, the situations we identified where the neutral
mutant has no effect on the epidemic final size can be divided into two different cases.
Firstly, under the assumption of a small within-host cumulative probability and a uniform
emergence distribution the mutant emerges very rarely within infected hosts and when
it does, there is a significant chance that it appears too late in the infection to compete
efficiently with the resident at either the within- or between-host levels. The result is an
epidemic that is dominated by the resident strain, therefore it is not surprising that the
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epidemic final size would not be affected by the neutral mutant. The second case is
when the within-host cumulative probability is so high that the mutant emerges very often,
and the emergence window is narrow and occurs early in the infection. Under these
conditions the mutant emerges in the majority of hosts infected with the resident and
it emerges early enough in the infection that it can spread efficiently both at the within-
and the between-host levels. The result is an epidemic where both strains contribute
significantly to the final size and the neutral mutant has almost no effect on the overall
dynamics. While this analysis may explain why a neutral mutant can sometimes have
an effect on the epidemic final size, it still does not resolve the pathological outcome
that two biologically indistinguishable strains are not structurally indistinguishable in our
mutation model. We have already argued that this is an inherent issue with our model by
its construction, but it is important to understand then to what extent it might invalidate
our conclusions. We refer to a 2009 paper published by Lipsitch et al. [193] where the
authors introduced the concept of "neutral null models", which are transmission models
of strain coexistence that meet the following two criteria when applied to functionally
indistinguishable strains: ecological dynamics should be independent of strain identities
and there should be no stable equilibrium frequency of the strains. The authors mention
that models which meet their null neutrality criteria cannot include mutation. They also
repeatedly emphasize though that there is nothing intrinsically wrong with non-neutral null
models, rather such models should simply be cautious when identifying mechanisms that
promote stable coexistence. With this in mind then we posit that the structural asymmetry
between the resident and the neutral mutant in our cross-scale model does not invalidate
our conclusions (especially since they are not quantitative) but rather makes it crucial to
identify the mechanisms by which this asymmetry affects our model’s results, as we have
done in the analyses of figures 4.16 and 4.23. We note that some ways we could alter
or extend our cross-scale model specifically to counteract the effects of the structural
asymmetry between the resident and mutant strains (of any fitness level) are:
• To increase the transmission bottleneck to include up to two strains. This would
lead to fewer cases where a mutant emerges within a host and fails to transmit to
new hosts but is still negatively affecting the between-host transmission rate of the
resident.
• To allow for backwards mutation. This would imply that individuals originally infected
with the mutant strain may have the resident strain emerge within them, thereby




In this chapter we developed a cross-scale model to describe the epidemiological and
evolutionary dynamics of influenza within a single season. Our model takes explicitly
into account processes that occur at the within-host level. The main links between the
within-host and population-level tiers of our cross-scale model are the between-host
transmission rates, which we assumed are linear functions of the within-host viral load.
We studied our model’s results under different forms for the within-host emergence density
of the mutant strain and showed that given a fixed within-host cumulative emergence
probability, a narrower emergence window earlier in the infection is the most beneficial
for the spread of a mutant strain both within-host and in the population.

Chapter 5
A cross-scale vaccination model for
the evolution of influenza
5.1 Introduction
In this chapter we develop a cross-scale vaccination model to describe the epidemio-
logical and evolutionary dynamics of influenza within a single season. Our model takes
explicitly into account dynamical processes that occur at the within-host level. The main
links between the two scales are the between-host transmission rates, which we assume
are linear functions of the within-host viral load. The effects of vaccination are captured
as an increase in the within-host viral clearance rates and affect the transmissibility of
the virus to new hosts. We will first examine the results of our cross-scale vaccination
model under the within-host derived emergence density that we formulated in section
3.5.1. In order to test the sensitivity of our results, we will then repeat our analysis using
two different functional forms for the within-host emergence density. One of our main
goals is to compare the results of our cross-scale vaccination model with those of our
population-level vaccination model from chapter 2 in order to gain a better understanding
of the advantages, disadvantages and potential necessity of explicitly linking the scales
when studying the spread and evolution of influenza in a single season.
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5.2 Background
We will base our cross-scale vaccination model on the Coombs model, which was pub-
lished by Coombs et al. in 2007 [68] and which we have already discussed in chapter
4. Since our cross-scale model requires input from a dynamical within-host model, we
will pair it with our extension of the Saenz model that includes vaccination. We originally
discussed and analyzed this model in 3.6.1. It is defined by the same of ODEs that define
our extended Saenz model, and vaccination is incorporated simply as an increase in the
clearance rate of the virus (c1 or c2 in our notation) in vaccinated individuals. Therefore
by construction vaccination reduces only the transmissibility of the infection but has no
impact on the susceptibility of vaccinated individuals. A vaccine that targets the resident
strain increases c1 from its reference value. The higher the increase, the more efficient
the vaccine is against the resident. The equivalent holds for a vaccine that targets only
the mutant or both strains.
We note that since we will need to refer to vaccinated individuals both at the within- and
between-host scales, we will slightly change the notation of our extended Saenz model
where Vi used to denote the within-host viral load of the ith strain. Instead we will use
the following notation:
• S: the class of fully-susceptible individuals at the between-host level
• V : the class of vaccinated individuals at the between-host level
• V̄ Si : the within-host viral load of the ith strain in an individual who used to be fully
susceptible and then became infected
• V̄Vi : the within-host viral load of the ith strain in an individual who was vaccinated
but became infected
5.3 Model Presentation
We will now present our cross-scale vaccination model for the epidemiological and evolu-
tionary dynamics of influenza within a single season. We will first motivate our model
and then present the equations that define it.
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Given the way in which we incorporated vaccination to our within-host model, our cross-
scale model assumes by construction that vaccination reduces infectiousness. This
stems from our assumption that vaccination increases the within-host viral clearance rate,
which leads to smaller viral loads throughout an individual’s infection. This in turn leads
to lower infectiousness due to our assumption that the population transmission rates
depend linearly on the within-host viral load. We will discuss this effect of the within-host
viral clearance rates on the population transmission rates in more detail in section 5.7.1
of this chapter. To capture the population heterogeneity due to vaccination status, we
have the following definitions:
• β Si j : the transmission rate from an individual who used to be fully susceptible and
became infected with strain i to new cases with strain j, where i, j ∈ 1,2. We note
that this is a function of the age of infection a and the within-host emergence time
α , but we omit writing this explicitly for now.
• βVi j : the transmission rate from an individual who was vaccinated and became
infected with strain i to new cases with strain j, where i, j ∈ 1,2.
• IS1 : the class of individuals who used to be fully susceptible and then became
infected with the resident strain (strain 1). We note that hosts in this class might
have the mutant strain (strain 2) emerge within them, which would result in two
strains circulating within them.
• IV1 : the class of individuals who were vaccinated and then became infected with
the resident strain. We note again that hosts in this class might have the mutant
strain emerge within them.
• IS2 : the class of individuals who used to be fully susceptible and then became
infected with the mutant strain. We note that hosts in this class can only have
the mutant strain circulating within them, because we do not allow for backwards
mutation in our model (mutation from strain 2 back to strain 1).
• IV2 : the class of individuals who were vaccinated and then became infected with
the mutant strain. We note again that hosts in this class can only have the mutant
strain circulating within them.
The key difference between these four infected classes as far as vaccination is concerned
is that the previously fully susceptible individuals in IS1 and I
S
2 will transmit the virus at
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a rate β S1 j and β
S





received the vaccine will transmit the virus at a rate βV1 j and β
V
2 j respectively, where
j ∈ 1,2.
We make some final observations before we present our cross-scale vaccination model:
• Fully susceptible and healthy vaccinated individuals are available to both the
resident and mutant strains for infection.
• Vaccinated individuals may be either healthy, in which case they are in the V
compartment, or infected, in which case they can be in the IV1 or I
V
2 compartments.
• A fully-susceptible individual can enter the IS1 compartment by being infected with
the resident strain either by a previously fully susceptible individual already in IS1 at
a rate β S11 or by a vaccinated infected individual in I
V
1 at a rate β
V
11. The same holds
with regards to how a healthy vaccinated individual can enter the IV1 compartment.
• A fully-susceptible individual can enter the IS2 compartment via four different ways.
The first is due to infection with the mutant strain by a previously fully susceptible
individual currently in IS1 who was originally infected with the resident strain but
then had the mutant emerge within them and is now transmitting both strains. This
occurs at a rate β S12. The second way is equivalent to the first but assumes instead
that the infecting individual is vaccinated and currently in IV1 and is transmitting the
mutant at a rate βV12. The third way is due to infection with the mutant strain by
a previously fully susceptible individual currently in IS2 who was infected with the
mutant strain and is now transmitting it at a rate β S22. Finally the fourth way is the
same as the third but instead assumes that the infecting individual is vaccinated
and currently in IV2 and is transmitting the mutant at a rate β
V
22. The equivalent four
ways also hold with regards to how a healthy vaccinated individual can enter the IV2
compartment. These infection pathways are illustrated in figure 5.1.
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Fig. 5.1 The different ways in which a fully susceptible individual can become infected with
the mutant strain in our cross-scale vaccination model.
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We will now present the equations of our cross-scale vaccination model in the case of
only two strains, a resident (strain 1) and a mutant (strain 2):






=−V (Λ1 +Λ2) (5.4)
kIS1 (t,0) = SΛ1 (5.5)
kIS2 (t,0) = SΛ2 (5.6)
kIV1 (t,0) =V Λ1 (5.7)
kIV2 (t,0) =V Λ2 (5.8)
where:
• S(t) denotes the number of susceptible individuals at time t of the epidemic.
• V (t) denotes the number of susceptible individuals at time t of the epidemic.
• ISi (t −a,0) represents the density (in a) of previously fully-susceptible individuals
who became infected with strain i at time t −a.
• IVi (t − a,0) represents the density (in a) of vaccinated individuals who became
infected with strain i at time t −a.
• The constant k is such that da = kdt. This accounts for the fact that ISi (t,a) and
IVi (t,a) are densities in a whereas the right hand side of equations (5.5)-(5.8) are
numbers.
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• The parameter β Si j(a) is the transmission rate from previously fully-susceptible
individuals who were infected with the ith strain a time units ago to new infections
with strain j.
• The parameter βVi j (a) is the transmission rate from vaccinated individuals who
were infected with the ith strain a time units ago to new infections with strain j.
Equation (5.3) is an integro-differential equation that describes how the number of fully-
susceptible individuals in the population varies over time. It needs to account for the new
infections generated by both vaccinated as well as previously fully-susceptible hosts of
all possible infection ages a ∈ [0,∞) who were initially infected with the ith strain and are
now infecting new cases with the jth strain, where i, j ∈ 1,2. The equivalent holds for
equation (5.4), which describes how the number of uninfected vaccinated individuals
varies over time. Equations (5.5)-(5.8) are renewal conditions which describe how new
infected cases of the jth strain are generated. They take into account the contact of
both fully-susceptible as well as healthy vaccinated individuals with infected hosts of all
possible infection ages and vaccination statuses who were initially infected with either
strain, but are now transmitting specifically the jth strain.
It is important to emphasize that while equations (5.3)-(5.8) describe the population
disease dynamics, they depend on the viral dynamics within infected hosts via the trans-
mission rates β Si j(a) and β
V
i j (a). More specifically, we assume that the transmission rates
are linear functions of the within-host viral load. We will discuss this in more detail in the
next section, in which we will go over our model’s assumptions. Since our cross-scale
model requires an explicit within-host dynamical model, we pair it with our extended
Saenz vaccination model from 3.6.1.
5.4 Model Assumptions
We will now discuss all the assumptions of our cross-scale vaccination model, and for
each one we will specify whether it originated from published work or if it is our own
addition.
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Assumptions taken from Saenz et al. [262]:
• On a cellular level infection always leads to death.
• Refractory cells are completely immune to infection. Once a cell becomes refrac-
tory it remains in this antiviral state for the duration of the infection.
Assumptions taken from Coombs et al. [68]:
• Cells can be infected only by a single strain. We note that this combined with the
Saenz assumption that infection always results in the death of the infected cell
means that target cells can only be infected once.
• The competition between the two strains is mediated purely through the avail-
ability of resources such as the target and prerefractory cells within-host and the
susceptible individuals at the population-level.
• The population transmission rates depend linearly on the viral load of the host.
Specifically
βi j(a) = bV̄j(a)
where b is a scaling constant, and i, j ∈ {1,2}. We adapt this assumption to our
model, in which we have different transmission rates for vaccinated and unvacci-
nated individuals. So we set
β
S





i j (a,α) = bV̄
V
j (a,α) (5.10)
where V̄ S denotes the viral load of an infected individual who used to be fully
susceptible, V̄V that of a vaccinated individual who became infected, b is a scaling
constant, a denotes the age of infection and α is the within-host emergence time
of the mutant strain. As we have previously demonstrated with the analysis of our
within-host model in chapter 3, the emergence time a has a significant impact on
the viral load of both strains. As a result α also has an effect on the population
transmission rates, given our definition of β S and βV in equations (5.9) and (5.10).
This linear dependence of the between-host transmission rates on the within-host
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viral load is a key assumption of our cross-scale vaccination model. We note that
we used the same assumption for our cross-scale model in chapter 4, and we
discussed its significance and implications in the Discussion section of that chapter.
Our own additional assumptions:
• Backwards mutation (from the mutant to the resident strain) is not possible. There-
fore β21(a,α) = 0 ∀a,α .
• Vaccination acts within-host by increasing the viral clearance rate(s). As we assume
that the vaccine is homologous to the resident strain, vaccination mainly acts by
increasing c1. We emphasize though that the vaccine can still have an impact
on the mutant too, so we will also investigate the effects of varying c2. In section
3.6.1 we discussed that our decision to incorporate vaccination in such a simplistic
way was motivated by the complicated nature and computational challenges of
cross-scale models. Moreover, using the results of our extended Saenz model’s
parameter sensitivity analysis, we showed that our decision to use ci instead of
another within-host strain-specific parameter should not affect our model’s results
in any fundamental way.
• On a population level infection leads to recovery. This is a simplifying assumption,
but applicable to seasonal influenza. It is why there is no disease-related mortality
rate in our model, as opposed to the Coombs model from [68] which focuses
primarily on HIV.
• Each individual can be initially infected by exactly one strain. No co-infection can
occur. The only case where more than one strains may co-circulate within a single
host is if the host was initially infected with the resident strain and then had the
mutant strain emerge during their infection.
• Vaccination occurs only prior to the onset of the outbreak. Once the epidemic starts
no further vaccination may take place. This is merely a simplifying assumption.
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5.5 Basic Properties
The population-level basic reproduction number Rr,p0 of the resident strain in our cross-







where β S11(a) is the rate at which previously fully-susceptible individuals who were initially
infected with the resident strain a time units ago and never had the mutant strain emerge
within them infect new individuals. Here Dwh denotes the duration of the infection.








Since in our model vaccination reduces infectiousness and introduces heterogeneity in
the host population, it is important to also consider the control reproduction number of
the disease Rc which is simply the reproduction number with control measures in place




















where βV11(a) is the rate at which vaccinated individuals who were initially infected with
the resident strain a time units ago and never had the mutant strain emerge within them
infect new individuals. Here S(0) and V (0) denote respectively the initial portion of
fully-susceptible and vaccinated individuals, and we have S(0)+V (0)≈ 1. We note that
V (0) is also the same as the vaccination coverage c in our model. Similarly the control





















As we mentioned in the previous section, we assume that infectiousness scales linearly
with the viral load. More specifically we defined
β
S
i j(a,α) = bV̄
S
j (a,α)
where V̄ S denotes the viral load of an infected individual who used to be fully susceptible,
b is a scaling constant and i, j ∈ {1,2}. If we substitute this into equation (5.11) for the








where V̄ S1 (a, /0) denotes the viral load of a previously fully-susceptible individual who was
infected with the resident strain and never had the mutant strain emerge within them.
5.6 Methods
We are interested in studying the emergence dynamics of a mutant strain in the popu-
lation, so we assume that initially there is only a resident strain causing the epidemic.
We further assume that some portion of the population has been vaccinated against the
resident strain prior to the onset of the outbreak. When an individual becomes infected
with the resident strain we keep track of the age of their infection because variations in
their within-host viral load will affect their population-level transmission rate. Similarly to
the implementation of our within-host model from chapter 3, we assume that when an
individual is infected with the resident strain there is a chance that errors will occur during
the within-host viral replication process which will lead to the emergence of a mutant
strain within that host. At the between-host level the consequence of this within-host
emergence is that the host may transmit either the resident or the newly emerged mutant
whenever they infect a new host, with a probability that depends on each strain’s viral
load at the time of transmission. This in turn can lead to two strains, a mutant and its
parent resident, circulating in the population and competing for hosts either until the end
of the epidemic or until one of them disappears.
Our model has the following initial conditions:
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• N = 1 is the total size of our population and we assume it remains fixed throughout
the outbreak.
• c=V (0)= 0.63 is the vaccination coverage. This matches the vaccination coverage
of our population-only vaccination model from chapter 2. It was taken from a report
published by Public Health England on the seasonal influenza vaccine uptake in
GP patients from the winter season 2017 up to 2018 [240].
• IS1 (0) = 10
−5 individuals.
• IV1 (0) = 0.
• IS2 (0) = I
V
2 (0) = 0. This is because we assume that the outbreak is initiated only by
the resident strain.
• Dp = 150 days. This is the duration of the outbreak, and we set it as 150 days to
cover the main winter season of influenza in the Northern hemisphere, namely
December-February, together with a month leading up to it and a month right after
it.
• Dwh = 5 days. This is the duration of the infection within a host.
• Rr,p0 = 2. This was chosen simply to satisfy reported values of the population-level
R0 of influenza. More specifically Cauchemez et al. report in [55] that R0 ranges
from 1.4 to 2.2.
5.6 Methods 205
Within-host model
Parameter Description Value Units Source



















ci Free virus clearance rate
for ith strain





, 1kγ Average duration of
eclipse phases
1/2 Days [262]




1/aw Average duration of
prerefractory phase
1/4 Days [262]








d IFN clearance 6.8 Rate of IFN
clearance day−1
[262]
φ IFN efficiency 56 (IFN fold change)−1
day−1
[262]
m IFN-reduced infectivity 0.9
α Time of emergence of
mutant strain
Varies Days
Dwh Infection duration 5 Days
Table 5.1 Parameters of the within-host tier of our cross-scale vaccination model.
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Between-host model
Parameter Description Value Units Source











c vaccination coverage 0.63 [240]
Table 5.2 Parameters of the between-host tier of our cross-scale vaccination model.
5.6.1 Implementation
The implementation of our cross-scale vaccination model is the same as the implemen-
tation of our cross-scale model, which we described in detail in section 4.5.1, with the
only difference being that we now need to account for vaccinated individuals. This is the
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pseudocode for our cross-scale vaccination model:
Algorithm 2: Pseudocode for cross-scale vaccination model
Initialization : c, da, dt > da, Dp, Dwh, PS(a),PV (a) ...
for time = da : da : Dp do
day= ⌊time⌋
if day=time then















check for emergence :
∀a NumTrialsS(a) = IS,day1 (a, /0)
∀a NumTrialsV (a) = IV,day1 (a, /0)
NumEmergencies(a) =
Binomial(NumTrialsS(a),PS(a))+Binomial(NumTrialsV (a),PV (a))
compute new infections :
r1 = ∑a ∑α β S11(a,α)I
S,day

















(S+V )(day) = exp(−(r1 + r2))× (S+V )(day−dt)
s = S(day−dt)(S+V )(day−dt)
numNewIn f s = (S+V )(day−dt)− (S+V )(day)
numNewSIn f s = Binomial(numNewSIn f s,s)
numNewVin f s = numNewIn f s−numNewSIn f s
S(day) = S(day−dt)−numNewSIn f s
V (day) =V (day−dt)−numNewV In f s








numNewIS2 = numNewSIn f s−numNewIS2
numNewIV2 = numNewV In f s−numNewIV2
else
update the ages of infection
check for emergence
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5.7 Results
We will now present the results of our cross-scale vaccination model. We underline that
all of our results assume a neutral mutant strain (δ2 = δ1 = 2), unless explicitly stated
otherwise. We divide our results into different sections depending on the assumed form
of the within-host emergence density. This is because, as we will discuss in more detail
in the following sections, our within-host derived emergence density comes with some
strict limitations. We are also interested in assessing the sensitivity of our model’s results
to the assumed form of the emergence density.
The structure of our Results section is as follows:
• In the first subsection we will present some of our model’s results that do not
depend in any way on the within-host emergence density.
• In the second subsection we will analyze our cross-scale vaccination model under
the the within-host derived emergence density fWH from 3.5.1.
• In the third subsection we will assume that the within-host emergence density fconst
remains constant throughout an individual’s infection. This means that our within-
host model no longer informs the emergence density, but the resulting framework
most closely resembles that of our population-level vaccination model from chapter
2.
• In the final subsection we will assume that the emergence density fWB is given by
a Weibull distribution. This is because the resulting density appears to capture well
the emergence dynamics that we originally expected our extended Saenz model to
produce.
5.7.1 The effects of the viral clearance rates
We first present some of our cross-scale vaccination model’s results that do not depend
on our choice of the within-host emergence density.
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Fig. 5.2 The transmission rates for a resident-only infection in our cross-scale vaccination
model for different values of the clearance rate c1. Their trajectory resembles the within-host
viral load curves, which is expected given our assumption that the transmission rates are
linear functions of the within-host viral loads.
Figure 5.2 shows the between-host transmission rates in the case of a resident-only
infection for three different values of the viral clearance rate c1. Since we assume that
vaccination acts at the within-host level by increasing the viral clearance rate(s), this fig-
ure illustrates the reduction in infectiousness of a vaccinated individual who has acquired
the infection. More specifically, the vaccine initially acts within-host by increasing c1. This
reduces the viral load of the resident strain throughout the infection. Since we assume
though that the population-level transmission rates are linear functions of the within-host
viral load, this reduction in the viral load implies a reduction in the between-host transmis-
sion rates. This is the mechanism via which vaccination has an effect both at the within-
and the between-host tiers of our cross-scale model. The reason we focus on c1 instead
of c2 is because we assume that the vaccine is homologous to the resident strain, so in
our framework it should mainly act by increasing c1. We note though that the vaccine
may still exert some pressure on the mutant strain by increasing c2 as well, but we will
examine this scenario in the next sections because its outcomes depend on the form of
the within-host emergence density.
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(a) The first value of c1 for which R
r,p
c becomes smaller than
1 is 13.
(b) The final size of the resident strain is computationally a
non-increasing function of c1 . We note that for c1 ≥ 13 we
have Rr,pc < 1 but we still ran the simulations of our cross-
scale vaccination model to obtain a final size.
Fig. 5.3 The effects of the viral clearance rate c1 on the resident’s control reproduction number R
r,p
c and the the final
size in a resident-only epidemic. Here c1 ranges from its reference value 5.2 up to 15 in vaccinated individuals. In
fully-susceptible individuals it remains fixed at its reference value across all simulations. All other relevant parameters
were fixed at their reference values from Tables 5.1 and 5.2.
Figure 5.3 shows the effects of varying the viral clearance rate c1 on the the resident’s
control reproduction number Rr,pc and the final size of the resident strain in a resident-only
epidemic. An epidemic with only the resident strain was achieved by simply setting the
within-host emergence density to 0. Since we assume that vaccination acts by increasing
the viral clearance rate within-host, we may think of varying c1 as varying the efficacy of
the vaccine against the resident. This is why our initial value for c1 is its reference value
of 5.2 (from Table 5.1). We note that the increase in c1 is only reflected in vaccinated
individuals. Fully-susceptible individuals who become infected have a clearance rate of
c1 = 5.2. This will apply to all our results that depend on varying the clearance rates c1
and c2 in the following sections as well. We can see in plot(a) that for any c1 larger than
13 the virus cannot invade the population. This helps inform our choice for the upper limit
of c1 that we will use in all our subsequent simulations of two-strain epidemics.
5.7.2 Results using the original within-host derived emergence den-
sity
We will now present some of our model’s results which depend on the choice of the
within-host emergence density. We start by using our within-host derived fWH as the
emergence density:
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where λ (α) is the rate of appearance, survival and adequate growth of a mutant strain
and is given by:














Fig. 5.4 The effects of the viral clearance rate c1 on the average final sizes of the two strains. The mean
final sizes were obtained by running 100 simulations of our cross-scale vaccination model for each value
of c1. All other parameters were fixed at their reference values from Tables 5.1 and 5.2. We underline
that the increase in c1 is reflected only in vaccinated individuals, who make up 63% of the population.
Figure 5.4 shows how the average final sizes of the two strains change as we vary
the viral clearance rate c1. We note again that our initial value for c1 is its reference
value 5.2, which describes a vaccine that is completely ineffective against the resident
strain because c1 = 5.2 is also the viral clearance rate in fully-susceptible individuals.
Increasing c1 past its reference value then denotes a vaccine that is increasingly efficient
in clearing the resident strain within-host. Figure 5.4 provides some interesting insight
into the conflicting effects of the within-host clearance rate c1 on the population-level
final size of the mutant strain. We see that initially as c1 increases so does the average
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final size of the mutant. We can attribute this to the advantage that the mutant gains
due to the action of a vaccine that is putting increasingly more pressure on the resident
strain both at the within- and between-host scales. After a certain value of c1 though
the vaccine-induced inhibition on the spread of the resident becomes so large that the
mutant has significantly fewer opportunities to emerge. This can explain the decreasing
portion of the mutant’s mean final size curve. We underline that this figure provides some
initial evidence that intermediate levels of immuno-protection are the most beneficial for
the emergence and spread of a mutant strain in our cross-scale vaccination model, which
was also the main result of our population-level vaccination model from chapter 2.
(a) Cross-scale vaccination model : the mean final size of the resident
strain as we vary the viral clearance rates c1 and c2 .
(b) Cross-scale vaccination model : the mean final size of the mutant
strain as we vary the viral clearance rates c1 and c2 . We note that
plots (a) and (b) are on different scales.
(c) Population-level vaccination model : the expected final size of the
resident strain as a function of the vaccine efficacy σi against each
strain.
(d) Population-level vaccination model : the expected final size of the
mutant strain as a function of the vaccine efficacy σi against each
strain. We note that plots (c) and (d) are on different scales.
Fig. 5.5 The effects of varying the viral clearance rates c1 and c2 on the average final sizes of the two strains in our cross-scale
vaccination model [plots (a) and (b)]. The mean final sizes were calculated by running 50 simulations of our cross-scale model for
each value of c1 and c2. All other parameters remained fixed at their reference values from Tables 5.1 and 5.2. Plots (c) and (d)
are the equivalent results from our population-level vaccination model from chapter 2, where σi denotes the portion by which the
vaccine reduces susceptibility to the ith strain.
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Figure 5.5 shows the effects of varying the viral clearance rates c1 and c2 on the average
final sizes of the two strains in our cross-scale vaccination model [plots (a) and (b)], and
then contrasts them with the equivalent results from our population-level vaccination
model from chapter 2 [plots (c) and (d)]. We can make the following observations:
• Varying the viral clearance rate c2 has very little effect on the mean final size of
the resident strain, as plot (a) shows. This is not surprising given our assumption
that the resident strain alone initiates the epidemic and therefore has some time
to circulate in the population without any competition. This gives it a significant
advantage over the mutant, which is then only slightly strengthened as the vaccine
becomes more efficient at clearing the mutant strain within-host (or equivalently as
c2 increases). Plot (c) shows that the same is true for the effects of the vaccine
efficacy σ2 against the mutant strain on the expected final size of the resident in
our population-level vaccination model.
• Plot (b) shows that intermediate values of the viral clearance rate c1 are the most
beneficial for the emergence and spread of the mutant in the population. As c1
increases vaccinated individuals who have acquired the infection become more
efficient in clearing it. This has a negative impact on the within-host viral load of
the resident, which translates to a reduction in the population-level transmission of
the resident due to our assumption that the between-host transmission rates are
linear functions of the within-host viral load. This inhibition to the resident strain
provides an advantage to the mutant, as the two strains are competing for available
resources both within- and between-host. This explains the increasing portion of
the mutant’s mean final size along the c1 axis. After a certain value of c1 though,
and more specifically the value which corresponds to the peak of the mutant’s final
size as c1 increases, the vaccine-induced pressure against the resident strain is
too large for it to spread efficiently. As a result there are fewer opportunities for
the mutant strain to emerge within infected individuals, leading to the decreasing
portion of its mean final size along the c1 axis that we see in plot (b). We note that
this pattern agrees with the equivalent result from our population-level vaccination
model, as a comparison with plot (d) shows.
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(a) Cross-scale vaccination model: the average final size of a weaker mutant
strain as a function of the viral clearance rates c1 and c2 . A deleterious mu-
tation is defined in our model by δ2 = 2.6, where δ2 is the death rate of cells
infected with the mutant. We have shown that for such a mutant Rm,p0 = 1.5.
(b) Cross-scale vaccination model: the average final size of a fitter mutant strain
as a function of the viral clearance rates c1 and c2 . A beneficial mutation is
defined in our model by δ2 = 1.6. We have shown that for such a mutant
Rm,p0 = 2.5. We note that the scales between plots (a) and (b) are different.
Fig. 5.6 The effects of varying the viral clearance rates c1 and c2 on the average final size of the mutant strain for two cases: a
deleterious mutation in plot (a) and a beneficial mutation in plot (b). A weaker mutant is characterized by δ2 = 2.6, which leads to
Rm,p0 = 1.5. A fitter mutant is defined by δ2 = 1.6, which leads to R
m,p
0 = 2.5. We note that the resident strain remained at R
r,p
0 = 2
for both plots. The mean final sizes were calculated by running 50 simulations of our cross-scale model for each value of c1 and c2.
All other parameters remained fixed at their reference values from Tables 5.1 and 5.2.
Figure 5.6 shows how the average final size of the mutant strain changes as we vary
the viral clearance rates c1 and c2 in two cases: a deleterious mutation in plot (a) and a
beneficial mutation in plot (b). We emphasize that for both these plots the parameters
that define the resident strain remained fixed at their reference values. We observe the
following:
• Plot (a) shows that our previous conclusion that intermediate values of c1 are the
most beneficial for the emergence and spread of a neutral mutant strain is not as
prominent in the case of a weaker mutant. While we still observe that the weaker
mutant reaches its largest final size for some intermediate values of c1, we can also
see that for small values of c2 varying c1 from intermediate up to large values does
not appear to have a significant effect on the final size of the mutant. This does
not agree with the pattern we observed in the case of a neutral mutant, but it could
be attributed to the fitness disadvantage of the weaker mutant. Our reasoning for
the decreasing portion of the average final size of the neutral mutant strain along
the c1 axis was that the vaccine-induced inhibition on the spread of the resident
significantly lowered the mutant’s chances of emerging at a population-level. But in
the case of a deleterious mutation the mutant’s chances of emerging within-host
and then spreading in the population while competing with the resident at both
scales are smaller compared to those of a neutral mutant. Therefore it is not
surprising that the efficacy of the vaccine against the resident strain has a less
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prominent impact on the final size of a weaker mutant strain as opposed to that of
a neutral mutant strain.
• Plot (b) shows that intermediate values of c1 are the most beneficial for the emer-
gence and spread of a fitter mutant strain in the population. We observe that the
fitter mutant can spread even at large values of c2, which was not the case for
either the weaker or the neutral strain.
(a) Cross-scale vaccination model: the average final size of the resident strain
against the vaccination coverage c and the viral clearance rate c1 .
(b) Cross-scale vaccination model: the average final size of the mutant strain
against the vaccination coverage c and the viral clearance rate c1 . We note
that the scales between plots (a) and (b) are different.
(c) Population-level vaccination model: the expected final size E(FS1) of the
resident strain against the vaccine efficacy σ1 and the vaccination coverage c.
(d) Population-level vaccination model : the expected final size E(FS2) of the
mutant strain against the vaccine efficacy σ1 and the vaccination coverage c.
We note that the scales between plots (c) and (d) are different.
Fig. 5.7 The effects of varying the viral clearance rate c1 and the vaccination coverage c on the average final sizes of the two strains
in our cross-scale vaccination model [plots (a) and (b)]. The mean final sizes were calculated by running 50 simulations of our
cross-scale model for each value of c1 and c. All other parameters remained fixed at their reference values from Tables 5.1 and
5.2. Plots (c) and (d) are the equivalent results from our population-level vaccination model from chapter 2, where σ1 denotes the
portion by which the vaccine reduces susceptibility to the resident strain.
Figure 5.7 illustrates the impact of varying the viral clearance rate c1 and the vaccination
coverage c on the mean final sizes of the two strains. Plot (a) shows that the mean final
size of the resident is computationally a decreasing function of c and c1, as expected.
Plot (b) on the other hand provides some interesting information as to the conditions
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which are most inducive to the emergence and spread of a mutant strain in the population.
We can identify three such scenarios:
• When both c and c1 have intermediate values.
• When c is intermediate and c1 is large.
• When c is large and c1 is small or intermediate.
These results highlight the key role of the vaccination coverage in reducing the burden
of influenza epidemics. They also show that a high vaccine-induced immune pressure
against the homologous resident strain is important not only because of its direct effects
in limiting the spread of the resident, but also because it inhibits the chances of a mutant
strain emerging and growing in the population. We note that these results are qualita-
tively very similar to the equivalent results of our population-level vaccination model from
chapter 2, as plots (c) and (d) illustrate.
(a) The cumulative within-host emergence probability
∫
f (α)dα as a function
of the within-host mutation rate ε . Here the largest value of ε that we tested is
ε = 2.82×10−10 and it leads to a cumulative within-host emergence probability
of 0.9.
(b) Cross-scale vaccination model: the average final size of a mutant strain as
a function of the viral clearance rate c1 and the within-host mutation rate ε .
Fig. 5.8 The effects of the within-host mutation rate ε on the within-host cumulative emergence probability and on the population-
level average final size of the mutant strain. The mean final size was calculated by running 50 simulations of our cross-scale model
for each value of c1 and ε . All other parameters remained fixed at their reference values from Tables 5.1 and 5.2.
Figure 5.8 illustrates the effects of the within-host mutation rate ε on the within-host
cumulative emergence probability
∫ Dwh
0 f (α)dα and on the population-level average final
size of a neutral mutant strain. We first discussed the mutation rate ε in section 3.5.1,
where we defined it as the number of substitutions per nucleotide per cell infection that
lead to an an antigenic change. We restricted our definition to only take into account the
HA- and NA-coding nucleotides and further assumed that only 10% of those nucleotides
can potentially generate an antigenic change and that the probability that they do is
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0.0005 per substitution. These values though were chosen semi-arbitrarily and led to
a within-host cumulative emergence probability of 0.73 for a weaker mutant, 0.91 for a
neutral mutant and 0.34 for a fitter mutant. Here, using plot (a) as a guide, we chose
values of ε ranging from 10−12 up to 5×10−8 and varied them against the viral clearance
rate c1 to study their effects on the mutant’s population-level final size. The results are
displayed in plot (b). We can see that for most values of ε which allow the mutant to
emerge and spread in the population, intermediate values of c1 lead to the largest final
sizes for the mutant. Plot (b) shows that as ε increases the interval of c1 values that
benefit the mutant increases as well. This is not surprising since a larger ε implies a
larger cumulative emergence probability. We also note that the very narrow emergence
window under fWH guarantees that if the mutant emerges it will emerge early enough
during an individual’s infection to still have plenty of resources available to it to grow
within-host. In our model this translates to high between-host transmission rates due to
their linear dependence on the viral load. Therefore as ε increases the mutant strain
gains a considerable competitive advantage against the resident strain. We see that if ε
is large enough then the mutant can emerge and spread in the population even for very
large values of c1 and even dominate the epidemic.
5.7.3 Results using a constant emergence density
We will now change our approach regarding the emergence density and instead of
deriving it from our within-host model we will assume that it remains constant throughout
an individual’s infection. This means that our within-host model no longer directly informs
the emergence probability. Nevertheless we are still interested in assessing the results
of our cross-scale vaccination model using a constant emergence density because it
most closely resembles the framework of our population-only vaccination model for the
evolution of influenza from chapter 2.





where p refers to the within-host cumulative emergence probability.
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Given our new definition for the emergence density fconst and its lack of dependence
on our within-host model, we need to redefine the way in which vaccination affects the
within-host emergence density. Let c1 ∈ [c1,re f ,C], where c1,re f denotes the reference
value for c1 (in our case 5.2). As c1 = c1,re f leads to a completely ineffective vaccine, we
want it to have no effect on fconst . On the other hand we set up c1 =C to lead to a zero
emergence density in vaccinated individuals. So we set:
fVconst(α|c1) = f Sconst(α)×
(
1−




where f Sconst and f
V
const denote the emergence densities in fully-susceptible and vaccinated
individuals respectively. We set C = 15 for the rest of our simulations. We have already
demonstrated that the resident strain cannot initiate an epidemic when c1 = 13 in a single-
strain epidemic, but we use c1 = 15 to investigate whether that could give such a large
competitive advantage to the mutant strain that the mutant alone could drive the epidemic.
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(a) The average final sizes of the resident and mutant strains
as a function of c1 when p = 0.003.
(b) The average final sizes of the resident and mutant strains
as a function of c1 when p = 0.05.
(c) The average final sizes of the resident and mutant strains
as a function of c1 when p = 0.1.
(d) The average final sizes of the resident and mutant strains
as a function of c1 when p = 0.5.
Fig. 5.9 The average final sizes of the resident and mutant strains when varying the viral clearance rate c1 for four
different values of the within-host cumulative emergence probability p. The average sizes were obtained after running
100 simulations of our cross-scale vaccination model for each value of c1. We note that the mean final size of the
resident strain is very small but still non-zero for all values of c1 and p tested here. We underline that the changes
in c1 are only reflected in vaccinated individuals, which make up 63% of our population. All non-varying parameters
remained fixed at their reference values from Tables 5.1 and 5.2.
Figure 5.9 illustrates the effects of varying the viral clearance rate c1 on the mean final
sizes of the two strains for four different values of the within-host cumulative emergence
probability p. We see that p appears to have a significant effect on the final size of the
mutant strain. Interestingly a pattern that remains constant among these four plots is
the general shape of the final size of the mutant as a function of c1, which appears to
indicate again that intermediate values of immuno-protection are the most inducive to
the emergence and spread of a mutant strain in a population.
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(a) The average final size of the resident strain as a function
of c1 and c2 .
(b) The average final size of the mutant strain as a function of
c1 and c2 .
Fig. 5.10 The average final sizes of the resident and the mutant strains when we vary the viral clearance rates c1 and
c2. The average sizes were obtained after running 50 simulations of our cross-scale vaccination model for each value
of c1 and c2. The within-host cumulative emergence probability was p = 0.003 for all simulations and the mutant was
assumed to be neutral. All other parameters remained fixed at their reference values from Tables 5.1 and 5.2.
Figure 5.10 shows how the average final sizes of the two strains change as we vary
the viral clearance rates c1 and c2. We chose p = 0.003 for the within-host cumulative
emergence probability of the mutant. This comes into contrast with our values for p
from chapter 4 which were significantly higher, but here we need to also account for the
detrimental effects of the homologous vaccine against the resident strain. We emphasize
though that our choice of p is not very important here, since we are interested in studying
the changes in the final size of the mutant as we vary c1 and c2, rather than its actual
prevalences. Figure 5.10 shows that the end results for both strains are qualitatively
very similar to the equivalent results of our cross-scale vaccination model in the previous
section, where we used the within-host derived emergence density fWH instead of fconst .
They are also very similar to the equivalent results of our population-level vaccination
model.
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(a) The average final size of the resident strain as a function
of c and c1 .
(b) The average final size of the mutant strain as a function
of c and c1 . We note that plots (a) and (b) are on different
scales.
Fig. 5.11 The average final sizes of the resident and the mutant strains as we vary the vaccination coverage c and the
viral clearance rate against the resident c1. The average sizes were obtained after running 50 simulations of our cross-
scale vaccination model for each value of c and c1. The within-host cumulative emergence probability was p = 0.003
for all simulations. All other parameters remained fixed at their reference values from Tables 5.1 and 5.2.
Figure 5.11 illustrates the effects of varying the vaccination coverage c and the within-
host viral clearance rate c1 on the average final sizes of the two strains, under the
assumption that the within-host emergence density is constant. Once again, our results
are qualitatively very similar to the equivalent results from our cross-scale vaccination
model when the emergence density is given by fWH and to the equivalent results from
our population-only vaccination model from chapter 2.
5.7.4 Results using the Weibull distribution
We will now choose a different functional form for the within-host emergence density
f . We will assume that f follows a Weibull distribution with scale parameter η = 2 and










where p again denotes the within-host cumulative emergence probability of the mutant
strain. We note that this is the same scaled Weibull distribution as in section 4.6.5.
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(a) The average final size of the resident strain as a function
of c1 and c2 .
(b) The average final size of the mutant strain as a function
of c1 and c2 . We note that plots (a) and (b) have different
scales.
Fig. 5.12 The average final sizes of the resident and the mutant strains when we vary the viral clearance rates c1 and c2
assuming that the emergence density is given by fWB. The average sizes were obtained after running 50 simulations
of our cross-scale vaccination model for each value of c1 and c2. The within-host cumulative emergence probability
was p = 0.003 and the mutant was assumed to be neutral for all simulations. All other parameters remained fixed at
their reference values from Tables 5.1 and 5.2.
Figure 5.12 illustrates how the average final sizes of the two strains change as we vary
the viral clearance rates c1 and c2, under the assumption that the within-host emergence
density is given by fWB. Plot (a) shows that the viral clearance rate against the mutant
strain c2 has very little effect on the mean final size of the resident strain. This is not
surprising given our assumption that the resident strain alone initiates the epidemic and
therefore has some time to circulate in the population without any competition. Plot
(b) on the other hand illustrates again the interesting and conflicting effects of the viral
clearance rate c1 on the average final size of the mutant. We see that intermediate
values of c1 are the most beneficial for the emergence and spread of the mutant in the
population. This is a pattern that we also have observed in the previous sections where
we assumed different forms for the emergence density, and it can be attributed to the
same factors. The increasing portion of the mutant’s mean final size can be explained
by the inhibition in both the within-host and the population-level spread of the resident
that a higher c1 entails. After some value of c1 though, the resident strain cannot spread
efficiently anymore, giving fewer opportunities to the mutant strain to emerge. This can
explain the decreasing portion of the plot along the c1 axis.
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(a) The average final size of the resident strain as a function
of c and c1 .
(b) The average final size of the mutant strain as a function
of c and c1 . We note that plots (a) and (b) are on different
scales.
Fig. 5.13 The average final sizes of the resident and the mutant strains against the viral clearance rate c1 and the
vaccination coverage c, assuming that the emergence density is given by fWB. The average sizes were obtained after
running 50 simulations of our cross-scale vaccination model for each value of c and c1. The within-host cumulative
emergence probability was p = 0.003 for all simulations. All other parameters remained fixed at their reference values
from Tables 5.1 and 5.2.
Figure 5.13 shows how the average final sizes of the two strains change as we vary
the vaccination coverage c and the viral clearance rate c1 under the assumption that
the emergence density is given by fWB. The results are very similar from a qualitative
perspective to the equivalent results of our cross-scale vaccination model under fWH
and under fconst as well as to the results of our population-level vaccination model from
chapter 2.
Overall, we studied the results of our cross-scale vaccination model under three different
scenarios: one where the emergence density is derived from our within-host model, one
where it remains constant throughout the duration of the infection and finally one where it
is given by a Weibull distribution. In all three cases varying the efficacy of the vaccine
against the resident strain (captured here via varying the within-host viral clearance rate
c1) led to the same conclusion: intermediate values of immuno-protection are the most
beneficial for the emergence and growth of a mutant strain in the population. This is also
the main result of the analysis of our population-level vaccination model from chapter
2. In the next section we will discuss at length the implications of these findings with
regards to the advantages and disadvantages of our cross-scale model compared to our
simpler population-level model.
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5.8 Discussion
In this chapter we developed a cross-scale model to study the epidemiological and
evolutionary dynamics of influenza within a single season that also incorporated the
effects of vaccination. Our cross-scale vaccination model is the same as the Coombs-
based cross-scale model that we presented in chapter 4, with the only difference that
we increased the within-host viral clearance rates in individuals who were assumed to
have received a vaccine prior to the onset of the epidemic. We again assumed that the
between-host transmission rates are linear functions of the within-host viral load and
used three different forms for the within-host emergence density of the mutant strain: our
within-host derived emergence density from 3.5.1, a constant emergence density and
finally a scaled Weibull emergence density. By varying the efficacy of the vaccine we
demonstrated that in all cases intermediate values of immuno-protection are the most
inducive to the emergence and subsequent spread of a mutant strain in the population.
We emphasize that this is the same conclusion that we reached using our population-level
vaccination model from chapter 2.
One of the main research questions that we wanted to answer via this thesis was whether
the explicit linking of the scales is essential to describe the effects of vaccination on the
single-season evolutionary dynamics of influenza, modelled here as the emergence and
spread of a mutant strain in the population. The analysis of our cross-scale vaccination
model combined with a comparison to the results of our population-level vaccination
model reveals that the two models produce qualitatively very similar results with regard to
the conditions which facilitate the growth of a mutant strain in the population. Therefore
we may conclude that if we only limit our focus to the question of how vaccination affects
the population-level final size of an emerging mutant strain then explicitly linking the
between- and within-host scales is not necessary. We emphasize though that using
a cross-scale model allows for research questions which cannot be answered from a
single-scale perspective, such as how the within-host mutation rate affects the between-
host spread of a mutant strain in the presence of a vaccine that is homologous to the
resident strain and has no effect on the mutant.
We incorporated the effects of vaccination in our model simply as an increase in the
within-host viral clearance rates. We first presented and analysed this within-host vac-
cination model in section 3.6.1. We note that this is a very simplistic way to account
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for the effects of vaccination, but given the complicated nature and computational in-
tensity of cross-scale models we wanted to include vaccination in a very simple way.
We have already discussed in 3.6.1 our decision to have vaccination affect specifically
the within-host viral clearance rates, as opposed to other within-host strain-specific
parameters such as the death rate of infected cells, and demonstrated that varying the
different strain-specific parameters has similar effects on the results of our within-host
model. Therefore we expect the results of our cross-scale vaccination model to remain
qualitatively similar if we use a different within-host strain-specific parameter to capture
the effects of vaccination.
An important future research project is repeating the analysis of our cross-scale vac-
cination model assuming different functional forms for the relationship between the
population-level transmission rates and the within-host viral load. We have already
addressed the lack of empirical data that could accurately define this relationship in the
Discussion section of chapter 4. Since the transmission rates are the main links of the
two scales in our model, testing the sensitivity of our model’s results to the assumed form
of the dependence of the transmission rates on the viral loads is of particular importance.
5.9 Summary
In this chapter we developed a cross-scale model for the epidemiological and evolu-
tionary dynamics of influenza within a single season that took into consideration the
effects of vaccination. We modelled the evolution of influenza as the emergence of
a mutant strain within hosts already infected by a resident strain, combined with the
mutant’s subsequent spread in the population. Our cross-scale model explicitly linked the
between- and within-host scales via the population-level transmission rates, which we
assumed are linear functions of the within-host viral load. The effects of vaccination were
captured simply as an increase in the within-host clearance rate of the virus. We varied
the assumed form of the within-host emergence density as well as the fitness of the
mutant strain and the efficacy of vaccination and illustrated that in all cases intermediate
values of immuno-protection were the most inducive to the emergence and spread of a




The main research question that drove this thesis is how vaccination affects the emer-
gence dynamics of a mutant strain and the subsequent competition dynamics with its
parent resident strain within-host, between-host and across-scales. We developed a
within-host, a between-host and a cross-scale model to investigate this and here we will
summarize some of our most important insights and conclusions:
Insights from the between-host model
Using our population-level vaccination model we showed that intermediate values of
immuno-protection are the most inducive to the emergence and spread of a mutant strain
in the population. We measured the efficacy of the vaccine using the proportion by which
it lowers susceptibility to infection. Our results showed that intermediate values of the
vaccine efficacy against the resident strain lead to the highest expected final size for the
mutant. We also showed that a small or intermediate vaccine coverage also facilitates
the between-host growth of an emerging mutant strain, even in the case that the efficacy
of the vaccine is large. Therefore the analysis of our between-host vaccination model
underlines the significance of not only having a vaccine that is very efficient in preventing
infection, but also of vaccinating large portions of the population.
The analysis of our between-host model also highlighted that the time of appearance
of the mutant strain is crucial in determining its survival and growth in the population. A
later emergence time implies that the already circulating resident strain has had more
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time to infect susceptible individuals and therefore deplete the emerging mutant’s pool
of potential resources. This is certainly not a surprising result, but it is linked to our
assumptions of no co-infection and full cross-immunity. More specifically, we assumed
that individuals can only be infected by a single strain and that a recovered individual
gains full immunity both from the infecting strain and the other circulating one. As we
argued in the Discussion section of chapter 2 though, both of these assumptions can be
justified within the scope of our model with empirical data as well as previously published
work.
Insights from the within-host model
The within-host appearance time of a mutant strain is very important in determining its
viability and growth. This is linked to our assumptions of no co-infection at the cellular
level and cell death following infection, and can be explained by the depletion of available
resources due to infection by the already circulating resident strain. In the context of
our extended Saenz model the resources that a mutant strain requires to grow are
susceptible target and prerefractory cells.
In chapter 3 we showed that the explicit inclusion of the innate immune response via
the action of type I interferon (IFN) as well as the inclusion of the cell eclipse phase
are important in determining the emergence window of a mutant strain. In our simple
two-strain TIV model the mutant’s effective reproduction number becomes smaller than 1
at 0.76 days at the latest. Therefore in that model emergence is not possible after the first
approximately 18 hours of infection. This is a very restrictive condition, and we attributed
it to the very fast depletion of target cells due to infection. The extended Saenz model
can partially mitigate this as it slows down viral kinetics via the inclusion of the eclipse
phase and the protective action of IFN which reduces the infectivity rate of the virus
towards prerefractory cells. The result is a wider emergence window that extends up to
the second day of infection, specifically up to the first 46.5 hours of infection. We showed
that this later emergence cutoff time can be attributed primarily to the slower depletion
of target cells in the extended Saenz model. We may argue though that even in our
two-strain Saenz model the population of target cells decreases very quickly, which we
attributed to the free mixing of virions with target cells. Therefore, while we underline that
explicitly incorporating the immune response is important when investigating the mutant’s
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emergence window, we posit that adding spatial structure to the extended Saenz model
will allow for a wider emergence window. More specifically if we adapt the framework
of Reperant et al. from [253] and break down the respiratory tract into three distinct
compartments, each with its own within-host model and initial population of target cells
and assume that infection begins in one compartment and can then slowly spread to
the other two, then the overall population of target cells should decrease more slowly
compared to our extended Saenz model.
Insights from the cross-scale model
The explicit linking of the scales is not necessary to capture the conflicting effects of
vaccination at the within- and between-host levels. As we have demonstrated, both
our between-host vaccination model from chapter 2 and our cross-scale vaccination
model from chapter 5 show that intermediate values of immuno-protection are the most
inducive for the emergence and spread of a mutant strain in the population. While the
between-host tier of our cross-scale model was explicitly informed by the emergence
dynamics of a mutant strain within-host, our population-level model considered only
implicitly the within-host processes that give rise to mutant strains via a parameter for the
mutation rate per infection, which was either varied or chosen by us. Both models though
illustrated that initially as the vaccine efficacy against the resident strain increases the
expected final size of the mutant strain increases as well due to the advantage that the
mutant gains from a vaccine that is hindering the growth of its competitor resident strain.
And both models then showed that there is a value for the vaccine efficacy after which
the vaccine-induced pressure on the resident strain is so large that the resident cannot
spread efficiently anymore, allowing significantly fewer opportunities for the mutant strain
to emerge and negatively impacting its expected final size. Therefore, we concluded that
explicitly linking the within- and between-host scales is not necessary in order to answer
the main driving question of this thesis, which is how vaccination affects the epidemio-
logical and evolutionary dynamics of influenza within a single season. As Mideo et al.
report in [210] though, "Almost all of the studies that have used nested models of disease
dynamics to date (2008) have not actually required nesting to accomplish their goals.
Despite this, these models have provided important insights about pathogen evolution".
We argue that the same holds for our cross-scale vaccination model, as it still provided
useful insights into how the within-host time of emergence affects the population-level
final size of both strains and how the within-host fitness of the two strains translates into
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their population-level fitness as captured by their basic reproduction numbers.
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